List of Contributors Numbers in parenthesis indicate the pages on which the authors’ contribution begins Albert Adell (527), Institut d’Investigacions Biome`diques de Barcelona (CSIC), IDIBAPS, Department of Neurochemistry and Neuropharmacology, Rossello 161, 08036 Barcelona, Spain Malin Andersson (251), Department of Biochemistry, Mass Spectrometry Research Center, Vanderbilt University School of Medicine, 465 21st Ave S, 9160 Medical Research Building III, Nashville, TN 37232, USA Francesc Artigas (527), Institut d’Investigacions Biomediques de Barcelona, Consejo Superior de Investigaciones Cientificas (CSIC), IDIBAPS, Department of Neurochemistry, Rossello 161, 6th floor, 08036 Barcelona, Spain Franc- ois Artru (659), Service d’Anesthe´sie-Re´animation, Groupement Hospitalier Est, Hospices Civils de Lyon, 59 Bd Pinel, 69677 Bron Cedex, France Nicole M. Avena (351), Department of Psychology, Princeton University, Princeton, NJ 08544, USA David A. Baker (33), Department of Biomedical Sciences, Marquette University, Schroeder Health Sciences Complex, Suite 426, PO Box 1881, Milwaukee, WI 53233, USA R. Billiras (485), Institut de Recherches Servier, Department of Psychopharmacology, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France Ernst Brodin (473), Pharmacological Pain Research, Department of Physiology and Pharmacology, Karolinska Institutet, SE-17177 Stockholm, Sweden Martin Brunner (625), Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria Peter M. Bungay (131), National Institutes of Health, Division of Bioengineering & Physical Science, Office of Research Services, Building 13/3N17, Bethesda, MD 20892-5766, USA Richard M. Caprioli (251), Department of Biochemistry, Mass Spectrometry Research Center, Vanderbilt University School of Medicine, 465 21st Ave S, 9160 Medical Research Building III, Nashville, TN 37232, USA Chandra S. Chaurasia (513), Food and Drug Administration, Division of Bioequivalence, Rockville, MD 20855, USA Vladimir I. Chefer (131), National Institute on Drug Abuse, National Institutes of Health, Integrative Neuroscience Section, Behavioral Neuroscience Branch, Baltimore, MD 21224, USA Kevin C. Chen (47), Department of Chemical & Biomedical Engineering, Florida State University, Rm B337, 2525 Pottsdamer Street, Tallahassee, FL 32310-6046, USA Belinda W.Y. Cheung (601), Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA L. Cistarelli (485), Institut de Recherches Servier, Department of Psychopharmacology, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France Thomas I.F.H. Cremers (17), Department of Biomonitoring and Sensoring,University of Groningen, University Center for Pharmacy, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands Fre´de´ric Dailler (659), Service d’Anesthe´sie-Re´animation, Groupement Hospitalier Est, Hospices Civils de Lyon, 59 Bd Pinel, 69677 Bron Cedex, France v
vi
Robert L. Dedrick (131), National Institutes of Health, Division of Bioengineering & Physical Science, Office of Research Services, Building 13/3N17, Bethesda, MD 20892-5766, USA Elizabeth C.M. de Lange (545), Leiden/Amsterdam Center for Drug Research, Leiden University, Division of Pharmacology, Gorleaus Laboratories, Einsteinweg 55, PO Box 9502, 2300 RA Leiden, The Netherlands Maria A. de Souza Silva (71), Institute of Physiological Psychology, Heinrich-Heine University of Du¨sseldorf, Universita¨tsstr. 1, 40225 Du¨sseldorf, Germany B. Di Cara (485), Institut de Recherches Servier, Department of Psychopharmacology, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France Matthijs G.P. Feenstra (317), Netherlands Institute for Neurosciences, Meibergdreef 33, 1105 AZ Amsterdam ZO, The Netherlands Marianne Fillenz (455), Department of Physiology, University of Oxford, Parks Road, Oxford, OX1 3PT, UK Raul R. Gainetdinov (399), Department of Cell Biology, Duke University Medical Center, Box 3287, Durham, NC 27710, USA Maria G. Giovannini (399), Department of Pharmacology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy S. Girardon (485), Institut de Recherches Servier, Department of Psychopharmacology, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France A. Gobert (485), Institut de Recherches Servier, Department of Psychopharmacology, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France Margareta Hammarlund-Udenaes (589), Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Box 591, 751 24 Uppsala, Sweden Luis Herna´ndez (267, 351), Escuela de Medicina, Laboratorio de Fisiologia de la Conducta, Universidad de los Andes, Me´rida 5101, Venezuela Bart G. Hoebel (351), Department of Psychology, Princeton University, Princeton, NJ 08544, USA K. Hoogenberg (645), Martini Hospital, Department of Internal Medicine, PO Box 30033, 9700 RM Groningen, The Netherlands Kirsten D. Huinink (217), Department of Psychiatry University Medical Centre Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB Groningen, The Netherlands Joseph P. Huston (71), Institute of Physiological Psychology, Heinrich-Heine University of Du¨sseldorf, Universita¨tsstr. 1, 40225 Du¨sseldorf, Germany Peter W. Kalivas (33), Department of Neurosciences, Medical University of South Carolina, BSB-403, 173 Ashley Ave, Charleston, SC 29425, USA Jan Kehr (111), Karolinska Institutet, Department of Physiology and Pharmacology, Nanna Svartz va¨g 2, 17177 Stockholm, Sweden Robert T. Kennedy (279), Department of Chemistry, University of Michigan, 930 N. University Ave, Ann Arbor, MI 48109-1055, USA Peter T. Kissinger (169), Bioanalytical Systems Inc. (BASi), 2701 Kent Avenue, West Lafayette, IN 479061350, USA Jakob Korf (217), Department of Psychiatry, University Medical Centre Groningen, University of Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands Thomas Lieutaud (659), Service d’Anesthe´sie-Re´animation, Groupement Hospitalier Est, Hospices Civils de Lyon, 59 Bd Pinel, 69677 Bron Cedex, France Astrid C.E. Linthorst (301), Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol, BS1 3NY, UK
vii
Adrian C. Michael (93), Department of Chemistry, University of Pittsburgh, 219 Parkman Ave, Pittsburgh, PA 15260, USA Yvette Michotte (233, 435), Department of Pharmaceutical Chemistry, Drug Analysis & Drug Information, Research Group Experimental Pharmacology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium M.J. Millan (485), Department of Psychopharmacology, Institut de Recherches Servicer, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France Paul F. Morrison (131), National Institutes of Health, Division of Bioengineering & Physical Science, Office of Research Services, Building 13/3N17, Bethesda, MD 20892-5766, USA Christian P. Mu¨ller (71), Institute of Physiological Psychology, Heinrich-Heine University of Du¨sseldorf, Universita¨tsstr. 1, 40225 Du¨sseldorf, Germany Markus Mu¨ller (625), Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria George G. Nomikos (183), Amgen Inc., Cambridge Research Center, Neuroscience, One Kendall Square, Bldg 1000, Cambridge, MA 02139, USA T.P. Obrenovitch (201), Pharmacy, School of Life Sciences, University of Bradford, Richmond Road, Bradford, West Yorkshire, UK William T. O’Connor (419), Applied Neurotherapeutics Research Group, School of Biomolecular & Biomedical Sciences, UCD Conway Institute, University College, Dublin Weite H. Oldenziel (17), Department of Biomonitoring and Sensoring, University of Groningen, University Center for Pharmacy, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands Ximena Pa´ez (351), Laboratory of Behavioral Physiology, School of Medicine, Universidad de los Andes, Me´rida 5101, Venezuela F. Panayi (485), Institut de Recherches Servier, Department of Psychopharmacology, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France Daniel Paredes (267), Escuela de Medicina, Laboratorio de Fisiologia de la Conducta, Universidad de los Andes, Me´rida 5101, Venezuela Giancarlo Pepeu (377), Department of Pharmacology, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy Pedro V. Rada (267, 351), Escuela de Medicina, Laboratorio de Fisiologia de la Conducta, Universidad de los Andes, Me´rida 5101, Venezuela Kieran Rea (17), Department of Pharmacology, National University of Ireland, Galway Bernard Renaud (659), Service de Biochimie, Hoˆpital Neurologique, Groupement Hospitalier Est, Hospices Civils de Lyon, 59 Bd Pinel, 69677 Bron Cedex, France and Plateforme de Neurochimie Fonctionnelle, Faculte´ de Pharmacie, Universite´ Claude Bernard et Institut Fe´de´ratif des Neurosciences de Lyon, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France J.M. Rivet (485), Institut de Recherches Servier, Department of Psychopharmacology, 125 Chemin de Ronde, 78290 Croissy sur Seine, Paris, France Hans Rollema (513), Pfizer Global Research and Development, Department of Neuroscience, Groton Laboratories, MS 8220-4159, Eastern Point Road, Groton, CT 06340, USA Sergio Rossell (267), Escuela de Medicina, Laboratorio de Fisiologia de la Conducta, Universidad de los Andes, Me´rida 5101, Venezuela Elham Rostami (675), Karolinska Institutet, Department of Physiology and Pharmacology, Nanna Svartz Rd 2, 171 77 Stockholm, Sweden Sophie Sarre (233), Department of Pharmaceutical Chemistry, Drug Analysis & Drug Information, Research Group Experimental Pharmacology, Vrije Universiteit Brussel, Laarbeeklaan 103, B-1090 Brussels, Belgium
viii
Ronald J. Sawchuk (601), Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Weaver-Densford Hall, Room 9-143, 308 Harvard St. SE, Minneapolis, MN 55455, USA A.J.M. Schoonen (645), Biomonitoring & Sensoring, Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands Trevor Sharp (5), Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK Ilse Smolders (435), Department of Pharmaceutical Chemistry, Drug Analysis & Drug Information, Research Group Experimental Pharmacology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium Tatyana D. Sotnikova (399), Department of Cell Biology, Duke University Medical Center, Box 3287, Durham, NC 27710, USA Carl-Olav Stiller (473), Clinical Pharmacology, Department of Medicine, Karolinska University Hospital, SE-17177, Stockholm, Sweden Bradley K. Taylor (473), Department of Pharmacology, Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA 70112-2699, USA Tung-Hu Tsai (573), Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, 155 Li-Nong Street Section 2, Taipei 112, Taiwan Sonia Tucci (267), Escuela de Medicina, Laboratorio de Fisiologia de la Conducta, Universidad de los Andes, Me´rida 5101, Venezuela Urban Ungerstedt (675), Karolinska Institutet, Department of Physiology and Pharmacology, Nanna Svartz Rd 2, 171 77 Stockholm, Sweden J. Urenjak (201), Pharmacy, School of Life Sciences, University of Bradford, Richmond Road, Bradford, West Yorkshire, BD7 1DP, UK Ben H.C. Westerink (17), Department of Biomonitoring and Sensoring, University of Groningen, University Center for Pharmacy, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands K.J.C. Wientjes (645), Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands Agustin Zapata (131), National Institute on Drug Abuse, National Institutes of Health, Integrative Neuroscience Section, Behavioral Neuroscience Branch, Baltimore, MD 21224, USA Tyra Zetterstro¨m (5), Department of Pharmacology, School of Pharmacy, De Montfort University, Leicester, UK
Preface
It is now about 25 years ago that Swedish researchers introduced microdialysis. The method represents an elegant technique based on a simple principle: the extracellular space is sampled via a dialysis membrane in a needle-like probe. Meanwhile, microdialysis has become a routine practice in numerous neuroscience laboratories and over the years many scientists have contributed to the development of the technique. We invited a number of them to summarize the significance of microdialysis for their particular field. The fascinating aspect of microdialysis is that it provides a direct look into extracellular compartments of living animals or humans. During the first years of its application, various ‘‘classical neurotransmitters’’ such as dopamine, serotonin, acetylcholine, GABA and glutamate were investigated with great enthusiasm and creativity. Throughout this volume much of these efforts are summarized. A critical evaluation of the physiological significance of compounds monitored by microdialysis is constantly needed. The first series of chapters in this volume deal with the specificity and interpretation of microdialysis data. Typical microdialysis issues are not ignored, such as the never ending discussions on the ‘‘recovery’’ and ‘‘true’’ extracellular concentrations of the sampled endogenous or exogenous compounds. Neurotransmitters are very efficiently removed after their release, and as a consequence they appear in the chromatograms as the tiniest peaks. Therefore, quantitation of these compounds puts high demands on the detection limits of analytical methods. Without the development of bioanalytical techniques such as liquid chromatography, electrochemical detection, capillary electrophoresis and liquid chromatography/ mass spectrometry, microdialysis would have no practical value. Several chapters in this volume are therefore dedicated to analytical chemistry aspects. Until now liquid chromatography in conjunction with electrochemical or fluorimetric detection has been the most widely used method. Capillary electrophoresis with laser-induced fluorimetric detection seems a very promising novel technique for the fast detection of small amounts of analytes. Note that the world speed record in microdialysis detection is presently in the hands of Dr. Hernandez’ group who were able to detect glutamate in 1 s samples (Chapter 3.3). Microdialysis combined with liquid chromatography/mass spectrometry is still progressing. This powerful analytical method will connect the probe directly to the world of peptidomics. As microdialysis combined with a guide canula is well tolerated in freely behaving animals, many scientists studied the chemistry of behaviour and have made remarkable progress. Animals that feed, run, mate or crave for drugs of abuse are equipped with probes while their neurotransmitter profile is simultaneously being recorded. Several contributions to this topic are included in this volume. Microdialysis is successfully applied in animal models of parkinsonism, stroke, depression, schizophrenia, etc. It is of great significance that the method is also applicable to genetically modified mice. Seven chapters deal with the role of microdialysis in drug development and PK-PD. Microdialysis is very suitable to study blood–brain transport mechanisms and protein binding. The method originated in brain research is still mostly focused on the central nervous system, but the number of applications in peripheral systems is also rapidly growing. By simultaneously sampling blood and brain tissue a full pharmacokinetic profile is obtained. The last three chapters of this volume are dedicated to clinical applications. Although bedside microdialysis in not yet routinely done, clinical studies have taught us much about the pathology of the brain ix
x
during conditions of certain neurological diseases and trauma. An interesting example of a clinical application is presented by the development of the human glucose sensor. In the near future more sophisticated sampling methods will certainly be introduced. Soon specific microsensors will deliver real-time chemical signals from the extracellular compartment with the help of telemetric devices. However, due to its simplicity and versatility, microdialysis will remain an efficient research tool for generations of biochemists and neuroscientists for many years to come. We hope that this book might inspire many scientists to further explore the opportunities of this fascinating technique. Ben H.C. Westerink Thomas I.F.H. Cremers
CHAPTER 1.1
What did we learn from microdialysis? Trevor Sharp1, and Tyra Zetterstro¨m2 1 Department of Pharmacology, University of Oxford, Oxford, UK Department of Pharmacology, School of Pharmacy, De Montfort University, Leicester, UK
2
Abstract: At the beginning of 1980s, microdialysis emerged as a novel method for monitoring brain neurochemistry in vivo. This was followed by a rapid, worldwide uptake of microdialysis and an explosion of papers reporting the application of the technique across a broad range of neuroscience research areas. This article discusses the historical background to in vivo neurochemical monitoring, and sets out the techniques available prior to the first microdialysis studies. Detail is then given of some of the events and people involved in one of the laboratories that played a central role in the development of microdialysis and the dissemination of this technique to the wider neuroscience community. Finally, some of the early experiments are outlined and used to illustrate a few of the many contributions that microdialysis has made to present-day neuroscience. neuroscience in which microdialysis has had particular value. First, we set out the background of in vivo neurochemical monitoring prior to the first microdialysis studies.
I. Introduction Since its inception and development in the early 1980s, microdialysis has arguably become one of the essential tools of modern neuroscience research. A quick search of recent literature databases reveals that the number of citations for ‘microdialysis/brain’ is comparable with those for ‘RT-PCR/brain,’ or indeed ‘microarray/brain’. Why did the neuroscience community take to this technique so keenly, and persist with it today largely in form unchanged from that developed over 20 years ago? Is this faith in the technique justified? The following is a personal perspective on the beginning of microdialysis and its emergence as a key neuroscience method. A particular emphasis is placed on its application to study CNS drug action. The reader is referred to other chapters in this book for an update on current developments and controversies relating to the technique, and for a broader perspective on the many areas of
II. Early studies of chemical transmission in the brain in vivo The background to microdialysis started with the studies in the 1950–1960s by groups of physiologists and pharmacologists, including Feldberg, Gaddum, Voigt and Mitchell, and their attempts to monitor chemical transmission in the living brain during a physiological event or in response to a drug challenge. Similar pioneering experiments by these workers and others (Feldberg and Gaddum, 1934; Dale et al., 1936) had already laid down the basic principles of chemical transmission at synapses in the periphery, and linked changes in transmitter secretion to functional outputs. The challenge was to carry these concepts forward to the complex neural networks of the brain. Many of these early studies investigated acetylcholine release because there was already a clear
Corresponding author: E-mail:
[email protected]
B.H.C. Westerink and T.I.F.H. Cremers (Eds.) Handbook of Microdialysis, Vol. 16 ISBN 0-444-52276-X
5
DOI: 10.1016/S1569-7339(06)16001-4 Copyright 2007 Elsevier B.V. All rights reserved
6
understanding of this messenger’s properties in peripheral neurones and there were useful bioassays available. Also, at that point of time, evidence of the huge diversity of chemical messengers in the brain was only just beginning to emerge. These early efforts to study chemical transmission in the brain principally utilised three approaches to detect transmitter secretion, all essentially based on perfusion of the extracellular space and chemical analysis of the perfusates: ventricular perfusion or sampling, cortical cup perfusion, and push–pull perfusion. Excellent reviews of these techniques and details of their early application can be found elsewhere (Myers, 1972; Moroni and Pepeu, 1984; Philippu, 1984). In early studies, perfusion of the cat’s ventricular system was achieved using a cannula inserted into one part of the system (typically lateral ventricles) and collection of the effluent using a cannula inserted into another part (e.g. aqueduct) (Bhattacharya and Feldberg, 1958; Carmichael et al., 1964). Chemical analysis of the ventricular contents, sometimes simply through repeated collection of the cerebrospinal fluid, remained in common use until the 1980s and extended to monoamines and other molecules (Tilson and Sparber, 1972; Elghozi et al., 1983; Sarna et al., 1984). Ventricular perfusion/sampling is a relatively non-invasive method to study brain neurochemistry in vivo, it has utility in large laboratory animals as well as small ones, and it has a clear translational value in that analogous measurements (cerebrospinal fluid sampling) can be carried out in humans. However, by its very nature this technique provides little direct information about chemical transmission in specific brain areas, which is obviously important in the context of understanding the complexities of brain function. The cortical cup technique enables sampling of chemicals released on the surface of the cerebral cortex (Moroni and Pepeu, 1984). This was achieved by placing a cylinder over the exposed cerebral cortex to form a small cup that was filled with physiological fluid, which was replaced and then analysed at regular intervals. Early studies demonstrated the utility of this method in sheep, cats and rabbits (Mitchell, 1963; Collier and Mitchell, 1966), largely in anaesthetised
preparations but also under non-anaesthetised conditions. Careful steps had to be taken to exclude contamination of the perfusion fluid by chemicals arising from blood, and methodological refinements allowed application of the technique in rats (Aquilonius et al., 1972). However, as with ventricular perfusion/sampling, a drawback of the cortical cup technique is the limited scope for regional brain analysis. Perfusion of specific brain areas was achieved using an open-ended arrangement of two concentric cannulae that allowed perfusion fluid to be ‘pushed’ into a particular brain area and then ‘pulled’ out to allow chemical analysis of the perfusates (see Philippu, 1984). The application of ‘push–pull’ perfusion to the brain has its origins in the works of Gaddum (1961) and others, in the 1960s, who adapted a system applied to subcutaneous tissue (Fox and Hilton, 1958), and the method played a dominant role in the field of in vivo neurochemistry for the next 25 years. As with ventricular perfusion and the cortical cup technique, studies with push–pull perfusion were focused on larger laboratory animals, often anaesthetised. Application in smaller animals was reported, but careful technical refinements of the cannula construction and perfusion conditions were necessary to minimise tissue disturbance from the open-ended system of perfusion (Myers et al., 1998). Studies utilising push–pull perfusion laid the foundations in many areas of in vivo neurochemical research that subsequently became a focus of microdialysis studies, including basic properties of transmitter release (Cheramy et al., 1981) and functional interactions between transmitter pathways (Glowinski et al., 1978; Philippu, 1984; Soubrie et al., 1984). The application of the above techniques was, however, often hampered by the challenge of detecting the trace amounts of transmitters in the perfusates using the relatively insensitive analytical methods available at the time. Transmitter detection was often at the limits of traditional bioassays, and reliable analysis was sometimes possible only through use of preloaded radio-labelled precursors or time-consuming radio-enzymatic methods. The eventual combination of push–pull perfusion with gas chromatography coupled to a
7
mass spectrometer provided the necessary sensitivity and specificity (e.g. Wolfensberger, 1984), but the application of this analytical technique clearly required specialist know-how and high start-up costs, which were available to only a few. Commencing in the 1970s, largely through the pioneering work of Adams and colleagues (McCreery et al., 1974; Conti et al., 1978), voltammetry offered a quite different approach to in vivo measurement of chemical transmission in the brain. This approach utilises various voltammetric scanning techniques to monitor levels of transmitter in the close vicinity of an implanted microelectrode. Although these early studies were restricted to measurement of those transmitter species that are electroactive, and specifically the monoamines (dopamine, noradrenaline and 5-HT), this technique held the promise of continuous online monitoring of transmitter secretion with high time resolution and anatomical specificity, and without the tissue disturbance associated with perfusion methods. However, despite initial enthusiasm it soon became apparent that the early voltammetric signals monitored in vivo comprised several chemical species, mostly monoamine metabolites and ascorbic acid. Therefore, at the end of the 1970s, it was recognised that significant advances in electrode design and voltammetric methodology would be needed to detect the monoamine transmitters themselves. As an alternative to direct in vivo monitoring of chemical transmission, neurochemical measurements of transmitter utilisation in post-mortem brain evolved during the 1960s to provide an index of transmitter activity immediately prior to removal of the tissue. This approach included ex vivo measurement of steady-state levels of transmitters and their metabolites, activity of key enzymes and rate of transmitter flux through biosynthetic or metabolic pathways. Measurements of transmitter utilisation were obtained within discrete brain regions across a range of species, and for a range of transmitters including catecholamines (Carlsson and Lindqvist, 1963; Roth et al., 1974; Westerink and Korf, 1976), 5-HT (Neff and Tozer, 1968; Fuller et al., 1974), GABA (Bertilsson et al., 1977) and acetylcholine (Racagni et al., 1976).
Studies of this sort, which were especially popular in the 1970s, laid down the first understanding of neurochemical mechanisms involved in transmitter utilisation in the brain and were applied to great effect to investigate the effect of physiological and pharmacological manipulations. However, measurement of transmitter utilisation, by its very nature, provides an indirect measure of transmitter released from the neurones. Also, complex experimental protocols and large numbers of animals were required to obtain a time resolution of the order of 10–20 min. Therefore, by the end of the 1970s, in vivo neurochemical techniques were available to study transmitter function in key brain structures of laboratory animals, but researchers were unable to approach many important questions because of the difficulties in routinely detecting the small amounts of transmitter released. In addition, the perfusion techniques were generally too invasive or too cumbersome for application in small laboratory animals (rats and mice), which at the time were the model of choice of many of the rapidly growing areas of in vivo neuroscience including neuropharmacology, functional neuroanatomy and especially behavioural science (for which there was also an obvious need to work without anaesthesia). On the other hand, voltammetry was much less invasive and could be used in small animals but the use of this technique was limited to a small number of electroactive transmitters, and at the time there were major uncertainties about the identity of the chemical species being monitored. In short, at the beginning of the 1980s, there was a strong need for an in vivo neurochemical technique that had the broad application and regional selectivity of perfusion methods, that could be linked to analytical methods with high sensitivity and selectivity and that was applicable to small laboratory animals.
III. The introduction of microdialysis There are various early descriptions of techniques in which the content of the brain extracellular space was sampled using probes constructed from semipermeable dialysis membranes. One of the earliest
8
involved a primitive dialysis bag that was temporarily implanted into the ventricular system of the dog, and then withdrawn for analysis of the bag contents (Bito et al., 1966). Of the many types of brain perfusion cannulae described, one consisted of two parallel cannulae and two electrodes called the ‘chemitrode’ developed by Delgado in Madrid (Delgado, 1962), and a variant of this, ‘the dialytrode’, which had a tip covered by a semipermeable membrane (Delgado et al., 1972; Cornish and Hall, 1979). The latter was not strictly a perfusion probe in that samples were withdrawn from the probe at regular intervals. In Stockholm, Ungerstedt had also picked up on the idea of designing perfusion probes constructed from a tube of semipermeable membrane (Ungerstedt and Pycock, 1974), and was specifically attracted by the concept of using such probes to act as an ‘artificial blood vessel’ to sample the brain extracellular space. Ungerstedt had already made seminal contributions to the anatomical mapping of dopamine pathways and modelling their function in behavioural paradigms (Ungerstedt, 1971), and he was now pressed by the idea of developing a technique capable of detecting dopamine release in the living brain. The attraction of perfusion probes based on a dialysis membrane was that there would be no direct contact between the brain tissue and the perfusion fluid. In theory this would circumvent any tissue damage caused by constant washing of tissue by the perfusion fluid, which occurred with openended perfusion cannulae, and at the same time provided an online clean-up of the samples of extracellular fluid. It was also hoped that the neurones and nerve terminals in the vicinity of the dialysis membrane remained bathed in ‘normal’ extracellular fluid rather than exogenous artificial media. Ungerstedt’s initial studies with probes constructed from thin dialysis membranes were hampered by difficulties in probe reliability and reproducibility, as well as difficulties in dopamine detection (Ungerstedt and Pycock, 1974). However, two events dramatically changed the situation. First, an intake of new graduate students (Tyra Zetterstro¨m and Ulf Tossman) in 1979 stimulated advances in probe design. Although simple in construction, the ‘dialysis-loop probe’ and ‘transcranial probe’ allowed problem-free perfusion of discrete
brain areas in a small laboratory animal (specifically the rat). Moreover, the Stockholm group found that animals could be perfused in the absence of anaesthesia by connecting the probes to a liquid swivel and using a harness to restrain the animal within the confines of a circular Perspex chamber. This step forward in probe construction was coincident with a second key development, the introduction into the Stockholm laboratory of a newly available HPLC with electrochemical detection assay, which had sufficient sensitivity to detect dopamine in the ‘dialysates’. This analytical technique had developed spectacularly in just a few years since its initial description (Kissinger et al., 1973), and was commercially available by the mid-1970s. As a consequence of these advances, within a short period of time, the group began to accumulate dialysis data on dopamine. In addition, as the group developed and expanded with additional students (including Nils Lindefors and Lars Sta˚hle) and technicians (including Agneta Eliasson and Anna Karin Collin who joined A˚se Hallstro¨m), the group’s interests diversified to include studies of other chemical messengers and also the simultaneous monitoring of transmitter release during behaviour (Tomas Ljungberg and Mario HerreraMarschitz). Although little data had been published at this stage (a manuscript submitted to Nature was returned with a report from a referee which doubted whether one could do useful neuroscience ‘in a salad bowl’), news of the work in Stockholm began to spread, and in 1981 a graduate student of Gaetano Di Chiara in Caligary (Assunta Imperato) visited Stockholm to learn the technique. Data on the brain dialysis technique were presented to an international audience in 1981, first at a Congress on dopamine receptor pharmacology in Japan in June (Ungerstedt et al., 1982), followed by an International Summer School of Brain Research at the Royal Netherlands Academy of Sciences in Amsterdam in September, and a few weeks later at a meeting of the European Neuroscience Association in Liege. Also present at the Amsterdam meeting was a graduate student (Trevor Sharp) from Charles Marsden’s group in Nottingham, which was pioneering the neurochemical application of
9
electrochemical detection methods (HPLC and in vivo voltammetry). As a consequence, interactions between Nottingham and Stockholm commenced leading to exchanges in people (Sharp joined the Ungerstedt group), transfer of HPLC know-how (poor-resolution cation-exchange liquid chromatography columns were replaced by high-efficiency reverse-phase HPLC columns), the setting up of the dialysis technique in the UK laboratory, and a joint paper reporting initial microdialysis measurements of dopamine (Zetterstro¨m et al., 1983). Numerous interactions between Stockholm and other groups in Sweden (Gothenberg, Lund) and around the world very quickly followed, and Ungerstedt established a spin-off company (Carnegie Medicine from which grew CMA) to facilitate development of the method and to further increase the accessibility. During this period the brain dialysis technique went through several name changes including ‘intracerebral dialysis,’ ‘intracranial dialysis’ and ‘transcranial dialysis’, before general opinion fell in favour of ‘microdialysis’. Ungerstedt was quick to realise the potential of the microdialysis method for studying not only dopamine but also other transmitter systems, and in the early 1980s his group (together with several local collaborators including Ernst Brodin and Bertil Freedholm) was utilising a range of analytical techniques (HPLC with electrochemical and fluorescent detection, radioimmunoassays) to demonstrate the presence in the dialysates of detectable amounts of numerous other chemical messengers including purines (adenosine; Zetterstro¨m et al., 1982), amino acids (GABA, glutamate and aspartate; Tossman et al., 1983) and neuropeptides (Substance P and other tachykinins; Brodin et al., 1983). This interest expanded to include markers of metabolism and hypoxia such as lactate (Hallstro¨m et al., 1989), which provided the basis for the clinical application of microdialysis that Ungerstedt and others developed over the ensuing years (Hillered et al., 1990; Meyerson et al., 1990).
IV. Early microdialysis studies in Stockholm Many of the initial microdialysis studies carried out by the Ungerstedt group focused on basic
aspects of dopamine pharmacology and neurochemistry. A succession of the group’s publications in the early 1980s demonstrated that extracellular dopamine showed dramatic changes in response to administration of a range of drugs. With today’s perspective, most of the observations accorded with predictions but at the time each result was a source of amazement because in most instances it was the first occasion that such measurements were possible. The findings included increases in dopamine in response to amphetamines, inhibitors of dopamine reuptake and metabolism, dopamine precursor loading, and dopamine receptor antagonists, and decreases in response to dopamine receptor agonists and dopamine neurotoxins (Zetterstro¨m et al., 1983, 1984, 1986a, c; Zetterstro¨m and Ungerstedt, 1984; Sharp et al., 1986b). Other emerging microdialysis groups independently obtained similar data (Imperato and Di Chiara, 1984; Kato et al., 1986; Kito et al., 1986; Westerink and Tuinte, 1986; Church et al., 1987; Butcher et al., 1988; Imperato et al., 1988). Many of the early microdialysis experiments in Stockholm were carried out in conscious animals, and this allowed a side-by-side comparison of changes in dopamine with alterations in behaviour, something that had not been achievable with earlier in vivo monitoring methods. An obvious starting point for such experiments was to study amphetamine, a drug with behavioural effects that had long been associated with increased release of dopamine. Using a simple behavioural chamber and home-made harness for securing perfusate collecting tubes (Sharp et al., 1986a), experiments demonstrated a close correlation between, on the one hand, amphetamine-induced behavioural stereotypes and dopamine released in striatum, and on the other hand, amphetamine-induced locomotor stimulation and dopamine released in the nucleus accumbens (Sharp et al., 1987a). These findings fitted closely the predictions of an earlier literature based on studies of the behavioural effects of dopamine lesions and intracerebral drug injection (Kelly, 1977). At this time some of the first microdialysis experiments correlating the behavioural effects of cocaine with changes in extracellular dopamine were also reported (Pettit and Justice, 1989).
10
Separate experiments found a strong correlation between the increase of striatal dopamine induced by amphetamine as well as L-DOPA, and rotation in rats with unilateral dopamine denervation (the ‘Ungerstedt rotation model’) (Zetterstro¨m et al., 1986b). The latter finding was the first direct evidence that L-DOPA increases dopamine output in dopamine denervated tissue, which of course was predicted from the known therapeutic efficacy of L-DOPA in Parkinson’s disease. The Stockholm laboratory in collaboration with Anders Bjorklund’s group in Lund also demonstrated that transplantation of rat foetal mesencephalic neurones into the striatum of dopamine denervated rats restored extracellular dopamine to near normal levels (Zetterstro¨m et al., 1986a; Strecker et al., 1987). Such data played a valuable role in the work by the Lund group and many others that provided a rational basis for the subsequent clinical trials of dopaminergic grafts in Parkinson’s patients. Although attempts in Stockholm to detect changes in dopamine release during the performance of conditioned and non-conditioned behavioural tasks were hampered by technical problems, many groups reported success in subsequent years (Westerink, 1995; see Feenstra, this volume). In the early experiments, it was immediately apparent that dialysate levels of dopamine metabolites (DOPAC and HVA) were up to 100 times greater than dopamine (Zetterstro¨m et al., 1983). This finding had clear implications for voltammetry studies using electrodes that could not readily discriminate between dopamine and the metabolites. Indeed, a side-by-side comparison of voltammetry (specifically, differential pulse voltammetry) and microdialysis helped reveal that DOPAC and not dopamine was a major contributor to the voltammetric signal for catechols (Sharp et al., 1984). Findings of high levels of uric acid in the dialysates (Zetterstro¨m et al., 1983) led to the discovery that another voltammetric signal, previously attributed to indoles (5-HT and its metabolites), was in fact contaminated by this purine metabolite (Crespi et al., 1983). Work of this sort, alongside efforts by many others, helped to stimulate advances in voltammetric methodology to increase monoamine selectivity, including the application of surface-modified electrodes
(Crespi et al., 1988) and the shift towards fast scanning voltammetry with its greater chemical and temporal resolution (Marsden et al., 1988; Kawagoe et al., 1993). Another issue raised by the early studies comparing dopamine and dopamine metabolites was that in many experiments there was a poor correlation between the two. These results were a surprise because the prevailing view was that the metabolites were a good marker of dopamine release as they were produced from recently released and reuptaken dopamine. To account for the findings a different view of dopamine neurochemistry emerged, in which the metabolites were seen to have originated from the metabolism of cytoplasmic newly synthesised dopamine, before it is released (Commisong, 1985; Zetterstro¨m et al., 1986c, 1988; Butcher et al., 1988). While this theory predicted the metabolism of large amounts of unused dopamine, the dopamine nerve terminal would have access to large amounts of dopamine derived directly from tyrosine hydroxylase under conditions of high demand (i.e. increased dopaminergic activity). The situation envisaged directly paralleled that independently proposed for 5-HT neurones (Grahame-Smith, 1974; Kuhn et al., 1985). These findings emphasised that the monoamine metabolites provided an indirect measure of monoamine release, and today the metabolites are rarely used for this purpose.
V. Microdialysis and neuropharmacology On the basis of the early microdialysis studies of the effects of pharmacological manipulation of the dopamine system, it was clear that the technique had great potential for the study of drug action and the development of novel therapeutic agents. As the range of transmitters accessible to study through microdialysis rapidly increased, the areas of neuropharmacology in which microdialysis had value quickly broadened to include the study of antidepressant and anxiolytic agents among many others (L’Heureux et al, 1986; Kalen et al, 1988; Pei et al., 1989; Sharp et al., 1989b; Adell and Artigas, 1991; Wright et al., 1992; Tanda et al., 1994). Today microdialysis is a frontline technique
11
in research aimed at the identification and characterisation of novel pharmacological strategies for the treatment of common, disabling psychiatric conditions such as mood disorder, anxiety and schizophrenia. It is very likely that the next generations of therapeutic drugs for these illnesses will be strongly supported by microdialysis data. Some of the current exciting areas of neuropharmacology in which microdialysis is playing an important role are reviewed by Millan and Artigas in other chapters of this book. Another area of neuropharmacology in which microdialysis has had a large impact is the study of psychostimulants and other classes of addictive drugs. Indeed, microdialysis data are a cornerstone of current biological theories implicating mesolimbic dopamine (Di Chiara and Imperato, 1988) and more recently cortical amino acid systems in the processes leading up to drug addiction (McFarland and Kalivas, 2001; Hotsenpiller and Wolf, 2002) (see the chapter by Di Chiara). Interestingly, microdialysis studies of the effects of drug challenges in animals are currently assuming a special importance in the guidance and development of exciting new non-invasive PET imaging techniques to monitor transmitter release in humans (Laruelle, 2000). This novel approach is based on radioligand displacement methodology, and studies are using transmitter release data derived from microdialysis studies to interpret displaceability (or lack of it) of specific radioligands by competing transmitter. The most successful example of this research to date is the use of PET radioligand displacement as a measure of dopamine release, and this approach has translated from animal studies through to investigations in patients with psychiatric and neurological disorders (Laruelle and Huang, 2001). Studies combining microdialysis and PET are ongoing in an attempt to guide the development of radioligand displacement methods to monitor the release of many other transmitters including 5-HT (e.g. Hirani et al., 2003). In addition to PET imaging, microdialysis is likely to play an increasing role in the development and validation of other imaging modalities (functional magnetic resonance imaging, magnetic resonance spectroscopy) to monitor transmitter release.
VI. Microdialysis problems The initial popularity of microdialysis was not without consideration for the shortcomings of the technique, and especially the likely tissue damage induced by probe implantation. Prior to the 1980’s there was an existing literature on the deleterious effects on brain tissue of implanted probes (Edvinsson et al., 1971), and there was a realistic prospect that a proportion of transmitter in the dialysates derived from blood leaked from damaged nerve terminals or arose from non-neuronal cells. A series of studies in the mid-1980s addressed the crucial question of whether, and to what extent, transmitters in the dialysates derived from normally functioning nerve terminals by the application of a range of ‘transmitter criteria’ (Di Chiara, 1990; Westerink, 1995). For the monoamines, dopamine, noradrenaline and 5-HT, and acetylcholine it became clear that under a wide variety of experimental conditions, and with few exceptions, dialysate contents of these transmitters indeed arose predominantly from neuronal secretion (Imperato and Di Chiara, 1984; L’Heureux et al., 1986; Consolo et al., 1987; Kalen et al., 1988; Sharp et al., 1989a; Sharp and Zetterstro¨m, 1992). Specifically, dialysate levels of these transmitters decreased when excitation-secretion coupled release mechanisms were inhibited (low calcium, blockade of voltage-gated sodium channels), and increased when neurones were stimulated. The case was less clear, however, for the principal amino acid transmitters, glutamate and GABA (Bourdelais and Kalivas, 1992; Kehr and Ungerstedt, 1988; Osborne et al., 1990; Smith and Sharp, 1994; Timmerman and Westerink, 1997). Indeed, it is only in recent years that a more complete picture of the origins of these transmitters has emerged, as discussed in detail elsewhere in this volume (Baker et al., 2002; Rea et al., 2005; see also Westerink, this volume). By its very nature, the time resolution of neurotransmission of the brain perfusion technique cannot approach that of neurophysiological recording methods. Nethertheless, even early studies demonstrated that microdialysis sampling intervals of
12
the order of a minute were achievable through application of microbore HPLC (Church and Justice, 1987; Sharp et al., 1987b). Arguably one of the main drawbacks of microdialysis, is the narrow time window of a few days in which transmitter measurements can be made before data interpretation becomes complicated by the proliferation of glial cells around the implanted probe (Imperato and Di Chiara, 1984; Stro¨mberg et al., 1985; Benveniste et al., 1987). This reaction probably alters the chemical milieu of the extracellular space surrounding the microdialysis probe, particularly in relation to amino acid reuptake, synthesis, metabolism and release in which glial cells play important roles. Moreover, the proliferation of glial cells likely acts as a barrier-limiting movement of molecules to and from the microdialysis probe. It remains to be seen whether these problems can be circumvented through further miniaturization of microdialysis probes or alterations in probe materials and perfusion media. Until this situation improves, experiments requiring repeated measurements over a period of time from the same animal (e.g. during behavioural training, chronic drug administration or a progressive neuronal lesion) will remain problematic. Details of the effects of microdialysis probe implantation on brain tissue continue to be documented. One current theory is that monoamine nerve terminals in the immediate vicinity of the probe are damaged, resulting in underestimation of basal extracellular dopamine levels (Borland et al., 2005). This might explain the long-standing ‘thorny issue’ of why basal extracellular levels of dopamine and the other monoamines estimated by microdialysis (nanomolar) are several orders of magnitude lower than those estimated by fast cyclic voltammetry (micromolar). In contrast, other voltammetric modalities (differental pulse voltammetry) produce estimates similar to microdialysis (Crespi et al., 1988), suggesting that we have not yet arrived at the full answer. Perhaps Adams (1990) had the right one, ‘‘There is little merit in arguing as to which technique is giving the more correct values – both have questions about the suitability of their in vitro calibration proceduresy’’.
VII. Conclusions Since its inception in the early 1980s, quite remarkable progress has been made through the application of microdialysis to monitor the neurochemistry of the brain in vivo. On the basis of early experiments in Stockholm and other cities around the world, several things quickly became apparent. Firstly, the technique could be applied in small laboratory animals (rats and eventually mice), which were emerging as a key model system for many areas of neuroscience. Secondly, the number of neurochemicals in the extracellular space that were accessible to microdialysis stretched well beyond dopamine to encompass most other major transmitters and many other key brain metabolites. This offered the possibility to investigate not only chemical aspects of neurotransmission but also many fundamental neurochemical mechanisms in the brain including those relating to cerebral metabolism, haemodynamic control and other energy-dependent processes. Thirdly, neurochemical measurements could be made in conscious animals, which opened up avenues for the investigation of the chemical basis of behaviour that had not existed previously. Finally, and importantly, at least at face value the method had a technical and theoretical simplicity, and reasonably low costs. All of this put the technology well within the grasp of a very wide community of neuroscientists, and unlocked areas of research that previously had been difficult to penetrate and continue to be investigated today. Just a few of the many areas of neuroscience that have gained from this technological advance, and the people that have contributed, are covered herein. References Adams, R.N. (1990) In vivo electrochemical measurements in the CNS. Prog. Neurobiol., 35: 297–311. Adell, A. and Artigas, F. (1991) Effects of clomipramine on extracellular serotonin in the rat frontal cortex. Adv. Exp. Med. Biol., 294: 451–454. Aquilonius, S.M., Lundholm, B. and Windbladh, B. (1972) Effects of some anticholinergics on cortical acetylcholine release and motor activity in rats. Eur. J. Pharmacol., 20: 224–230.
13 Baker, D.A., Xi, Z.X., Shen, H., Swanson, C.J. and Kalivas, P.W. (2002) The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci., 22: 9134–9141. Benveniste, H., Drejer, A., Schousboe, A. and Diemer, N.H. (1987) Regional cerebral glucose phosphorylation and blood flow after insertion of a microdialysis fiber through the dorsal hippocampus in the rat. J. Neurochem., 49: 729–734. Bertilsson, L., Mao, C.C. and Costa, E. (1977) Application of principles of steady-state kinetics to the estimation of gamma-aminobutyric acid turnover rate in nuclei of rat brain. J. Pharmacol. Exp. Ther., 200: 277–284. Bhattacharya, B.K. and Feldberg, W. (1958) Perfusion of cerebral ventricles: effects of drugs on outflow from the cisterna and the aqueduct. Br. J. Pharmacol. Chemother., 13: 156–162. Bito, L., Davson, H., Levin, E., Murray, M. and Snider, N. (1966) The concentrations of free amino acids and other electrolytes in cerebrospinal fluid, in vivo dialysate of brain, and blood plasma of the dog. J. Neurochem., 13: 1057–1067. Borland, L.M., Shi, G., Yang, H. and Michael, A.C. (2005) Voltammetric study of extracellular dopamine near microdialysis probes acutely implanted in the striatum of the anesthetized rat. J. Neurosci. Methods, 146: 149–158. Bourdelais, A.J. and Kalivas, P.W. (1992) Modulation of extracellular gamma-aminobutyric acid in the ventral pallidum using in vivo microdialysis. J. Neurochem., 58: 2311–2320. Brodin, E., Lindefors, N. and Ungerstedt, U. (1983) Potassium evoked in vivo release of substance P in rat caudate nucleus measured using a new technique of brain dialysis and an improved substance P-radioimmunoassay. Acta Physiol. Scand. Suppl., 515: 17–20. Butcher, S.P., Fairbrother, I.S., Kelly, J.S. and Arbuthnott, G.W. (1988) Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J. Neurochem., 50: 346–355. Carlsson, A. and Lindqvist, M. (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh.), 20: 140–144. Carmichael, E.A., Feldberg, W. and Fleischhauer, K. (1964) Methods for perfusing different parts of the cat’s cerebral ventricles with drugs. J. Physiol., 173: 354–367. Cheramy, A., Leviel, V. and Glowinski, J. (1981) Dendritic release of dopamine in the substantia nigra. Nature, 289: 537–542. Church, W.H. and Justice, J.B. (1987) Rapid sampling and determination of extracellular dopamine. Anal. Chem., 59: 712–716. Church, W.H., Justice, J.B. Jr. and Byrd, L.D. (1987) Extracellular dopamine in rat striatum following uptake inhibition by cocaine, nomifensine and benztropine. Eur. J. Pharmacol., 139: 345–348. Collier, B. and Mitchell, J.F. (1966) Release of acetylcholine from the cerebral cortex during stimulation of the optic pathway. Nature, 210: 424–425. Commisong, J.W. (1985) Monoamine metabolites: their relationship and lack of relationship to monoaminergic neuronal activity. Biochem. Pharmacol., 34: 1127–1131.
Consolo, S., Fu Wu, C., Fiorentini, F., Ladinsky, H. and Vezzani, A. (1987) Determination of endogenous acetylcholine release in freely moving rats by transtriatal dialysis coupled to a radioenzymatic assay: effect of drugs. J. Neurochem., 48: 1459–1465. Conti, J.C., Strope, E., Adams, R.N. and Marsden, C.A. (1978) Voltammetry in brain tissue: chronic recording of stimulated dopamine and 5-hydroxytryptamine release. Life Sci., 23: 2705–2715. Cornish, K.G. and Hall, R.E. (1979) A modification of the dialytrode for simultaneous CNS recording and chemical stimulation. Pharmacol. Biochem. Behav., 10: 389–392. Crespi, F., Martin, K.F. and Marsden, C.A. (1988) Measurement of extracellular basal levels of serotonin in vivo using nafion-coated carbon fibre electrodes combined with differential pulse voltammetry. Neuroscience, 27: 885–896. Crespi, F., Sharp, T., Maidment, N. and Marsden, C. (1983) Differential pulse voltammetry in vivo–evidence that uric acid contributes to the indole oxidation peak. Neurosci. Lett., 43: 203–207. Dale, H.H., Feldberg, W. and Voigt, M. (1936) Release of acetylcholine at voluntary motor nerve endings. J. Physiol., 86: 353–380. Delgado, J.M.R. (1962) Pharmacological modifications of social behaviour. In: Paton, W.D.M. (Ed.), Pharmacological Analysis of Central Nervous System Action. Pergamon Press, Oxford, pp. 265–292. Delgado, J.M., DeFeudis, F.V., Roth, R.H., Ryugo, D.K. and Mitruka, B.M. (1972) Dialytrode for long term intracerebral perfusion in awake monkeys. Arch. Int. Pharmacodyn Ther., 198: 9–21. Di Chiara, G. (1990) In-vivo brain dialysis of neurotransmitters. Trends Pharmacol. Sci., 11: 116–121. Di Chiara, G. and Imperato, A. (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A., 85: 5274–5278. Edvinsson, L., Nielsen, K.C., Owman, C. and West, K.A. (1971) Alterations in intracranial pressure, blood-brain barrier, and brain oedema after sub-chronic implantation of a cannula into the brain of conscious animals. Acta Physiol. Scand, 82: 527–531. Elghozi, J.L., Mignot, E. and Le Quan-Bui, K.H. (1983) Probenecid sensitive pathway of elimination of dopamine and serotonin metabolites in CSF of the rat. J. Neural Transm., 57: 85–94. Feldberg, W. and Gaddum, J.H. (1934) The chemical transmitter at synapses in a sympathetic ganglion. J. Physiol., 81: 305–319. Fox, R.H. and Hilton, S.M. (1958) Bradykinin formation in human skin as a factor in heat vasodilatation. J. Physiol., 142: 219–232. Fuller, R.W., Perry, K.W., Wong, D.T. and Molloy, B.B. (1974) Effects of some homologues of 4-chloroamphetamine on brain serotonin metabolism. Neuropharmacology, 13: 609–614. Gaddum, J.H. (1961) Push–pull cannulae. J. Physiol., 155: 1P. Glowinski, J., Niecoullon, A. and Cheramy, A. (1978) Regulations of the activity of the nigrostriatal dopaminergic
14 pathways by cortical, cerebellar, and sensory neuronal afferences. Adv. Biochem. Psychopharmacol., 19: 75–87. Grahame-Smith, D.G. (1974) How important is the synthesis of brain 5-hydroxytryptamine in the physiological control of its central function? Adv. Biochem. Psychopharmacol., 10: 83–91. Hallstro¨m, A., Carlsson, A., Hillered, L. and Ungerstedt, U. (1989) Simultaneous determination of lactate, pyruvate, and ascorbate in microdialysis samples from rat brain, blood, fat, and muscle using high-performance liquid chromatography. J. Pharmacol. Methods, 22: 113–124. Hillered, L., Persson, L., Ponten, U. and Ungerstedt, U. (1990) Neurometabolic monitoring of the ischaemic human brain using microdialysis. Acta Neurochir. (Wien), 102: 91–97. Hirani, E., Sharp, T., Sprakes, M., Grasby, P. and Hume, S. (2003) Effect of endogenous 5-HT on [11C]MICRODIALYSISL 100907 binding investigated in rat brain using PET and immediate early gene expression. Synapse, 50: 251–260. Hotsenpiller, G. and Wolf, M.E. (2002) Extracellular glutamate levels in prefrontal cortex during the expression of associative responses to cocaine related stimuli. Neuropharmacology, 43: 1218–1229. Imperato, A. and Di Chiara, G. (1984) Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J. Neurosci., 4: 966–977. Imperato, A., Tanda, G., Frau, R. and Di Chiara, G. (1988) Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J. Pharmacol. Exp. Ther., 245: 257–264. Kalen, P., Strecker, R.E., Rosengren, E. and Bjo¨rklund, A. (1988) Endogenous release of neuronal serotonin and 5-hydroxyindoleacetic acid in the caudate-putamen of the rat as revealed by intracerebral dialysis coupled to high-performance liquid chromatography with fluorimetric detection. J. Neurochem., 51: 1422–1435. Kato, T., Dong, B., Ishii, K. and Kinemuchi, H. (1986) Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J. Neurochem., 46: 1277–1282. Kawagoe, K.T., Zimmerman, J.B. and Wightman, R.M. (1993) Principles of voltammetry and microelectrode surface states. J. Neurosci. Methods, 48: 225–240. Kehr, J. and Ungerstedt, U. (1988) Fast HPLC estimation of gamma-aminobutyric acid in microdialysis perfusates: effect of nipecotic and 3-mercaptoproprionic acids. J. Neurochem., 51: 1308–1310. Kelly, P.H. (1977) Drug-induced motor behaviour. In: Iversen, L.L., Iversen, S.D. and Snyder, S.H. (Eds.), Handbook in Psychopharmacology. Plenum Press, New York, pp. 295–332. Kissinger, P.T., Refshuage, C.J., Dreiling, R., Blank, L., Freman, R. and Adams, R.N. (1973) An electrochemical detector for liquid chromatography with picogram sensitivity. Anal. Lett., 6: 465–477.
Kito, S., Shimoyama, M. and Arakawa, R. (1986) Effects of neurotransmitters or drugs on the in vivo release of dopamine and its metabolites. Jpn. J. Pharmacol., 40: 57–67. Kuhn, D.M., Wolf, W.A. and Youdim, M.B. (1985) 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats. Br. J. Pharmacol., 84: 121–129. Laruelle, M. (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab., 20: 423–451. Laruelle, M. and Huang, Y. (2001) Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. Q. J. Nucl. Med., 45: 124–138. L’Heureux, R., Dennis, T., Curet, O. and Scatton, B. (1986) Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission. J. Neurochem., 46: 1794–1801. Marsden, C.A., Joseph, M.H., Kruk, Z.L., Maidment, N.T., O’Neill, R.D., Schenk, J.O. and Stamford, J.A. (1988) In vivo voltammetry–present electrodes and methods. Neuroscience, 25: 389–400. McCreery, R.L., Dreiling, R. and Adams, R.N. (1974) Voltammetry in brain tissue: quantitative studies of drug interactions. Brain Res., 73: 23–33. McFarland, K. and Kalivas, P.W. (2001) The circuitry mediating cocaine-induced reinstatement of drug-seeking behavior. J. Neurosci., 21: 8655–8663. Meyerson, B.A., Linderoth, B., Karlsson, H. and Ungerstedt, U. (1990) Microdialysis in the human brain: extracellular measurements in the thalamus of parkinsonian patients. Life Sci., 46: 301–308. Mitchell, J.F. (1963) The spontaneous and evoked release of acetylcholine from the cerebral cortex. J. Physiol., 165: 98–116. Moroni, F. and Pepeu, G. (1984) The cortical cup technique. In: Marsden, C. (Ed.), Measurement of Transmitter Release In Vivo. Wiley, Chichester, pp. 63–80. Myers, R.D. (1972) Methods for perfusing different structures of the brain. In: Myers, R.D. (Ed.), Methods in Psychobiology. Academic Press, London, pp. 169–211. Myers, R.D., Adell, A. and Lankford, M.F. (1998) Simultaneous comparison of cerebral dialysis and push–pull perfusion in the brain of rats: a critical review. Neurosci. Biobehav. Rev., 22: 371–387. Neff, N.H. and Tozer, T.N. (1968) In vivo measurement of brain serotonin turnover. Adv. Pharmacol., 6: 97–109. Osborne, P.G., O’Connor, N.T., Drew, K.L. and Ungerstedt, U. (1990) An in vivo microdialysis characterization of extracellular dopamine and GABA in dorsolateral striatum of awake freely moving and halothane anaesthetised rats. J. Neurosci. Methods, 34: 99–105. Pei, Q., Zetterstrom, T. and Fillenz, M. (1989) Both systemic and local administration of benzodiazepine agonists inhibit the in vivo release of 5-HT from ventral hippocampus. Neuropharmacology, 28: 1061–1066. Pettit, H.O. and Justice, J.B. (1989) Dopamine in the nucleus accumbens during cocaine self-administration as studie by in
15 vivo microdialysis. Pharmacol. Biochem. Behav., 34: 899–904. Philippu, A. (1984) Use of push–pull perfusion cannulae to determine the release of endogenous neurotransmitters in distinct brain areas of anaesthetised and freely moving animals. In: Marsden, C. (Ed.), Measurement of Transmitter Release In Vivo. Wiley, Chichester, pp. 3–38. Racagni, G., Cheney, D.L., Zsilla, G. and Costa, E. (1976) The measurement of acetylcholine turnover rate in brain structures. Neuropharmacology, 15: 723–736. Rea, K., Cremers, T.I. and Westerink, B.H. (2005) HPLC conditions are critical for the detection of GABA by microdialysis. J. Neurochem., 94: 672–679. Roth, R.H., Walters, J.R. and Morgenroth, V.H. III. (1974) Proceedings: effects of alterations in impulse flow on transmitter metabolism in central dopaminergic neurons. Psychopharmacol. Bull., 10: 40. Sarna, G., Hutson, P.H. and Curzon, G. (1984) A technique for repeated sampling of cerebrospinal fluid in freely moving rats and its uses. J. Physiol. (Paris), 79: 536–537. Sharp, T., Bramwell, S.R., Clark, D. and Grahame-Smith, D.G. (1989a) In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. J. Neurochem., 53: 234–240. Sharp, T., Bramwell, S.R. and Grahame-Smith, D.G. (1989b) 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br. J. Pharmacol., 96: 283–290. Sharp, T., Ljungberg, T., Zetterstrom, T. and Ungerstedt, U. (1986a) Intracerebral dialysis coupled to a novel activity box–a method to monitor dopamine release during behaviour. Pharmacol. Biochem. Behav., 24: 1755–1759. Sharp, T., Maidment, N.T., Brazell, M.P., Zetterstro¨m, T., Ungerstedt, U., Bennett, G.W. and Marsden, C.A. (1984) Changes in monoamine metabolites measured by simultaneous in vivo differential pulse voltammetry and intracerebral dialysis. Neuroscience, 12: 1213–1221. Sharp, T. and Zetterstro¨m, T. (1992) In vivo measurement of monoamine neurotransmitter release and metabolism using brain microdialysis. In: Stamford, J.A. (Ed.), Monitoring Neuronal Activity: A Practical Approach. Oxford, University Press, pp. 147–179. Sharp, T., Zetterstro¨m, T., Ljungberg, T. and Ungerstedt, U. (1987a) A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res., 401: 322–330. Sharp, T., Zetterstro¨m, T., Series, H.G., Carlsson, A., Yrahame-Smith, D.G. and Ungerstedt, U. (1987b) HPLC-EC analysis of catechols and indoles in rat brain dialysates. Life Sci., 41: 869–872. Sharp, T., Zetterstro¨m, T. and Ungerstedt, U. (1986b) An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis. J. Neurochem., 47: 113–122. Smith, S.E. and Sharp, T. (1994) An investigation of the origin of extracellular GABA in rat nucleus accumbens measured in
vivo by microdialysis. J. Neural Transm. Gen. Sect., 97: 161–171. Soubrie, P., Reisine, T.D. and Glowinski, J. (1984) Functional aspects of serotonin transmission in the basal ganglia: a review and an in vivo approach using the push–pull cannula technique. Neuroscience, 13: 605–625. Strecker, R.E., Sharp, T., Brundin, P., Zetterstro¨m, T., Ungerstedt, U. and Bjo¨rklund, A. (1987) Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience, 22: 169–178. Stro¨mberg, I., Herrera-Marschitz, M. and Ungerstedt, U. (1985) Chronic implants of chromaffin tissue into the dopamine-denervated striatum. Effects of NGF on graft survival, fiber growth and rotational behaviour. Exp. Brain Res., 60: 335–349. Tanda, G., Carboni, E., Frau, R. and Di Chiara, G. (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl.), 115: 285–288. Tilson, H.A. and Sparber, S.B. (1972) Studies on the concurrent behavioral and neurochemical effects of psychoactive drugs using the push–pull cannula. J. Pharmacol. Exp. Ther., 181: 387–398. Timmerman, W. and Westerink, B.H. (1997) Brain microdialysis of GABA and glutamate: what does it signify? Synapse, 27: 242–261. Tossman, U., Eriksson, S., Delin, A., Hagenfeldt, L., Law, D. and Ungerstedt, U. (1983) Brain amino acids measured by intracerebral dialysis in portacaval shunted rats. J. Neurochem., 41: 1046–1051. Ungerstedt, U. (1971) Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiol. Scand. Suppl., 367: 1–48. Ungerstedt, U. and Pycock, C. (1974) Functional correlates of dopamine neurotransmission. Bull. Schweiz. Akad. Med. Wiss., 30: 44–55. Ungerstedt, U., Herrera-Marschitz, M., Jungnelius, U., Sta˚hle, L., Tossman, U. and Zetterstro¨m, T. (1982) Dopamine synaptic mechanisms reflected in studies combining behavioural recordings and brain dialysis. In: Kohsaka, H. (Ed.), Advances in Dopamine Research. Pergamon Press, Oxford and New York, pp. 219–231. Westerink, B.H. (1995) Brain microdialysis and its application for the study of animal behaviour. Behav. Brain Res., 70: 103–124. Westerink, B.H. and Korf, J. (1976) Regional rat brain levels of 3,4-dihydroxyphenylacetic acid and homovanillic acid: concurrent fluorometric measurement and influence of drugs. Eur. J. Pharmacol., 38: 281–291. Westerink, B.H. and Tuinte, M.H. (1986) Chronic use of intracerebral dialysis for the in vivo measurement of 3,4-dihydroxyphenylethylamine and its metabolite 3,4-dihydroxyphenylacetic acid. J. Neurochem., 46: 181–185. Wolfensberger, M. (1984) Gas-chromatographic and massfragmentographic measurement of amino acids released into brain perfusates collected in vivo by push–pull cannula techniques. In: Marsden, C. (Ed.), Measurement of Transmitter Release In Vivo. Wiley, Chichester, pp. 39–62.
16 Wright, I.K., Upton, N. and Marsden, C.A. (1992) Effect of established and putative anxiolytics on extracellular 5-HT and 5-HIAA in the ventral hippocampus of rats during behaviour on the elevated X-maze. Psychopharmacology (Berl.), 109: 338–346. Zetterstro¨m, T. and Ungerstedt, U. (1984) Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis. Eur. J. Pharmacol., 97: 29–36. Zetterstro¨m, T., Brundin, P., Gage, F.H., Sharp, T., Isacson, O., Dunnett, S.B., Ungerstedt, U. and Bjorklund, A. (1986a) In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res., 362: 344–349. Zetterstro¨m, T., Herrera-Marschitz, M. and Ungerstedt, U. (1986b) Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats using intracerebral dialysis. Brain Res., 376: 1–7. Zetterstro¨m, T., Sharp, T., Collin, A.K. and Ungerstedt, U. (1988) In vivo measurement of extracellular dopamine and
DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur. J. Pharmacol., 148: 327–334. Zetterstro¨m, T., Sharp, T., Marsden, C.A. and Ungerstedt, U. (1983) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J. Neurochem., 41: 1769–1773. Zetterstro¨m, T., Sharp, T. and Ungerstedt, U. (1984) Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur. J. Pharmacol., 106: 27–37. Zetterstro¨m, T., Sharp, T. and Ungerstedt, U. (1986c) Further evaluation of the mechanism by which amphetamine reduces striatal dopamine metabolism: a brain dialysis study. Eur. J. Pharmacol., 132: 1–9. Zetterstro¨m, T., Vernet, L., Ungerstedt, U., Tossman, U., Jonzon, B. and Fredholm, B.B. (1982) Purine levels in the intact rat brain. Studies with an implanted perfused hollow fibre. Neurosci. Lett., 29: 111–115.
CHAPTER 1.2
Microdialysis of glutamate and GABA in the brain: analysis and interpretation Ben H.C. Westerink1,, Kieran Rea2, Weite H. Oldenziel1 and Thomas I.F.H. Cremers1 1
Department of Biomonitoring and Sensoring, University Center for Pharmacy, University of Groningen, Groningen, The Netherlands 2 Pharmacology Department, National University of Ireland, Galway
Abstract: Numerous studies have analyzed glutamate and GABA in microdialysis samples. It is a common practice among most researchers to relate changes in extracellular levels of glutamate and GABA directly to the activity of the corresponding neurons. However, several authors have expressed concern about this practice as basal values of glutamate and (to a certain extent) GABA do not fulfill the criteria for exocytotic release. In the present chapter, the significance and origin of glutamate and GABA as detected in microdialysates is discussed. In particular, the role of glial cells in the release and metabolism of the amino acids is emphasized. Special attention is given to the chemical analysis of GABA. productive and as many as 1,000 papers have been produced over the past 15 years. However, in contrast to neurotransmitters, such as the catecholamines, serotonin, and acetylcholine, it has been difficult to prove that levels of GABA and glutamate in dialysates originate from neuronal activity as the basal levels of these transmitters do not fulfill the criteria of exocytosis (calcium- and sodium-channel dependency) (Westerink et al., 1987; Millan et al., 1991; Herrera-Marschitz et al., 1996; Miele et al., 1996; Timmerman and Westerink, 1997). Despite the uncertainty of the origin of glutamate and GABA in dialysates, it is a common practice in most microdialysis studies to relate changes in extracellular levels directly to the activity of the corresponding neurons. In this chapter, we try to find explanations for the typical properties of GABA and glutamate in microdialysis experiments.
I. Introduction GABA and glutamate are the main inhibitory and excitatory neurotransmitters, respectively, in the central nervous system (CNS). Both neurotransmitters play an important role not only in the physiology of the brain, but also in various pathophysiological concepts, such as depression, schizophrenia, and epilepsy. In addition, the transmitters are implicated in the mechanism of action of a variety of centrally acting drugs. Therefore, detection of the synaptic release of glutamate and GABA directly into the brains of freely moving animals is of great significance to help us better understand of the role that these transmitters play in the homeostasis, as well as the pathology, of the CNS. Synaptic release of GABA and glutamate is often estimated by analysis of their extracellular concentrations in the brain, and in this regard, the microdialysis method is frequently used to monitor these transmitters. Research along this line has been very
II. Analysis of GABA and glutamate Microdialysis samples are relatively clean, as the dialysis membrane excludes cell fragments and
Corresponding author: E-mail:
[email protected]
B.H.C. Westerink and T.I.F.H. Cremers (Eds.) Handbook of Microdialysis, Vol. 16 ISBN 0-444-52276-X
17
DOI: 10.1016/S1569-7339(06)16002-6 Copyright 2007 Elsevier B.V. All rights reserved
18
large molecules, such as proteins. Amino acids in these samples are currently analyzed with chromatographic methods, such as HPLC or capillary electrophoresis (CE) without prior purification. II.A. HPLC analysis of GABA and glutamate To improve the chromatographic behavior and sensitivity of detection, amino acids are first derivatized with fluorogenic reagents, which are specific for primary amines, such as o-phthalaldehyde (OPA), fluorescamine, or naphthalene-2,3-dicarboxaldehyde (NDA) (Stobaugh et al., 1983; Jacobs et al., 1986). These fluorophores react with amines in the presence of a nucleophile (usually CN for NDA and a alkylthiol for OPA) to form electroactive and fluorescent derivatives. In microdialysis studies, OPA is most frequently used. The derivatization reaction occurs within minutes at room temperature. The reaction scheme is depicted in Fig. 1. For alkylthiol, mercaptoethanol or 3-mercaptopropionic acid are often used. Some authors use 3-mercaptopropionic acid and alkaline hypochlorite as these conditions increase the fluorescence of the derivatives and improve the stability of the fluorophores toward oxidation (Fiorino et al., 1989). Automated mixing followed by injection is often applied to perform the coupling reaction followed by online HPLC separation. For GABA, there is some concern in the literature about the stability of the reaction product with OPA. The poor stability (and also the stench of the thiol compound) was overcome by using tert-butylthiol (Allison et al., 1984) or by substitution of the OPA-alkylthiol reaction with an OPA-sulphite reaction (Smith and Sharp, 1994). However, it is our experience that the OPA-mercaptoethanol reaction product, once injected onto O
S R' H H
R'-SH
+
R-NH2
N R
O Fig. 1. The scheme for the reaction between amino acids, ophthalaldehyde (OPA) and alkylthiol.
the separation column, is very stable even at retention times as long as 60 min (Rea et al., 2005). A typical analysis of GABA and glutamate in the dialysates is carried out as follows. The derivative reagent consists of 100 mg OPA dissolved in 2-mL methanol and added to 200-mL 0.5-mol/L NaHCO3 containing 20-mL 2-mercaptoethanol. The reagent is freshly prepared daily. The pH is adjusted to 9.5 with NaOH. Next, 30 mL microdialysate samples is derivatized with 50-mL OPA/mercaptoethanol reagent, mixed, and allowed to react for 2 min. Fifty microliters of the reaction mixture is then injected by an autosampler onto the HPLC apparatus. The derivatization mixture is separated using an isocratic mobile phase and measured by fluorometric or electrochemical detection. The mobile phase consists of 70 mM di-sodium hydrogen phosphate, 400 mM EDTA, 0.15% (v/v) tetrahydrofurane, and methanol. To determine the optimal separation conditions, the organic modifier concentration can be varied between 30 and 40% (v/v) methanol. For optimal separation, the pH of the mobile phase is adjusted between 4.0 and 6.0 with phosphoric acid. The retention time of most of the derivatized amino acids is not very dependent on the pH; however, the GABA derivative is an exception in this respect. In our hands, there is only a small pH window in which GABA is reliably separated from the interfering peaks by fluorescence detection (Rea et al., 2005). A representative HPLC system consists of a reverse-phase column (e.g., 150 mm 4.6 mm; particle size, 3 mm), a high-precision pump (flow rate, 1.0 mL/min), and a fluorimetric (excitation l ¼ 350 nm, emission l ¼ 450 nm) or electrochemical detector. II.B. Capillary electrophoresis of GABA and glutamate Microdialysis produces small samples of volumes often less than 20 mL, making them of interest for separation by CE. Similarl to the HPLC methods, NDA or OPA are used as derivatizing agents and the reaction products are quantified by fluorimetric or electrochemical detection (O’Shea et al., 1992). Recently, various authors have demonstrated that the detection limit, and therefore, the temporal resolution of the microdialysis
19
experiment can be further improved, when CE is coupled with laser-induced fluorescence detection (CE–LIFD) (see references in Sauvinet et al., 2003). With such an approach, a sampling time of 1–30 s can be performed (see also Chapter 3.3). In a typical analysis of GABA and glutamate on CE, a 0.5-mL microdialysis sample is derivatized for 30 s with fluorescein isothiocyanate (14 h at room temperature) (Rada et al., 2003). Glutamate and GABA are then separated on a CE system equipped with an argon laser tuned at 488 nm. A disadvantage of the CE method is that the handling of nanoliter samples requires special care and specialized equipment. II.C. Online sensors for glutamate in microdialysates In the case of sampling glutamate by microdialysis, samples have been analyzed by continuous online detection ex vivo using enzyme-based miniaturized devices. One method makes use of the fluorescent properties of reduced nicotinamide adenine dinucleotide (NADH) formed by the metabolism of glutamate to a-ketoglutarate by glutamate oxidase, in the presence of NAD+ (Obrenovitch et al., 1993). In another approach, glutamate is electrochemically detected after conversion to H2O2 by glutamate dehydrogenase. To that end, amperometric electrodes have been constructed that detect H2O2 at glassy carbon surfaces modified by osmium-poly(4-vinylpyridine)gel and horseradish peroxidase (Niwa et al., 1996; Shi et al., 2003). As the samples are not separated by chromatography, the specificity of the electrode for glutamate is a matter of concern. Preventing interference of the detection by reducing compounds, such as ascorbic acid requires special pretreatment of the electrodes with ascorbic acid oxidase.
III. Microdialysis of glutamate: interpretation III.A. The origin of glutamate in the extracellular fluid questioned When neurotransmitters such as dopamine, noradrenaline, serotonin, and acetylcholine are sampled
Fig. 2. Effect of TTX infusion on extracellular levels of GABA and dopamine in the brain. Closed circles: dopamine, results obtained from Feenstra and Botterblom (1996). Open symbols: various studies on microdialysis of GABA, summarized in Timmerman and Westerink (1997).
by microdialysis, infusion of a sodium-channel blocker (e.g., tetrodotoxin TTX) or calcium-free Ringer leads to a rapid decline of the transmitter levels in the dialysis samples (Westerink et al., 1987). An example of this type of experiment is shown in Fig. 2. By using a 5-min sampling time, infusion of TTX resulted in a rapid and almost complete disappearance of dopamine from the extracellular fluid (ECF) (Feenstra and Botterblom, 1996). This result clearly demonstrates that dopamine sampled by microdialysis is very likely of synaptic origin. However, when similar experiments are performed for glutamate, the transmitter output does not respond. Therefore, various authors have expressed serious doubts whether glutamate sampled by microdialysis is derived from synaptic release (Westerink et al., 1987; Millan et al., 1991; Herrera-Marschitz et al., 1996; Miele et al., 1996; Timmerman and Westerink, 1997). An explanation for the peculiar behavior of glutamate in the ECF might be found in the specific role that this transmitter plays in neurotransmission. To assure a high signal-to-noise ratio of neurotransmission and to avoid excitotoxic actions of glutamate, the extracellular concentrations should be kept low (Katayama et al., 1990; Bergles
20
et al., 1999; Amara and Fontana, 2002). Released glutamate immediately needs to be removed from the synaptic cleft. For that reason, high-affinity glutamate transporters are localized in the vicinity of the synapse (Diamond and Jahr, 1997; Lehre and Danbolt, 1998). Glutamate concentrations in the synaptic cleft may reach concentrations of several millimoles and it has been calculated that glutamate transporters have the potency to bring concentrations in the ECF locally down to 20 nmol. Although these transporters are also present on glutamate neurons, the astroglial cells seem to play a dominant role in this respect. The intracellular concentration of glutamate in neurons is in the order of 10 mM, whereas in astrocytes, the concentration does not exceed 50 mM (due to the fact that glutamate in astrocytes is metabolized to glutamine). Several authors assume that (extrasynaptic) extracellular concentration of glutamate has to be maintained at 1–3 mM to assure a high signal-to-noise ratio for neurotransmission and to avoid excitotoxic actions of glutamate on neurons. Indeed, glutamate concentrations in the ECF determined by microdialysis are in the range of 1–4 mM (Zilkha et al., 1995; Niwa et al., 1996; Shiraishi et al., 1997; Lada et al., 1998); however, microsensor experiments have indicated concentrations around 25 mM (Kulagina et al., 1999; Oldenziel et al., submitted). As the glutamate transporters are not evenly distributed over the glial membranes, it is to be expected that the glutamate concentration will also display a heterogeneous concentration in the ECF. Moreover, there is accumulating evidence that astrocytes also release glutamate, which means that at certain sites, glutamate release will dominate over uptake (see further discussion below). Therefore, different extracellular compartments of glutamate might exist in the ECF. III.B. Is glutamate able to escape from the synaptic cleft? The first task of released glutamate is to mediate rapid point-to-point transmission within the synaptic cleft implicating that within a time frame of milliseconds, concentrations of several millimoles are reached and again removed. However,
under certain conditions, the transmitter seems to be able to escape from the synaptic cleft to stimulate extra- and heterosynaptic receptors in the perisynaptic environment (Arnth-Jensen et al., 2002; Rusakov and Lehre, 2002). This process is referred to as ‘‘spill-over’’. The extent of this glutamate spill-over depends on the amount and rate of escape of glutamate, the distance between adjacent synapses, and the location and abundance of glutamate transporters (Bergles et al., 1999). As the amount of transmitter spill-over is determined by the activity of the glutamate neurons, it has been hypothesized that certain perisynaptic receptors are only reached by glutamate during intense stimulus patterns. As the degree of astroglial wrapping of the synapse determines the distance that glutamate is able to migrate out of the synaptic cleft (Hawkins et al., 1995), the transporters appear to have a strategic role in the modulation of glutamate neurotransmission. The transporters may modify the time course of synaptic events, as well as the extent and pattern of activation, and desensitization of receptors outside the synaptic cleft and at neighboring synapses. Glutamate high-affinity transport is now recognized as a dynamic process. A variety of soluble compounds, for example, glutamate itself, cytokines, and growth factors, can influence the expression and activity of the glutamate transporters, and the extent to which astrocytic processes wrap around synapses (Danbolt, 2001; Amara and Fontana, 2002). These mechanisms allow a time-dependent modification of the efficacy of glutamate uptake, which in turn can shape extrasynaptic glutamergic transmission (Oliet et al., 2001; Nedergaard et al., 2002). Taken together, evidence is accumulating that under certain conditions, glutamate is able to escape from the synaptic cleft. During these conditions, glutamate might appear in ECF sampled by microdialysis. III.C. Glutamate released from astroglial cells: gliotransmission and other mechanisms For a long time, it was thought that astrocytes were passive cells with only an intermediate function between blood vessels and neurons. As astrocytes show only few responses to
21
electrophysiological recording techniques, the absence of electrical activity was interpreted as functional inactivity (Nedergaard et al., 2002; Volterra and Meldolesi, 2005). Nowadays, it is recognized that in many aspects, astrocytes are similar to neurons. Astrocytes communicate with each other by changing intracellular calcium, and gap junctions connect them with one another. Ca2+ signals may spread between astrocytes in the form of Ca2+ waves. Spontaneous calcium oscillations in astrocytes can excite neighboring neurons, but neurons can also activate astrocytes. In response to these changes in intracellular calcium, astrocytes release neurotransmitters, often described as gliotransmitters, whereas the process is called gliotransmission. This mechanism was first revealed in 1994 when increases in [Ca2+]i were shown to induce glutamate release followed by neuronal activation (Parpura et al., 1994). It is interesting to note that one of the first gliotransmitters described was glutamate. Over the years, the number of proposed gliotransmitters has increased (e.g., ATP, adenosine, D-serine, proteins, and peptides). The finding that astrocytes communicate chemically has triggered research on their functional role. Although many functions of astrocytes still need to be revealed, it is evident that they play a key role in many processes in the CNS, for example, in the glutamate–glutamine cycle, in the regulation of the cerebral blood flow, in the regulation, modulation, and synchronization of neuronal activities in both neurogenesis and synaptogenesis, in learning and memory, and in pathological processes in the brain (Nedergaard et al., 2002; Volterra and Meldolesi, 2005). However, a profound difference between the two cell types is the timescale: glial Ca2+ signals propagate at rates of micrometers per second, whereas action potentials propagate at rates of meters per second (Haydon, 2001). Several mechanisms of glutamate release from astroglia have now been described. Glutamate is released from astrocytes across the plasma membrane through specialized proteins, such as channels and transporters (Volterra and Meldolesi, 2005). Some mechanisms act during control conditions; others are only activated during
pathological states. Here, the different types of glutamate release that have been proposed are summarized. (1) Glutamate release regulated by volume-sensitive organic anion channels (VSOACs), also referred as volume-regulated anion channels (VRACs). Hypo-osmotic solutions activate these channels as part of the volume regulation and allow the efflux of aspartate, taurine, glutamate, chloride, and other anions in a calcium-independent manner. Activation of metabotropic glutamate receptors is also associated with astrocytic swelling (Hansson et al., 2000). (2) Glutamate released by GAP-junction hemichannels: they release both ATP and glutamate, and their opening probability is controlled by changes in intracellular Ca2+ concentrations (Hansson et al., 2000; Volterra and Meldolesi, 2005). (3) Glutamate release controlled by the purinergic P2X7 receptor: this receptor is gated by ATP and has been proposed to be involved in the release of glutamate as well as D-aspartate. It shares some properties with the GAP-junction hemichannels, including the increased opening probability at low Ca2+ concentration, but their pharmacology is different (Wang et al., 2004). (4) Sodium-dependent high-affinity heteroexchange mechanisms for glutamate and ascorbate, for glutamate and GABA, and for glutamate and glycine have been reported, but are poorly characterized (Raiteri et al., 2002). (5) Glutamate release mediated by a prostaglandin-dependent mechanism (Bezzi et al., 1998). (6) Reversal of sodium-dependent uptake by glutamate transporters: this does not seem to occur during normal brain functioning. It relates the massive release of glutamate from neurons and astrocytes after traumatic or ischemic injury to brain tissue (Benveniste et al., 1984; Katayama et al., 1990). (7) Glutamate release coupled to the cystineglutamate exchanger: this is a sodiumdependent glutamate transporter, which
22
can operate in the reverse mode, that is, cystine is exchanged for glutamate by transporting one molecule of cystine intracellularly for one molecule of glutamate out of the cell. The accumulated cystine is reduced to cysteine and in turn converted to glutathione (Warr et al., 1999; Baker et al., 2002; Chen and Swanson, 2003; Xi et al., 2003). (See Chapter 1.3 for further discussion.) III.D. Is glutamate released from astrocytes detectable in microdialysates? It is of interest to know whether the aforementioned mechanisms of glutamate release from astrocytes are detectable in microdialysates. Glutamate release from astrocytes is described as nonvesicular, although recently, a sort of vesicular release has been observed in the hippocampus (Bezzi et al., 2004). Nonexocytotic release of glutamate may occur via plasma membrane channels. Therefore, astrocytic release of glutamate will not likelyrespond to infusion of sodium-channel blockers (TTX). Similarly, most of the described release mechanisms from astrocytes are calcium independent or make use of mobilization of intracellular calcium stores. In this regard, depletion of calcium during microdialysis experiments will probably not affect glutamate release from astrocytes. It is hypothesized that astrocytic mGlu receptors sense glutamate that is released during synaptic transmission to adjust its extracellular concentration by modulating uptake activity. Interestingly, stimulation or inhibition of mGlu receptors by infusion of appropriate agonists/ antagonists was detectable in glutamate levels in microdialysates (Xi et al., 2003). As expected, this type of glutamate release was found to be TTX independent. Baker et al. (2002) provided evidence that by using specific agonists and antagonists, the cystine–glutamate antiporter is detectable in microdialysates (see Chapter 1.3). At present, it is a matter of debate whether this exchanger contributes to extracellular glutamate release during normal brain function or whether it occurs when the
energy metabolism of astrocytes is compromised (Nedergaard et al., 2002; Hertz and Zielke, 2004; Cavelier and Atwell, 2005). However, Baker et al. (2002) demonstrated that glutamate released by the antiporter was able to modify dopamine transmission. Other types of glutamate releases from astrocytes, for example, related to VSOACs, GAPjunction hemichannels, and the prostaglandin dependent as well as the purinergic P2X7 receptor mechanisms have poorly been studied so far in microdialysis studies. Presently, it is a matter of debate whether the different release mechanisms from astrocytes to operate under normal or pathological conditions. It is emphasized that implantation of a microdialysis probe causes extensive damage to brain, which implicates that this method represents a pathological rather than a physiological condition (see further discussion in Section III.H). III.E. Other sources of extracellular glutamate Apart from its role in neurotransmission, glutamate fulfills various other functions in the CNS. It serves as a precursor for peptide and protein synthesis, is involved in fatty acid synthesis, contributes to the regulation of ammonia levels, serves as a precursor for GABA, and is involved in carbohydrate metabolism. It is of interest to note that in terms of energy balance, the majority of glutamate metabolism in the brain is directed to glutamate release and uptake (see Chapter 1.3). As blood levels of glutamate are around 100 mmol/L, the general circulation should be considered as a possible source of extracellular glutamate. However, studies based on infusion of glutamate into the bloodstream indicated that the neurotransmitter penetrates the brain only after a considerable delay (Hawkins et al., 1995). Artificial sources of glutamate produced during microdialysis experiments should not be ruled out. It was recently shown that microbial contamination of the microdialysis system might confound glutamate detection because microorganisms can metabolize glutamate from glutamine. Sterilization of probes and tubing is necessary for implantation periods longer than 24 h (Zhou et al., 2002).
23
In our laboratory, we have observed that simply ‘handling’ of tubing that has been used before, can produce glutamate. These sources of glutamate are obviously not TTX dependent. Recently, the presence of D-glutamate in rat brain samples was reported (Quan and Liu, 2003). As D-glutamate is only transported by the lowaffinity glutamate uptake system and not converted inside astroglia to glutamine (Pow and Crook, 1996), its levels might accumulate in the ECF. As HPLC separations do not differentiate between the enantiomers, the possible contributions of D-glutamate to glutamate levels in the ECF need further investigation. However, preliminary experiments in our laboratory have shown that D-glutamate levels are less than 10% of Lglutamate and that this enantiomer does not respond to infusion of elevated potassium. III.F. Is synaptic glutamate detectable in microdialysates during excessive neuronal stimulation? Although many authors agree that basal levels of glutamate in microdialysis samples are not derived from synaptic processes, various attempts have been made to detect synaptic glutamate during excessive neuronal stimulation. To achieve these conditions, different strategies were applied. Chemical stimulation of glutamate release by infusions of excitatory agents via the microdialysis probe has been performed in various studies. Infusion of high potassium concentration (60–100 mM) increases the release of glutamate drastically. This increase is easily detectable in microdialysates and was characterized as calcium dependent. The evoked glutamate is supposed to be of synaptic origin, although release from astrocytes as part of the internal cell volume regulation (Kimelberg et al., 1995) cannot be excluded. Another way to enhance transmitter release is to prolongate the opening of potassium channels by infusing the potassium-channel blocker, 4-aminopyridine. This resulted in an increase in glutamate levels in microdialysates, which was largely TTX dependent (Pena and Tapia, 2000). Infusion of the glutamate high-affinity transport blockers, TBOA, resulted in a pronounced
increase of glutamate (to 300% of controls). However, this increase in glutamate was not TTX dependent (Xi et al., 2003) which indicates that glutamate accumulating under these conditions in microdialysates is primarily derived from astrocytes. A different but rather successful approach to detect synaptic glutamate is to activate the cellbody area of glutamatergic neurons by chemical stimulation and to monitor simultaneously, the transmitter in the terminal area. In this regard, application of substance P in the substantia nigra increased extracellular levels of glutamate in the striatum (Reid et al., 1990). In comparable experiments, local administration of NMDA in the frontal cortex increased glutamate levels in the striatum (Palmer et al., 1989; Dijk et al., 1995). In several studies, electrical stimulation of the cell-body areas of glutamate pathways has been successfully applied to increase extracellular glutamate levels in microdialysates of the corresponding nerve terminal areas. For example, stimulation of the medulla, sciatic nerve or raphe magnus increased glutamate in areas of the spinal cord (Kapoor et al., 1990; Paleckova et al., 1992; Sorkin and McAdoo, 1993). Electrical stimulation of the nervus vagus increased glutamate levels in the nucleus tractus solitarius (Allichin et al., 1994), whereas stimulation of the nucleus paragigantocellularis increased glutamate in the ipsilateral locus coeruleus (Liu et al., 1999). Electrical stimulation of the prefrontal cortex induced an increase (in 5 s samples) of extracellular glutamate in the striatum of anesthetized rats (Lada et al., 1997; Arnth-Jensen et al., 2002). Application of a 10-s train of pulses induced a rapid increase in glutamate to 200–300% of controls that returned to basal values within 60 s. The increase in glutamate was calcium and TTX dependent. The stimulation of glutamate was suppressed by the m-glutamate receptor agonist, 1-aminocyclopentane-trans-1,3-dicarboxylate. Tucci et al. (2000) demonstrated that electrical stimulation of the prefrontal cortex increased glutamate in the nucleus accumbens. Some of the results of the chemical or electrical stimulation experiments were shown to be TTX dependent, but it is emphasized that TTX infusion
24
is not always the right control experiment as infusion of sodium-channel blockers also blocks the transmission of the applied (electrical or neuronal) stimulation and the subsequent physiological and behavioral effects. Certain types of behavior stimulations are accompanied by characteristic changes (often an increase) in extracellular levels of glutamate in microdialysis experiments. In several studies, extracellular glutamate was recorded during restraint stress. Substantial increases in glutamate levels to 200–450% of basal values lasting for 10–20 min were reported for the prefrontal cortex, hippocampus, nucleus accumbens, and striatum (see references in Timmerman and Westerink, 1997). Photic stimulation of the conscious rat increased extracellular glutamate in the visual cortex to 200% of controls for at least 3 min (Reyes et al., 2002), and formalin injection into the hind paw resulted in an increase of extracellular glutamate that lasted for 2 min in certain subareas of the hypothalamus (preoptic area but not in lateral and ventromedial hypothalamus) (Silva et al., 2004). Results with a different time scale were presented by Rosell et al. (2003), who stimulated a whisker of the rat and sampled glutamate in the motor cortex. By using CE coupled to laser-induced fluorescence detection, they were able to determine glutamate in 1 s microdialysis samples (see also Chapter 3.3). Upon whisker stimulation, glutamate was increased in the 1 s sample only; in the 2 s sample, glutamate again fell back to control values, although the whisker stimulation was continued. The results of the 1-s lasting increase in glutamate content contrasts with the 2–20 min lasting increases in glutamate that were observed in the behavioral experiments discussed above. These data demonstrate the importance of the time scale in detecting physiological changes in extracellular glutamate. It is likely that glutamate displaying subsecond increases reflects different origin than glutamate that was enhanced in behavioral experiments lasting several minutes. An intriguing question is whether the above-described behavior-induced changes are calcium and TTX dependent. It was found that handling stressinduced increases in glutamate that persisted in the presence of TTX (Timmerman and Westerink,
1997). Even mild activation of rats induces changes in glutamate levels in the ECF. Grooming–induced by dropping water onto the rat’s snout–increased extracellular glutamate in the striatum to 200% of controls (Miele et al., 1996). However, a similar increase was seen when the experiment was performed in the presence of TTX. In contrast, there is a report about feedinginduced increase in extracellular glutamate in the nucleus accumbens that was found to be TTX dependent (Saulskaya and Mikhailova, 2004). The study that used formalin injection into the hind paw described increases in glutamate that were both TTX and calcium dependent (Silva et al., 2004). However, the specificity of this observation is questioned by the fact that other amino acids, such as arginine and aspartate also responded in a calcium- and TTX-dependent manner. In conclusion, evidence is provided that glutamate from synaptic sources is detectable in microdialysates collected during excessive stimulation of glutamate pathways. The behavioral experiments have so far produced most interesting but also complex results. A rapid increase in glutamate with a time scale of 1 s was detected apart from changes in glutamate that were lasting during several minutes. It is unclear whether these different processes relate to synaptic release at the present time, as in most of these experiments, the TTX and calcium dependency of the observed effects was not consistently studied or demonstrated. It is tempting to speculate that changes of glutamate in subseconds time frame are related to synaptic activity, whereas changes in minutes might represent astrocytic (nonexocytotic) release. III.G. A new approach detecting extracellular glutamate: the use of microsensors Carbon fibers (diameter 10 mm) have been used to study the dynamics of the release of neurotransmitters, such as dopamine and serotonin. As these compounds are directly oxidized at the carbon surface, changes in transmitter level in the subsecond time frame can be monitored. Carbon fiber-based glutamate microsensors have been constructed by applying electroactive polymers and specific enzymes that oxidize glutamate in vivo
25
(Kulagina et al., 1999). However, the use of these microsensors is limited by a number of points. First, the response time of these sensors is rather slow (10 s) due to slow diffusion of glutamate through the polymer. Second, the sensors are sensitive to ascorbate and uric acid, and the levels of these compounds in the brain are high and difficult to control (Oldenziel et al., in press). However, a most interesting observation was made by Kulagina et al. (1999), who reported that glutamate detected in the brain by microsensors displayed TTX dependency. Recently, these observations were confirmed by two different laboratories: Day et al. (2006) by using keramic-based glutamate sensors and Oldenziel et al. (submitted) who optimized the microsensor concept of Kulagina et al. (1999). The observation that microsensors can detect TTX-dependent glutamate whereas microdialysis probes do might not have a significant impact on future research on extracellular glutamate. III.H. Interpretation of extracellular glutamate: two recording methods, two different sources? Recent evidence indicates that microsensors are able to sample TTX-sensitive glutamate that may be derived from synaptic and/or perisynaptic sites. The absence of effects of calcium depletion or sodium-channel blockers on glutamate concentrations, as determined by microdialysis, suggests that this source of glutamate may represent a different pool of origin, such as astrocytic glutamate released by gliotransmission. This would mean that both methods are complementary. However, it is emphasized that the implantation of the microdialysis probe creates an artificial cavity in the brain, where active proliferating astroglial cells and microcytes will accumulate. Soon after implantation, this cavity will be surrounded by scar tissue. It should also be pointed out that implantation of a microdialysis probe causes extensive damage to brain. It has been shown that the dialysis probe creates a disrupted zone of tissue that extends as far as 1.4 mm from the implantation site. In contrast, electron microscopy of the track created by a carbon fiber revealed that the tissue damage was confined to a distance of 3 mm (see also Chapter
1.6). Therefore, the microdialysis method might represent a pathological rather than a physiological condition. This effect certainly complicates the interpretation of glutamate sampled by microdialysis.
IV. Microdialysis of GABA: interpretation Similar to glutamate, there is a debate in the literature about the neuronal origin of GABA in microdialysis samples. Studies that investigated the effect of infusion of TTX or calcium-free Ringer solutions on GABA levels in dialysates produced inconsistent results. Calcium omission and TTX infusion have been reported to be partly effective (Osborne et al., 1990; Drew and Ungerstedt, 1991; Campbell et al., 1993; Singewald et al., 1993; Rakovska et al., 1998), slightly effective (Stengard and O’Connor, 1994), or nonresponsive (Morari et al., 1993; Bourdelais and Deutch, 1994; Timmerman and Westerink, 1995; Ferraro et al., 2000) in reducing basal GABA levels. In the studies that reported effects of TTX (summarized in Fig. 2), GABA levels decreased only slowly, reaching a statistical significance after 30–60 min of the start of infusion. These results are in strong contrast with the fast-transmitter role that GABA is supposed to play in the CNS. Fig. 2 shows that the response of GABA to TTX is incomplete and much slower when compared with dopamine. Another controversy in the literature is the inability to detect effects of GABA autoreceptor agonists in microdialysis experiments. It is well known from in vitro studies that activation of GABAB autoreceptors by specific agonists, such as baclofen, strongly decrease GABA release as result of an inhibitory autoreceptor feedback mechanism (Waldmeier et al., 1988; Baumann et al., 1990; Lanza et al., 1993; Lambert and Wilson, 1994). However, in microdialysis studies, baclofen was found to have little (Bourdelais and Kalivas, 1992) or no effect (Waldmeier et al., 1992; Richards et al., 1995; Timmerman and Westerink, 1995) on basal GABA levels. Because of the limited response of GABA to TTX, Ca++ omission, and baclofen, some
26
investigators have questioned the neuronal origin of GABA in microdialysates. In this regard, it has been postulated that GABA measured by microdialysis may be derived from nonclassical neurotransmission, such as reversed uptake by carrier-mediated processes (Bernath and Zigmond, 1988; Pin and Bockaert, 1989) or from nonneuronal or cytoplasmic pools (Bernath and Zigmond, 1989), such as glial cells (Campbell et al., 1993; Timmerman and Westerink, 1997). IV.A. A critical comment on the analysis of GABA Because of the discrepancies listed above, we have recently investigated whether the chromatographic separation of GABA may have contributed to the controversial findings of numerous microdialysis studies on this neurotransmitter. To that end, we critically evaluated a method that was most frequently used by us and others: derivatization of dialysates with OPA-mercaptoethanol followed by HPLC and fluorescence detection. To delay the retention time of the GABA derivative, the methanol content of the mobile phase was reduced. When the retention time of GABA was increased to 60 min, we noticed that there were several peaks coeluting close to GABA. These peaks were nondistinguishable from GABA, when the retention time was adjusted to values less than 30 min.In contrast to other amino acids and many interfering compounds, the retention time of the GABA derivative appeared to be very sensitive to the pH of the mobile phase. Fig. 3 shows that a small pH change in the order of 0.03 units moved the GABA peak over three other unknown peaks. It is emphasized that pH dependence of the retention of GABA derivative is often overlooked in the literature as the
applied pH of the mobile phase differs strongly among the various methods (pH 3.6–6.1). After having analyzed pooled microdialysis samples, using a large range of chromatographic conditions (pHs ranging from 6.00, 5.95, and so on; decreasing by 0.05 pH units, to 4.0) at the various methanol concentrations (30, 35, 40, 45, and 50%), it was concluded that stringent pH and methanol conditions are required. A pH of 5.2570.02 was the only window in the pH range that allowed a reliable separation. At our end, a retention time of 60 min is a prerequisite for a reliable chromatographic separation of GABA. With the adapted method, low basal GABA levels were obtained in microdialysis samples: 2.45, 2.95, and 3.6 fmol/mL sample/mm dialyzing membrane in dialysates from hippocampus, striatum, and prefrontal cortex, respectively. These results are significantly lower than many values reported in the literature (range 1. 6–300 fmol/mL sample/ min; n ¼ 39). The low GABA levels that were obtained support the specificity of the present approach. Under the modified chromatographic conditions, it was observed for the first time in our laboratory that TTX infusion (60 min) resulted in a consistent decrease of GABA in all brain regions studied. GABA decreased to 30% (hippocampus), 45% (striatum), and 55% (prefrontal cortex) of controls. Even so, the omission of Ca++ (60 min) caused a decrease to 55, 60, and 67% of control GABA basal levels in microdialysates from hippocampus, striatum, and prefrontal cortex, respectively (see for hippocampus, Fig. 4). This indicates that a significant portion of GABA measured by the modified analytical approach is indeed of neuronal origin.
Fig. 3. The effect of minor changes in pH on the chromatographic behavior of GABA in microdialysates.
27
Fig. 4. Effect of infusion of TTX or calcium-free Ringer on extracellular levels of GABA in the hippocampus.
Fig. 5. Effect of infusion of baclofen on extracellular levels of GABA in the hippocampus.
Next, we investigated the controversy in the literature about the inability to detect effects of autoreceptor agonists, such as baclofen. With the adapted analytical approach, infusion of baclofen decreased the GABA levels to 35% of controls in various brain regions (see for hippocampus, Fig. 5). These results are in good agreement with data from in vitro studies (Waldmeier et al., 1988; Baumann et al., 1990; Lanza et al., 1993; Lambert and Wilson, 1994). It is unclear to what extent GABA values reported in the literature were influenced by an incomplete chromatographic separation. For example, we have not studied the chromatographic conditions in conjunction with electrochemical detection. But the fact that we could easily and consistently demonstrate effects of TTX, calcium omission, and baclofen might inspire other workers to inspect critically their chromatographic conditions. It is unclear at the present time, whether the methods based on CE provides the required specificity of GABA in microdialysates. The best way to investigate this issue is to perform microdialysis experiments during which extracellular levels of GABA are supposed to decline (e.g., administration of TTX, depletion of calcium or infusion of baclofen). As far as we know, these experiments have not been published till date. It is interesting to note that in a recent study that used
CE, GABA levels decreased to 40% of controls after infusion of a GABA synthesis inhibitor (Sauvinet et al., 2003). IV.B. On the origin of GABA in microdialysates Although we have demonstrated that GABA levels established during the infusion of TTX, baclofen, or calcium omission consistently decreased, its response is still relatively slow and does not go further down to 40% of controls. It is evident that GABA levels in microdialysates are less responsive when compared with the ‘‘slow-acting’’ neurotransmitters, such as dopamine (compare dopamine in Fig. 2 with GABA in Fig. 4). Here, we refer to the discussion on the origin of glutamate in dialysates (see above). The fact that GABA–similar to glutamate–after being released is taken up by high-affinity transporters into glial cells that might lead to a similar explanation as given for glutamate. It is likely that the microdialysis probe is in much closer contact with the overwhelming majority of glial cells and subsequently, with the glial GABA pool rather than with the released transmitter in the synaptic cleft. In other words, microdialysis probes can only indirectly detect synaptic release by sampling the accumulating GABA in glial cells. We hypothesize that the GABA source in glial cells acts like a buffer that controls the GABA concentration in
28
the ECF. Dilution of the glial pool buffer may explain the time delay in the changes of extracellular GABA shown in Figs. 4 and 5. V. Conclusions It is unlikely that basal values of glutamate in dialysates represent neuronal release. Evidence is accumulating that basal glutamate is derived from different astrocytic pools. More research is indicated to resolve the relation between glutamate in dialysis samples and glutamate neurotransmission. During excessive neuronal activity, glutamate might escape from the synaptic cleft and might have access to the dialysis probe. Pathological release processes, resulting from tissue damage caused by the dialysis probe, might contribute significantly to glutamate levels in microdialysis samples. The latter assumption is supported by the finding that microsensors are able to detect TTXsensitive glutamate. The chromatographic separation of the OPA derivative of GABA is crucial for reliable detection of GABA in dialysates. We hypothesize that the transfer of GABA from synaptic sites to the dialysis probe is delayed because the probe is sampling GABA partly derived from glial cells. References Allichin, R.E., Batten, T.F., McWilliams, P.N. and Vaughan, P.F. (1994) Electrical stimulation of the vagus increases extracellular glutamate recovered from the nucleus tractus solitarii of the cat by in vivo microdialysis. Exp. Physiol., 79: 265–268. Allison, L.A., Mayer, G.S. and Shoup, R.E. (1984) o-Phthalaldehyde derivatives of amines for high-speed liquid chromatography/electrochemistry. Anal. Chem., 56: 1089–1096. Amara, S.G. and Fontana, A.C.K. (2002) Excitatory amino acid transporters: keeping up with glutamate. Neurochem. Int., 41: 313–318. Arnth-Jensen, N., Jabaudon, D. and Scanziani, M. (2002) Cooperation between independent hippocampal synapses is controlled by glutamate uptake. Nat. Neurosci., 5: 325–331. Baker, D.A., Xi, Z.X., Shen, H., Swanson, C.J. and Kalivas, P.W. (2002) The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci., 22: 9134–9141. Baumann, P.A., Wicki, P., Stierlin, C. and Waldmeier, P.C. (1990) Investigations on GABAB receptor-mediated autoinhibition of GABA release. Naunyn Schmiedebergs Arch. Pharmacol., 341: 88–93.
Benveniste, H., Dreje, J., Schousbroe, A. and Diemer, H. (1984) Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem., 43: 1369–1374. Bergles, D.E., Diamond, J.S. and Jair, C.E. (1999) Clearance of glutamate inside the synapse and beyond. Curr. Opin. Neurobiol., 9: 293–298. Bernath, S. and Zigmond, M.J. (1988) Characterization of [3H]GABA release from striatal slices: evidence for a calciumindependent process via the GABA uptake system. Neuroscience, 27: 563–570. Bernath, S. and Zigmond, M.J. (1989) Dopamine may influence striatal GABA release via three separate mechanisms. Brain Res., 476: 373–376. Bezzi, P., Carmignoto, G., Pasti, L., Vesce, S., Rossi, D., Rizzini, B.L., Pozzan, T. and Volterra, A. (1998) Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature, 391: 281–285. Bezzi, P., Gundersen, V., Galbete, J.L., Seifert, G., Steinhauser, C., Pilati, E. and Volterra, A. (2004) Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nat. Neurosci., 7: 613–620. Bourdelais, A.J. and Deutch, A.Y. (1994) The effects of haloperidol and clozapine on extracellular GABA levels in the prefrontal cortex of the rat: an in vivo microdialysis study. Cereb. Cortex, 6: 69–77. Bourdelais, A.J. and Kalivas, P.W. (1992) Modulation of extracellular gamma-aminobutyric acid in the ventral pallidum using in vivo microdialysis. J. Neurochem., 58: 2311–2320. Campbell, K., Kalen, P., Wictorin, K., Lundberg, C., Mandel, R.J. and Bjorklund, A. (1993) Characterization of GABA release from intrastriatal striatal transplants: dependence on host-derived afferents. Neuroscience, 53: 403–415. Cavelier, P. and Atwell, D. (2005) Tonic release of glutamate by a DIDS-sensitive mechanism in rat hippocampal slices. J. Physiol., 564: 397–410. Chen, Y. and Swanson, R.A. (2003) The glutamate transporters EAAT2 and EAAT3 mediate cysteine uptake in cortical neuron cultures. J. Neurochem., 84: 1332–1339. Danbolt, N.C. (2001) Glutamate uptake. Prog. Neurobiol., 65: 1–105. Day, B.K., Pomerleau, F., Burmeister, J.J., Huettl, P. and Gerhardt, G.A. (2006) Microelectrode array studies of basal and potassium-evoked release of L-glutamate in the anesthetized rat brain. J. Neurochem., 96: 1626–1635. Diamond, J.S. and Jahr, C.E. (1997) Transporters buffer synaptically released glutamate on a submillisecond time scale. J. Neurosci., 17: 4672–4687. Dijk, S.N., Francis, P.T., Stratmann, G.C. and Bowen, D.M. (1995) NMDA-induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5-HT1A antagonist. Br. J. Pharmacol., 115: 1169–1174. Drew, K.L. and Ungerstedt, U. (1991) Pergolide presynaptically inhibits calcium-stimulated release of gamma-aminobutyric acid. J. Neurochem., 57: 1927–1930.
29 Feenstra, M.G.P. and Botterblom, M.H.A. (1996) Rapid sampling of extracellular dopamine in the rat prefrontal cortex during food consumption, handling and exposure to novelty. Brain Res., 742: 17–24. Ferraro, L., O’Connor, W.T., Glennon, J., Tomasini, M.C., Bebe, B.W., Tanganelli, S. and Antonelli, T. (2000) Evidence for a nucleus accumbens CCK2 receptor regulation of rat ventral pallidal GABA levels: a dual probe microdialysis study. Life Sci., 68: 483–496. Fiorino, A., Frigo, G. and Cucchetti, E. (1989) Liquid chromatographic analysis of amino and imino acids in protein hydrolysates by post-column derivatization with o-phthalaldehyde and 3-mercaptopropionic acid. J. Chromatogr., 476: 83–92. Hansson, E., Muyderman, H., Leonova, J., Allansson, L., Sinclair, J., Blomstrand, F., Thorlin, T., Nilsson, M. and Ronnback, L. (2000) Astroglia and glutamate in physiology and pathology: aspects on glutamate transport, glutamateinduced cell swelling and gap-junction communication. Neurochem. Int., 37: 317–329. Hawkins, R.A., DeJoseph, M.R. and Hawkins, P.A. (1995) Regional brain glutamate transport in rats at normal and raised concentrations of circulating glutamate. Cell Tissue Res., 281: 207–214. Haydon, P.G. (2001) Glia: listening and talking to the synapse. Nat. Rev. Neurosci., 2: 185–193. Herrera-Marschitz, M., You, Z.B., Goiny, M., Meana, J., Silveira, S., Godukhin, O.V., Chen, Y., Espinoza, S., Petterson, E., Loidl, C.F., Lubec, G., Andersson, K., Nylander, I., Terenius, L. and Ungerstedt, U. (1996) On the origin of extracellular glutamate levels monitored in the basal ganglia of the rat by in vivo microdialysis. J. Neurochem., 66: 1726–1735. Hertz, L. and Zielke, H.R. (2004) Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci., 27: 735–743. Jacobs, W.A., Leburg, M.W. and Madaj, E.J. (1986) Stability of o-phthalaldehyde-derived isoindoles. Anal. Biochem., 156: 334–340. Kapoor, K., Nakahara, D., Blood, R.J. and Chalmers, J.P. (1990) Preferential release of neuroactive amino acids from the ventrolateral medulla of the rat in vivo as measured by microdialysis. Neuroscience, 37: 187–191. Katayama, Y., Becker, P., Tamura, T. and Hovda, D. (1990) Massive increases in extracellular potassium and the indiscriminate release of glutamate following concussive brain injury. J. Neurosurg., 73: 889–900. Kimelberg, H.K., Rutledge, E., Goderie, S. and Charniga, C. (1995) Astrocytic swelling due to hypotonic or high K+ medium causes inhibition of glutamate and aspartate uptake and increases their release. J. Cereb. Blood Flow Metab., 15: 409–416. Kulagina, N.V., Shankar, L. and Michael, A.C. (1999) Monitoring glutamate and ascorbate in the extracellular space of brain tissue with electrochemical microsensors. Anal. Chem., 71: 5093–5100. Lada, M.W., Vickroy, T.W. and Kennedy, R.T. (1997) High temporal resolution monitoring of glutamate and aspartate in vivo using microdialysis on-line with capillary electrophoresis with laser-induced fluorescence detection. Anal. Chem., 69: 4560–4565.
Lada, M.W., Vickroy, T.W. and Kennedy, R.T. (1998) Evidence for neuronal origin and metabotropic receptor-mediated regulation of extracellular glutamate and aspartate in rat striatum in vivo following electrical stimulation of the prefrontal cortex. J. Neurochem., 70: 617–625. Lambert, N.A. and Wilson, W.A. (1994) Temporally distinct mechanisms of use-dependent depression at inhibitory synapses in the rat hippocampus in vitro. J. Neurophysiol., 72: 121–130. Lanza, M., Fassio, A., Gemignani, A., Bonanno, G. and Raitiri, M. (1993) CGP 52432: a novel potent and selective GABAB autoreceptor antagonist in rat cerebral cortex. Eur. J. Pharmacol., 24: 191–195. Lehre, K.P. and Danbolt, N.C. (1998) The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. J. Neurosci., 18: 8751–8757. Liu, N., Ho, I. and Rockhold, R.W. (1999) Contribution of glutamatergic systems in locus coeruleus to nucleus paragigantocellularis stimulation-evoked behavior. Pharmacol. Biochem. Behav., 63: 555–567. Miele, M., Boutelle, M.G. and Fillenz, M. (1996) The source of physiologically stimulated glutamate efflux from the striatum of conscious rats. J. Physiol., 497: 745–751. Millan, M.H., Obrenovitch, T.P., Sarna, G.S., Lok, S.Y., Symon, L. and Meldrum, B.S. (1991) Changes in rat brain extracellular glutamate concentration during seizures induced by systemic picrotoxin or focal bicuculline injection: an in vivo dialysis study with on-line enzymatic detection. Epilepsy Res., 9: 86–91. Morari, M., O’Connor, W.T., Ungerstedt, U. and Fuxe, K. (1993) N-Methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA, and glutamate levels in the dorsolateral neostriatum of the halothane-anesthetized rat: an in vivo microdialysis study. J. Neurochem., 60: 1884–1893. Nedergaard, M., Takano, T. and Hansen, J. (2002) Beyond the role of glutamate as a neurotransmitter. Nat. Rev. Neurosci., 3: 748–755. Niwa, O., Torimitsu, K., Morita, K., Osborne, P.G. and Yamamoto, K. (1996) Concentration of extracellular L-glutamate released from cultured nerve cells measured with a small-volume online sensor. Anal. Chem., 68: 1865–1870. Obrenovitch, T.P., Richards, D.A., Sarna, G.S. and Symon, L. (1993) Combined intracerebral microdialysis and electrophysiological recording: methodology and applications. J. Neurosci. Methods, 47: 139–145. Oldenziel, W.H., Beukema, W. and Westerink, B.H.C. (2004) Improving the reproducibility of hydrogel-coated glutamate microsensors by using an automated dipcoater. J. Neurosci. Methods, 140: 117–126. Oldenziel, W.H., Dijkstra, G., Cremers, T.I.F.H. and Westerink, B.H.C. (in press) In vivo monitoring of extracellular glutamate in the brain with a microsensor. Brain Res. Oliet, S.H.R., Piet, R. and Poulain, D.A. (2001) Control of glutamate clearance and synaptic efficacy by glial coverage of neurons. Science, 292: 923–936.
30 O’Shea, T.J., Weber, P.L., Bammel, B.P., Lunte, C.E., Lunte, S.M. and Smyth, M.R. (1992) Monitoring excitatory amino acid release in vivo by microdialysis with capillary electrophoresis-electrochemistry. J. Chromatogr., 608: 189–195. Osborne, P.G., O’Connor, W.T., Drew, K.L. and Ungerstedt, U. (1990) An in vivo microdialysis characterization of extracellular dopamine and GABA in dorsolateral striatum of awake freely moving and halothane anaesthetised rats. J. Neurosci. Methods, 34: 99–105. Paleckova, V., Palecek, J., McAdoo, D.J. and Willis, W.D. (1992) The non-NMDA antagonist CNQX prevents release of amino acids into the rat spinal cord dorsal horn evoked by sciatic nerve stimulation. Neurosci. Lett., 148: 19–22. Palmer, A.M., Hutson, P.H., Lowe, S.L. and Bowen, D.M. (1989) Extracellular concentrations of aspartate and glutamate in rat neostriatum following chemical stimulation of frontal cortex. Exp. Brain Res., 75: 659–663. Parpura, V., Basarsky, T.A., Liu, F., Jeftinija, K., Jeftinija, S. and Haydon, P.G. (1994) Glutamate-mediated astrocyteneuron signalling. Nature, 369: 744–747. Pena, F. and Tapia, R. (2000) Seizures and neurodegeneration induced by 4-aminopyridine in rat hippocampus in vivo: role of glutamate- and GABA-mediated neurotransmission and of ion channels. Neuroscience, 101: 547–561. Pin, J.P. and Bockaert, J. (1989) Two distinct mechanisms, differentially affected by excitatory amino acids, trigger GABA release from fetal mouse striatal neurons in primary culture. J. Neurosci., 9: 648–656. Pow, D.V. and Crook, D.R. (1996) Direct immunocytochemical evidence for the transfer of glutamine from glial cells to neurons: use of specific antibodies directed against the D-stereoisomers of glutamate and glutamine. Neuroscience, 70: 295–302. Quan, Z. and Liu, Y.-M. (2003) Capillary electrophoretic separation of glutamate enantiomers in neural samples. Electrophoresis, 24: 1092–1096. Rada, P., Mendialdua, A., Hernandez, L. and Hoebel, B.G. (2003) Extracellular glutamate increases in the lateral hypothalamus during meal initiation, and GABA peaks during satiation: microdialysis measurements every 30 s. Behav. Neurosci., 117: 222–227. Rakovska, A., Giovannini, M.G., Della Corte, L., Kalfin, R., Bianchi, R. and Pepeu, G. (1998) Neurotensin modulation of acetylcholine and GABA release from the rat hippocampus: an in vivo microdialysis study. Neurochem. Int., 33: 335–340. Raiteri, L., Raiteri, M. and Bonanno, G. (2002) Coexistence and function of different neurotransmitter transporters in the plasma membrane of CNS neurons. Prog. Neurobiol., 68: 287–309. Rea, K., Cremers, T.I. and Westerink, B.H. (2005) HPLC conditions are critical for the detection of GABA by microdialysis. J. Neurochem., 94: 672–679. Reid, M.S., Herrera-Marschitz, M., Kehr, J. and Ungerstedt, U. (1990) Striatal dopamine and glutamate release: effects of intranigral injections of substance P. Acta Physiol. Scand., 140: 527–537.
Reyes, E., Rosell, S., Paredes, D., Rada, P., Tucci, S., Gonzalez, L.E. and Hernandez, L. (2002) Haloperidol abolished glutamate release evoked by photic stimulation of the visual cortex in rats. Neurosci. Lett., 327: 149–152. Richards, D.A., Lemos, T., Whitton, P.S. and Bowery, N.G. (1995) Extracellular GABA in the ventrolateral thalamus of rats exhibiting spontaneous absence epilepsy: a microdialysis study. J. Neurochem., 65: 1674–1680. Rosell, S., Gonzalez, L.E. and Hernandez, L. (2003) One-second time resolution brain microdialysis in fully awake rats. Protocol for the collection, separation and sorting of nanoliter dialysate volumes. J. Chromatogr. B, 784: 385–393. Rusakov, D.A. and Lehre, K.P. (2002) Perisynaptic asymmetry of glia: new insights into glutamate signalling. Trends Neurosci., 25: 492–494. Saulskaya, N.B. and Mikhailova, M.O. (2004) Increased glutamate release into the intercellular space of the nucleus accumbens (N. accumbens) during substitution of food reinforcement with aversive or neutral stimuli. Behav. Physiol., 34: 109–113. Sauvinet, V., Parrot, S., Benturquia, N., Bravo-Moraton, E., Renaud, B. and Denoroy, L. (2003) In vivo simultaneous monitoring of gamma-aminobutyric acid, glutamate, and L-aspartate using brain microdialysis and capillary electrophoresis with laser-induced fluorescence detection: analytical developments and in vitro/in vivo validations. Electrophoresis, 24: 3187–3196. Shi, G., Yamamoto, K., Zhou, T., Xu, F., Kato, T., Ji-ye, J. and Jin, J. (2003) On-line biosensors for simultaneous determination of glucose, choline, and glutamate integrated with a microseparation system. Electrophoresis, 24: 3266–3272. Shiraishi, M., Kamiyama, Y., Huttemeier, O.C. and Benveniste, H. (1997) Extracellular glutamate and dopamine measured by microdialysis in the rat striatum during blockade of synaptic transmission in anesthetized and awake rats. Brain Res., 759: 221–227. Silva, E., Hernandez, L., Quinonez, B., Gonzalez, L.E. and Colasante, C. (2004) Selective amino acids changes in the medial and lateral preoptic area in the formalin test in rats. Neuroscience, 124: 395–404. Singewald, N., Guo, L. and Phillipu, A. (1993) Release of endogenous GABA in the posterior hypothalamus of the conscious rat; effects of drugs and experimentally induced blood pressure changes. Naunyn Schmiedenergs Arch. Pharamcol., 347: 402–406. Smith, S. and Sharp, T. (1994) Measurement of GABA in rat brain microdialysates using o-phthaldialdehyde-sulphite derivatization and high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B, 652: 228–233. Sorkin, L.S. and McAdoo, D.J. (1993) Amino acids and serotonin are released into the lumbar spinal cord of the anesthetized cat following intradermal capsaicin injections. Brain Res., 607: 89–98. Stengard, K. and O’Connor, W.T. (1994) Acute toluene exposure decreases extracellular gamma-aminobutyric acid in the globus pallidus but not in striatum: a microdialysis study in awake, freely moving rats. Eur. J. Pharmacol., 292: 43–46.
31 Stobaugh, J.F., Repta, A.J., Sternson, L.A. and Garren, K.W. (1983) Factors affecting the stability of fluorescent isoindoles derived from reaction of o-phthalaldehyde and hydroxyalkylthiols with primary amines. Anal. Biochem., 135: 495–504. Timmerman, W. and Westerink, B.H.C. (1995) Extracellular gamma-aminobutyric acid in the substantia nigra reticulata measured by microdialysis in awake rats: effects of various stimulants. Neurosci. Lett., 197: 21–24. Timmerman, W. and Westerink, B.H.C. (1997) Brain microdialysis of GABA and glutamate: what does it signify? Synapse, 27: 242–261. Tucci, S., Contreras, Q., Paez, X., Gonzalez, L., Rada, P. and Hernandez, L. (2000) Medial prefrontal transection enhances social interaction. II: neurochemical studies. Brain Res., 887: 259–265. Volterra, A. and Meldolesi, J. (2005) Astrocytes, from brain glue to communication elements: the revolution continues. Nat. Rev. Neurosci., 6: 626–640. Waldmeier, P.C., Stocklin, K. and Feldtrauer, J.J. (1992) Weak effects of local and systemic administration of the GABA uptake inhibitor, SK&F 89976, on extracellular GABA in the rat striatum. Naunyn Schmiedebergs Arch. Pharmacol., 345: 544–547. Waldmeier, P.C., Wicki, P., Feldtrauer, J.J. and Baumann, P.A. (1988) Potential involvement of a baclofen-sensitive autoreceptor in the modulation of the release of endogenous
GABA from rat brain slices in vitro. Naunyn Schmiedebergs Arch. Pharmacol., 337: 289–295. Wang, X., Arcuino, G., Takano, T., Lin, J., Peng, W.G., Wan, P., Li, P., Xu, Q., Liu, Q.S., Goldman, S.A. and Nedergaard, M. (2004) P2X7 receptor inhibition improves recovery after spinal cord injury. Nat. Med., 10: 821–827. Warr, O., Takahashi, M. and Attwell, D. (1999) Modulation of extracellular glutamate concentration in rat brain slices by cystine-glutamate exchange. J. Physiol., 514: 783–793. Westerink, B.H.C., Tuntler, J., Damsma, G., Rollema, H. and de Vries, J.B. (1987) The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn Schmiedebergs Arch. Pharmacol., 336: 502–507. Xi, Z.X., Shen, H., Baker, D.A. and Kalivas, P.W. (2003) Inhibition of non-vesicular glutamate release by group III metabotropic glutamate receptors in the nucleus accumbens. J. Neurochem., 87: 1204–1212. Zhou, F., Braddock, J.F., Hu, Y., Zhu, X., Castellani, R.J., Smith, M.A. and Drew, K.L. (2002) Microbial origin of glutamate, hibernation and tissue trauma: an in vivo microdialysis study. J. Neurosci. Methods,, 119: 121–128. Zilkha, E., Obrenovitch, T., Koshy, A., Kusakabe, J. and Bennetto, H. (1995) Extracellular glutamate: on-line monitoring using microdialysis coupled to enzyme-amperometric analysis. J. Neurosci. Methods,, 60: 1–9.
CHAPTER 1.3
Insights into glutamate physiology: contribution of studies utilizing in vivo microdialysis David A. Baker1 and Peter W. Kalivas2, 2
1 Department of Biomedical Sciences, Marquette University, Milwaukee, WI, USA Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, SC, USA
Abstract: Glutamate as the primary excitatory neurotransmitter is critical to most aspects of brain functioning in the normal and diseased states and as a result, there is great interest in monitoring in vivo fluctuations. Microdialysis is the most commonly used technique to sample in vivo glutamate levels, however, the significance of dialysate glutamate have been questioned because of the myriad of physiological functions involving glutamate as well as the widespread observation that basal levels of glutamate are primarily maintained by nonvesicular release mechanisms. The present chapter reviews the cycling of glutamate and synthesis-precursors such as glutamine and demonstrates that it is difficult to delineate a separate metabolic and neurotransmitter pool of glutamate in the extrasynaptic space. Further, evidence is presented indicating that synaptic and extrasynaptic pools of glutamate are capable of modulating neurotransmission by stimulating glutamate receptors. Potential cellular mechanisms underlying vesicular and nonvesicular glutamate release are reviewed regarding the extent to which each may contribute to glutamate signaling. It is concluded that studies utilizing in vivo microdialysis to monitor extrasynaptic pools of glutamate are complimentary to electrophysiological approaches that monitor synaptic glutamate, and that in vivo microdialysis can be used to advance our understanding of glutamate signaling in the normal and diseased states; indeed, future studies utilizing in vivo microdialysis have the potential to identify novel therapeutic targets for a variety of neurological disorders. neurotransmitter in the brain are complicated by the various physiological functions involving glutamate that may be unrelated to its role as a neurotransmitter. The relevance of dialysate glutamate levels have been questioned due to the various metabolic functions of glutamate coupled with the widespread observation that basal levels of glutamate sampled using in vivo microdialysis are primarily maintained by nonvesicular release mechanisms (Bradford et al., 1987; Miele et al., 1996; Timmerman and Westerink, 1997; Baker et al., 2003). The scrutiny regarding the relevance of nonvesicular glutamate has contributed, in part, to studies seeking to further characterize cellular processes regulating synaptic glutamate. The benefit of these efforts is that identifying the relevance
Efforts to unravel the pathology underling a myriad of neurological disorders, including ALS, ischemia, drug addiction, and schizophrenia will likely require a complete understanding of the cellular processes contributing to glutamate neurotransmission in the normal and diseased states. Glutamate is ubiquitously expressed throughout the mammalian central nervous system where it functions as the primary excitatory neurotransmitter. Given its vital role in most aspects of brain functioning, there is great interest in monitoring in vivo glutamate fluctuations. Attempts to sample glutamate functioning as the primary excitatory Corresponding author: E-mail:
[email protected]
B.H.C. Westerink and T.I.F.H. Cremers (Eds.) Handbook of Microdialysis, Vol. 16 ISBN 0-444-52276-X
33
DOI: 10.1016/S1569-7339(06)16003-8 Copyright 2007 Elsevier B.V. All rights reserved
34
of extrasynaptic glutamate has expanded our understanding of glutamate signaling and may have identified novel therapeutic targets in the treatment of addiction and schizophrenia which is reminiscent of Eugene Ionesco’s sentiment, ‘‘It is not the answer that enlightens but the question’’. Collectively, these studies have provided a mere hint at the fascinating, complex regulation of the cellular processes underlying glutamate signaling and indicates that the uniqueness of these processes precludes constraints that might define the relevance of traditional neurotransmitters. The mammalian central nervous system contains abundant glutamate, with neuronal intracellular concentrations in the millimolar range and extrasynaptic levels ranging between 0.2 and 7 mM in rats (Benveniste et al., 1984; Ronne-Engstrom et al., 1995; Baker et al., 2003). The mean distance between synapses, as estimated in the hippocampal dentate gyrus, is 0.5 mm (Rusakov and Kullmann, 1998; Ventura and Harris, 1999). Within this space, there are numerous cellular processes capable of regulating glutamate signaling; the complexity of the cellular machinery regulating glutamate neurotransmission is evident from the sheer number of receptors, uptake transporters, and release mechanisms (for review see Danbolt, 2001). The identification of these processes is critical to our understanding of how glutamate signaling contributes to brain functioning in the normal and diseased states and must be appreciated when examining the relevance of extrasynaptic glutamate.
I. Glutamate sampling techniques A variety of techniques are available to sample in vivo levels of glutamate, including microdialysis and voltammetry (Hutchinson et al., 2002; Fillenz, 2005). The noninvasive procedures nuclear magnetic resonance spectroscopy (Had-Aissouni et al., 2002) represents a newer approach, however, few studies have used this technique, and as a result, it is difficult to compare findings obtained with this technique to microdialysis and voltammetry. Microdialysis and voltammetry represent complementary rather than redundant procedures as each makes a unique contribution to the field of in
vivo neurochemistry on the basis of respective advantages and disadvantages. Advantages of voltammetry include temporal resolution and vastly reduced tissue damage. The significance of reduced tissue damage has been suggested to contribute to the observation that glutamate measured using carbon fiber electrodes coated with glutamate oxidase detects a much higher basal value (29 mM; Kulagina et al., 1999) than what is obtained with microdialysis (0.2–7.0 mM; Benveniste et al., 1984; Ronne-Engstrom et al., 1995; Baker et al., 2003). Further, basal levels sampled using in vivo voltammetry are at least partially reflective of synaptic release since levels are reduced by 25–80% following infusion of 100 mM TTX (Kulagina et al., 1999). This is in contrast to the findings using microdialysis in which basal levels are typically insensitive to TTX (Bradford et al., 1987; Miele et al., 1996; Timmerman and Westerink, 1997; Baker et al., 2003), although much lower concentrations of TTX have been used (e.g., 10 mM; Verma and Moghaddam, 1998; Baker et al., 2002). It is important to note that reductions in basal glutamate levels in the striatum sampled using microdialysis have been obtained using inhibitors of voltage-gated calcium channels (Baker et al., 2002; Xi et al., 2002) or following calcium depletion (Dawson et al., 1995), but see Westerink et al. (1989) and You et al. (1994). These data indicate that both in vivo voltammetry and microdialysis sample vesicular and nonvesicular glutamate. A second advantage of voltammetry relates to temporal resolution; voltammetry permits rapid sampling as short as 100 ms. Microdialysis typically involves sampling times of 5–20 min, although this is dictated by the analytical technique used to determine analyte concentrations. Indeed, the use of capillary electrophoresis coupled with laserinduced fluorescence permits rapid microdialysis sampling times of p5 s (Lada et al., 1998; Rossell et al., 2003). Voltammetry also results in less tissue damage since the diameter of the electrodes range between 1 and 30 mm whereas microdialysis probes are typically X200 mm. Advantages of microdialysis include the range of chemicals that can be sampled, ability to perfuse surrounding tissue with various compounds, and enhanced chemical resolution. As a result, in vivo microdialysis has seen
35
a wider range of applications than in vivo voltammetry. Owing to the physical limitations, in vivo microdialysis and voltammetry are incapable of directly measuring neurotransmitter levels released into the synapse. The diameter of electrodes used for voltammetry (1–30 mm) or microdialysis probes (200–300 mm; see Drew et al., 2004) greatly exceed the size of the synaptic cleft (15 nm), at least as estimated in the CA1 region of the hippocampus (Glavinovic´, 1999). As a result, both techniques sample extrasynaptic pools of neurotransmitters. The extrasynaptic pool of classical neurotransmitters, such as dopamine, largely consists of synaptic overflow; thereby permitting a measure of synaptic fluctuations. This is evident from studies that have shown that blockade of voltage-gated sodium and calcium channels, which prevents exocytosis, drastically reduces extrasynaptic levels of monoamines (Westerink et al., 1987; Osborne et al., 1991; Kato et al., 1992; Morari et al., 1993). However, in the case of amino acid neurotransmitters, it is evident that dialysate levels are maintained by both vesicular and nonvesicular release since levels are only partially sensitive to blockade of voltage-dependent Na+ and Ca2+ channels (Bradford et al., 1987; Miele et al., 1996; Timmerman and Westerink, 1997; Baker et al., 2003). Nonvesicular glutamate release has also been detected in hippocampus and prefrontal cortex using electrophysiological recordings (Jabaudon et al., 1999; Angulo et al., 2004; Cavelier and Attwell, 2005), indicating that nonvesicular release is not unique to the nucleus accumbens nor is it an artifact of microdialysis. The capacity of in vivo monitoring techniques to sample extrasynaptic glutamate provides complimentary measures to the capacity of electrophysiological techniques to monitor synaptic glutamate.
II. Astrocytes maintain neuronal glutamate The significance of dialysate glutamate have been questioned because of the myriad of physiological functions involving glutamate as well as the widespread observation that basal levels of glutamate are primarily maintained by nonvesicular release
mechanisms. Metabolic functions range from protein or peptide synthesis to oxidative degradation yielding carbon dioxide and water for energy metabolism (Fonnum, 1993; Had-Aissouni et al., 2002). The compartmentalization of glutamate is necessary to permit the various physiological functions. The largest of these pools is known as the metabolic pool. A smaller neuronal pool is releasable from the nerve endings during neurotransmission and is thought to represent the glutamate neurotransmitter pool. The separate, glial pool is believed to serve the recycling of transmitter glutamate. Thus, the metabolic pool of glutamate is restricted to the intracellular domain of neurons, whereas the latter two pools involve the trafficking of glutamate and precursor substrates that can be used by neurons to replenish neurotransmitter levels (Danbolt, 2001; Rothman et al., 2003). Indeed, studies using 13C nuclear magnetic resonance spectroscopy measuring the flow of 13C label from glucose to glutamate to glutamine suggest that glutamate release and metabolic recycling cannot be distinguished from glutamate neurotransmission (Rothman et al., 2003). Thus, it has been argued that it is inaccurate to view metabolic and neurotransmitter glutamate as functionally distinct pools, but rather evidence of a highly coordinated interaction between neurons and astrocytes needed to maintain glutamate signaling (Rothman et al., 2003). It has long been appreciated that clearance of synaptically released glutamate represents an important contribution to glutamate signaling by astrocytes. Glutamate that is synaptically released by neurons is primarily cleared by diffusion and the activity of sodium-dependent glutamate transporters (XAG). The family of XAG transporters are located on both astrocytes (e.g., GLAST and GLT) and neurons (EAAC and EAAT4); however, the glial transporters GLT and GLAST are more active in clearing glutamate relative to the cloned neuronal transporters (for review see Danbolt, 2001). The capacity of glutamate uptake by astrocytes is evident in estimates (Lehre and Danbolt, 1998) that glial cells have 15,000–21,000 transporters per mm3 tissue, compared with 2,000 for the neuronal transporter EEAT4 (Dehnes et al., 1998). The need for this capacity to clear
36
glutamate is evident when considering that individual vesicles may contain 400–4,300 molecules of glutamate and that the average synapse has 20 release sites that can be refilled every 10 s (Stevens and Tsujimoto, 1995). It is interesting to speculate that there is an evolutionary advantage underlying the predominant role for astrocytes in glutamate uptake since glutamate uptake also results in sodium uptake. The uptake of each glutamate molecule requires the cotransport of 2–3 Na2+ ions glutamate transport; thus the potential to transport up to 8,600 molecules of glutamate, and consequently up to 25,800 sodium molecules, per second would greatly increase neuronal metabolic demands to maintain sodium concentration gradients and membrane potentials. Regardless, the result is a high rate of glutamate trafficking from neurons to astrocytes. Further, neurons, unlike astrocytes, cannot synthesis glutamate from glucose (Hertz et al., 1999) nor does glutamate easily penetrate the blood-brain barrier (McCall et al., 1979; Smith, 2000). Thus, neurons are dependent on astrocytes to maintain glutamate levels needed to support synaptic release. Astrocytes do not return glutamate to neurons, but instead supply precursors that can be used for glutamate synthesis. Precursors that can be utilized by astrocytes to synthesis glutamate include glutamine as well as a-ketoglutarate and tricarboxylic acid (TCA) cycle intermediates including lactate or pyruvate (Waagepetersen et al., 1998; Garcia-Espinosa et al., 2004). Glutamate-glutamine is thought to be the primary metabolic fate of synaptic glutamate taken into astrocytes. The cycle occurs when glutamate in astrocytes is amidated to glutamine by the addition of ammonia, a reaction catalyzed by the glial enzyme glutamine synthetase. Glutamine is then released into the extracellular space where it can be taken up into neurons and converted to glutamate by phosphatase-activated glutaminase (Kvamme et al., 1988; Danbolt, 2001); the advantage of using glutamine to restore neuronal glutamate levels is that glutamine will not produce excitotoxicity because it does not stimulate glutamate receptors. Evidence that glutamine is used to synthesize the neurotransmitter pool of glutamate is provided by studies indicating that blockade of
glutamine synthetase reduces glutamate release detected in vivo in the frontal cortex or hippocampal formation (Bo¨ttcher et al., 2003) or in the striatum (Paulsen and Fonnum, 1989). However, glutamine is not solely used as a precursor to maintain the neurotransmitter pool of glutamate; astrocytes as well as nonglutamatergic neurons take up glutamine from the extracellular space; additional uses of glutamine include the synthesis of GABA or as a metabolic fuel. Further, studies have demonstrated that at least some glutamate neurons lack the enzyme needed to convert glutamine into glutamate (Ottersen et al., 1998). Thus, additional substrates must be utilized by neurons to maintain glutamate levels since there is less than a 1:1 relationship between the precursor glutamine and synthesized glutamate. Neuronal glutamate levels can also be maintained by utilizing a-ketoglutarate or a-ketoglutarate products (Schousboe et al., 1997). a-Ketoglutarate in astrocytes is ultimately converted to pyruvate and subsequently lactate; all of these products can be released from astrocytes and taken up by neurons for the synthesis of glutamate (Waagepetersen et al., 1998; Hertz et al., 1999; Garcia-Espinosa et al., 2004). Interestingly, blocking glutamine synthetase also results in an increase in extracellular levels of lactate and pyruvate (Bo¨ttcher et al., 2003). These data indicate that the same pool of glutamate, most likely synaptically released glutamate, serves as a substrate for both glutamine and a-ketoglutarate metabolic pathways. In vivo microdialysis or voltammetry are unlikely to sample pools of glutamate utilized in the metabolic pathways glutamine and a-ketoglutarate metabolic pathways. The metabolic fate of glutamate in either astrocytes or neurons is restricted to intracellular pools of glutamate, and trafficking of substrate for metabolic functions does not involve the transfer of glutamate, but rather precursors used for subsequent synthesis of glutamate. It is important to consider that the only point of extracellular transfer of glutamate to support either metabolic pathway is the synaptic release of glutamate from neurons which is then cleared by glial XAG transporters. This is confirmed in studies using nuclear magnetic resonance spectroscopy to monitor the fate of 13C isotope
37
from a [1-13C] glucose precursor in terms of subsequent labeling of glutamine, lactate, and glutamate (for review see Rothman et al., 2003). These studies have demonstrated that metabolic fate of glutamate in astrocytes is inexplicablely linked to large neurotransmitter pools in neurons. The need to parse out metabolic glutamate even in the extrasynaptic space from glutamate contributing to neurotransmission is apparent from observations that basal, extrasynaptic glutamate can influence signaling by stimulating extrasynaptic glutamate receptors.
III. Glutamate receptors Glutamate signaling involves activation of ionotropic (NMDA, AMPA, and kainate) and metabotropic (mGluR1–7) receptors; stimulation of these receptors underlies most of the excitatory neurotransmission in the mammalian brain. Given the importance of the activity of glutamate receptors to brain functioning, an important point to consider regarding the significance of glutamate sampled using in vivo microdialysis is whether this pool of glutamate is stimulating glutamate receptors. Interestingly, ionotropic and metabotropic glutamate receptors are located both within the synaptic cleft as well as extrasynaptically, and extrasynaptic glutamate receptors can modulate the release of an impressive array of neurotransmitters including glutamate, GABA, substance P, dopamine, and norepinephrine (Ozawa et al., 1998; Cartmell and Schoepp, 2000; Gomes et al., 2003). This indicates the possibility that extrasynaptic glutamate maintained primarily by nonvesicular release contributes to signaling of a number of neurotransmitter systems. Excitatory postsynaptic currents (EPSCs) in most mammalian central neurons have a fast a-amino-3-hydroxy-5-methyl-4-isoazole-proprionic acid (AMPA) receptor-mediated component, lasting a few milliseconds, and a slow N-methyl-Daspartic acid (NMDA)-receptor-mediated component, lasting hundreds of milliseconds. Therefore, voltage-clamped glutamate EPSCs appear biphasic, with a very fast AMPA transient, and a much slower NMDA tail. As a result, both NMDA and
AMPA receptors are indispensable to brain functioning in the normal and diseased state. An interesting, puzzling attribute is that AMPA receptors are not only located within the synapse, but also are found on extrasynaptic neuronal and glial processes. It is unclear that AMPA receptors, which have relatively low affinity for glutamate (EC50 ¼ 0.1–0.5 mM; Patneau and Mayer, 1990), would be directly stimulated by extrasynaptic glutamate levels which are routinely estimated in the low micromolar. However, AMPA receptors located on glial cells in the hippocampus or cerebellum appear to directly appose presynaptic neurons and recent data indicates that these receptors may be stimulated by quantal release of glutamate resulting in concentrations within the affinity range of AMPA receptors (Bergles et al., 2000; Matsui and Jahr, 2003; Matsui et al., 2005). As a result of the poor temporal resolution associated with microdialysis coupled with HPLC analysis of analyte concentration, in vivo characterization of this effect will likely require the use of microdialysis coupled with capillary electrophoresis/laser-induced fluorescence or in vivo voltammetry. Various attributes of the NMDA receptor poses the possibility that these receptors may be stimulated by extrasynaptic glutamate. First, in contrast AMPA receptors, NMDA receptors exhibit very high affinity for glutamate that is within the range of extracellular glutamate. Extant data indicate that NMDA receptors are present in both the synaptic cleft and the extrasynaptic space and that the subcellular distribution may be determined by subunit composition; these receptors comprised NR1 and NR2 subunit, including NR2A, NR2B, NR2C, and NR2D. NMDA receptors comprised NR1/NR2A subunits localized in the synapse and are characterized by rapid offset kinetics while receptors comprised NR1/NR2B subunits which are extrasynaptic and exhibit slow kinetics (Stocca and Vicini, 1998; Rumbaugh and Vicini, 1999; Tovar and Westbrook, 1999). The offset kinetics may reflect separate sources of stimulation; the slow offset kinetics of extrasynaptic receptors may indicate stimulation from a pool of glutamate that is not rapidly cleared. However, these receptors, which are characterized by high permeability to
38
calcium, are unlikely to receive continual endogenous stimulation, in part because these receptors are subjected to voltage-dependent blockade by magnesium. Several studies have demonstrated that NMDA receptors can be stimulated by both vesicular and nonvesicular glutamate (Jabaudon et al., 1999; Angulo et al., 2004; Cavelier and Attwell, 2005). Some of these studies found that the stimulation of NMDA receptors by nonvesicular release was not apparent until glutamate uptake by XAG transporters was removed by the nonspecific glutamate uptake inhibitor DL-threo-beta-benzyloxyaspartate (TBOA; Jabaudon et al., 1999; Angulo et al., 2004; Cavelier and Attwell, 2005). Interestingly, NMDA receptors that were stimulated with glutamate uptake intact have been suggested to be extrasynaptic (Breukel et al., 1998; Angulo et al., 2004). Further, in the absence of magnesium blockade, these receptors appear to contribute to background current levels detected using patch clamp recordings indicating that extrasynaptic glutamate receptors may be subject to tonic stimulation (Gottesman and Miller, 2003; Angulo et al., 2004). Collectively, these studies pose the possibility that NMDA receptors may be stimulated by extrasynaptic glutamate, and that XAG transporters actively compartmentalize extrasynaptic and synaptic glutamate. The subcellular localization is an important determinant of the physiological function of the NMDA receptor. In support, several studies implicate extrasynaptic NMDA receptors as auto- or heteroreceptors capable of regulating the release of glutamate, GABA, and monoamines (Pittaluga and Raiteri, 1990; Krebs et al., 1991; Wang et al., 1992; Malva et al., 1994). Interestingly, the release of glutamate by extrasynaptic NMDA receptors can involve vesicular (Wang et al., 1992; Malva et al., 1994) or nonvesicular glutamate (Breukel et al., 1998). Given that NMDA receptors are not located on glia, this indicates that in addition to astrocytes, neurons are capable of ligand-mediated nonvesicular release. Metabotropic glutamate receptors are perhaps the most likely of all receptors to receive tonic stimulation by extrasynaptic glutamate levels. These receptors classified as groups I (mGluR1 and 5), II
(mGluR2 and 3), and III (mGluR4, 6, 7, and 8) exhibit a very high affinity for glutamate that is comparable with NMDA receptors (Conn and Pin, 1997; Anderson and Swanson, 2000). Unlike NMDA receptors, however, these receptors are not subjected to voltage-dependent magnesium blockade. With the exception of mGluR1 and 6, each of the receptors are expressed either on presynaptic neurons (mGluR2, 4, 7, and 8) or on astrocytes (mGluR3 and 5) indicating that most receptors are in the extrasynaptic domain. Group I receptors are positively linked to phospholipase C and largely thought to augment ionotropic receptor function glutamate neurotransmission (Bordi and Ugolini, 1999). Groups II and III are negatively coupled to adenylyl cyclase and function as auto- and heteroreceptors capable of negative modulation of glutamate neurotransmission. As a result, metabotropic glutamate receptors have been shown to modulate synaptic glutamate signaling. Extant data utilizing in vivo microdialysis indicate that group II mGluRs receive tonic stimulation. The existence of endogenous stimulation of these receptors is evident from studies demonstrating that infusion of the group II mGluR antagonist (RS)-1-amino-5-phosphonoindan-1carboxylic acid (APICA) produces a significant increase in extracellular glutamate (Baker et al., 2002), which is Ca2+-dependent (Xi et al., 2002). These data are consistent with the notion that group II mGluRs function as autoreceptors to regulate vesicular release of glutamate (Baskys and Malenka, 1991; Cochilla and Alford, 1998; Hu et al., 1999; Xi et al., 2002) or as heteroreceptors capable of regulating synaptic release of other neurotransmitters including glutamate and GABA (Conn and Pin, 1997; Cartmell and Schoepp, 2000). Interestingly, tonic stimulation of group II mGluR originates from nonvesicular glutamate release from cystine–glutamate exchange. In support, infusion of the cystine–glutamate exchange inhibitor (S)-4-carboxyphenylglycine (CPG) prevents the APICA-induced rise in glutamate. A similar conclusion can be drawn from the observation that cystine application to cortical or accumbens tissue slices produces a decrease in the frequency of mini EPSCs (Moran et al., 2005). Further, blockade of this effect by CPG
39
demonstrates that the reduction in the frequency of mini EPSCs depends on nonvesicular glutamate release from cystine–glutamate antiporters, and blockade of this effect by the group II mGluR antagonist LY341495 shows that the reduction in the frequency of mini EPSCs is also dependent on stimulation of group II mGluRs. Collectively, these data indicate that nonvesicular glutamate released from cystine–glutamate antiporters regulates glutamate neurotransmission by stimulating group II mGluRs. In addition, these data imply that the contribution of cystine–glutamate antiporters to glutamate neurotransmission occurs in both the prefrontal cortex and nucleus accumbens (Baker et al., 2002; Melendez et al., 2005), posing the possibility that cystine–glutamate antiporters may function in this capacity throughout the brain. These are significant findings, in part, because glutamate released from cystine–glutamate exchange is sampled by in vivo microdialysis (Baker et al., 2002). Collectively, these data strongly indicate that microdialysis is sampling glutamate that is nonvesicular yet capable of regulating glutamate signaling. The extant data regarding receptor distribution, function, and kinetics support pharmacological data indicating that nonvesicular glutamate modulates neural signaling involving a wide-array of neurotransmitters by stimulating both ionotropic and metabotropic glutamate receptors. Fluctuations in nonvesicular glutamate may contribute to a variety of pathologies arising through altered signaling of these systems. As a result, it is important to characterize the cellular mechanisms underlying basal, extrasynaptic glutamate sampled using in vivo microdialysis because these mechanisms likely modulate glutamate signaling. As a result, these processes may have profound therapeutic significance for a myriad of disorders.
IV. Cellular processes capable of glutamate release Synaptic, vesicular release from neurons is widely studied, however, as indicated earlier, measures of glutamate by in vivo microdialysis are maintained largely by nonvesicular release. Interestingly, there are number of cellular mechanisms capable of
glutamate release that may involve both neurons and astrocytes. These mechanisms include vesicular release from astrocytes (Bezzi et al., 2004; Kreft et al., 2004; Zhang et al., 2004), as well as nonvesicular release from cystine–glutamate exchange (Baker et al., 2002; Moran et al., 2005), astrocytic gap junction hemichannels (Ye et al., 2003), volume-sensitive organic anion channels (VSOACs; Kimelberg et al., 1990; Strange et al., 1996; Basarsky et al., 1999), hydrolysis of N-acetylaspartylglutamate (Blakely et al., 1988; Zhou et al., 2005), or reversal of sodium-dependent transporters (Levi and Raiteri, 1993). Further, there are recent reports indicating that glutamate may be synthesized from glutamine hydrolysis in the extrasynaptic space (Mena et al., 2005). Despite the importance of glutamate in both the synaptic and extrasynaptic space, surprisingly little is known regarding the relative importance of these mechanisms to glutamate signaling. However, nonvesicular release is detected using electrophysiological approaches indicating that it is not an artifact of microdialysis and that this pool of glutamate can stimulate glutamate receptors (Jabaudon et al., 1999; Angulo et al., 2004; Cavelier and Attwell, 2005; Moran et al., 2005). As a result, microdialysis is a critical tool in determining the contribution of these release mechanisms unique to the role that glutamate plays in vivo in normal and pathological brain functioning. Evidence that astrocytes are a key component of glutamate signaling stems from observations that these cells are capable of glutamate release involving exocytosis (for review see Haydon, 2001; Newman, 2003). Recently, a synaptic-like microvesicle capable of uptake, storage, and release of glutamate has been identified in hippocampal astrocytes (Bezzi et al., 2004; Kreft et al., 2004; Zhang et al., 2004). The loading of these vesicles, similar to neurons, involves the activity of vesicular glutamate transporters; the fusion of these vesicles to the plasma membrane has been shown to be calcium-dependent. Unlike neurons, the process is not dependent on the opening of voltage-gated calcium channels, but instead by IP3-mediated calcium release from endoplasmic reticulum following activation of a variety of G-coupled receptors (Volterra and Meldolesi,
40
2005). Receptors that may be capable of elevating intracellular levels of calcium that have been found on astrocytes include metabotropic glutamate, muscarinic, histamine, substance P, and noradrenergic receptors (for review see Verkhratsky et al., 1998). Stimulation of NMDA receptors on neurons contributes to vesicular glutamate release from neurons. In support, data obtained using immunogold electron microscopy indicate that extrasynaptic NMDA receptors on dendrites of cortical pyramidal cells face glial processes (Kharazia and Weinberg, 1999). Further, glutamate released from astrocytes results in inward currents that are susceptible to NMDA receptor inhibition (Parpura et al., 1994; Araque et al., 1998; Parpura and Haydon, 2000). The contribution of vesicular glutamate release from astrocytes to dialysate glutamate levels is unknown because traditional attempts to inhibit vesicular release in neurons, including blockade of voltage-dependent sodium and calcium channels, would not alter vesicular glutamate release from astrocytes. Given that this source of glutamate is released into the extrasynaptic space, it seems likely that dialysate glutamate concentrations sampled in vivo microdialysis may originate, in part, from vesicular glutamate release from astrocytes. These studies indicate the importance of microdialysis to contribute to investigate the contribution of these unique release mechanisms to in vivo glutamate signaling. Glutamate may also be released through hemichannels located on astrocytes. The opening of hemichannels resulting in glutamate release can be demonstrated in divalent cation-free solution (Ye et al., 2003) indicating that is most likely to contribute to glutamate release under pathological conditions. In support, ambient levels of calcium are thought to maintain hemichannels in the closed state, however, reductions in calcium may result in a small portion of hemichannel opening during normal physiological conditions (Liu et al., 1995; Hofer and Dermietzel, 1998; Kamermans et al., 2001). As a result, additional studies examining changes in basal glutamate levels following blockade of hemichannels has the potential to contribute to our understanding of glutamate signaling.
The cystine–glutamate antiporter represents a nonvesicular release mechanism of glutamate release that appears to be critical for synaptic glutamate transmission (Baker et al., 2002; Moran et al., 2005). The antiporter is a plasma membrane bound, Na+-independent, anionic amino acid transporter that exchanges extracellular cystine for intracellular glutamate (Bannai et al., 1986; Danbolt, 2001) and exists as two separate proteins, the light chain xCT unique to cystine–glutamate antiporters and the heavy chain 4F2 that is common to many amino acid transporters (Sato et al., 1999; Bridges et al., 2001). Similar to Na+-dependent glutamate transporters, the antiporter is ubiquitously distributed throughout the body; and in the brain, the antiporter is thought to be located on both neurons and glia (Cho and Bannai, 1990; Murphy et al., 1990; Danbolt, 2001). Evidence suggests that nonvesicular glutamate release via cystine–glutamate exchange is a fundamental component of glutamate neurotransmission in the nucleus accumbens (see Fig. 1). First, nonvesicular glutamate release is the primary source of glutamate in the nucleus accumbens, as assessed using in vivo microdialysis (Baker et al., 2002). This report indicated that reverse dialysis of cystine–glutamate exchange inhibitors reduced
Fig. 1. Schematic illustrates the regulation of vesicular glutamate release by cystine–glutamate antiporters. Extracellular cystine is exchanged for intracellular glutamate by cystine/ glutamate antiporters. Glutamate released from these antiporters has been shown to provide tonic stimulation to group II mGluRs, which regulate vesicular glutamate release through a PKA-dependent mechanism.
41
basal extracellular levels by 60%. In this same report, blockade of voltage-gated sodium or calcium channels produced a 10–20% decrease in dialysate glutamate levels (Baker et al., 2002). Second, glutamate released from the antiporter provides endogenous stimulation to group II mGluRs which is evident from the observation that blockade of group II mGluRs produces a significant increase in extracellular glutamate levels in the nucleus accumbens (Hu et al., 1999; Baker et al., 2002; Xi et al., 2002). However, prior blockade of cystine–glutamate antiporters prevents this increase in glutamate, which is consistent with the removal of endogenous stimulation of group II mGluRs (Baker et al., 2002). These findings obtained using in vivo microdialysis were replicated using patch clamp recordings in frontal cortical and accumbens tissue slices. Briefly, cystine applications produced a decrease in the frequency of mini EPSCs, spontaneous EPSCs, as well as evoked EPSCs. These effects were blocked by cystine–glutamate antiporter inhibitor or a group II mGluR antagonist (Moran et al., 2005). Collectively, these studies imply that, at least in the prefrontal cortex and nucleus accumbens, nonvesicular glutamate release from cystine–glutamate antiporters regulates glutamate neurotransmission. Group II mGluRs also function as heteroreceptors regulating dopamine release (Hu et al., 1999) indicating that nonvesicular glutamate released from cystine/glutamate exchange and sampled using in vivo microdialysis also regulates synaptic levels of neurotransmitters other than glutamate. In support, blockade of cystine–glutamate antiporters produces an increase in extracellular dopamine in the nucleus accumbens which can be reversed by restoring tone to group II mGluRs (Baker et al., 2002). Volume-sensitive organic anion channels (VSOAC) represent another mechanism contributing to nonvesicular pools of extracellular glutamate. Activation of VSOACs occurs to maintain cell volume through a process called regulatory volume decrease (RVD). VSOACs are permeable to a variety of organic anions including glutamate (Jackson and Strange, 1993; Strange et al., 1996; Basarsky et al., 1999). 5-Nitro-2-(3-phenylpropyamino) benzoic acid (NPPB) or tamoxifen can be
used to block VSOACs. However, while the contribution of VSOACs to in vivo basal levels has not been determined, VSOACs are known to contribute to glutamate neurotransmission in a pathological state. Spreading depression is a wave of glial and neuronal depolarization that propagates through the CNS and can lead to excitotoxic damage (Gorji, 2001). Glutamate release through VSOACs occurs during spreading depression, and blockade of these channels can depress the rate of spreading depression (Basarsky et al., 1999). N-acetyl aspartylglutamate (NAAG) is endogenous and abundantly expressed, and can be metabolized by NAALAdase inhibitors in the extracellular space to N-acetylaspartate and glutamate. This poses the possibility that NAAG hydrolysis may contribute to basal glutamate levels detected using microdialysis. Interestingly, NAAG also functions as a group II mGluR agonist and a partial agonist at NMDA receptors (Westbrook et al., 1986; Wroblewska et al., 1997; Bruno et al., 1998). It is unclear whether the NAALAdase inhibitor 2-(phosphonomethyl)pentanedioic acid (2-PMPA) decreases basal glutamate levels, but 2-PMPA significantly reduces elevated glutamate following transient middle cerebral artery occlusion (Slusher et al., 1999). These data illustrate that NAAG metabolism may contribute to pathogenic glutamate signaling during an ischemic event.
V. Synaptic origin of stimulated release The preceding sections detail that extrasynaptic glutamate sampled by in vivo microdialysis is likely maintained by nonvesicular and vesicular release from both neurons and astrocytes. However, an interesting question is whether microdialysis can sample synaptic glutamate. First, striatal dialysis levels are at least partially maintained by vesicular release from neurons since dialysate levels are partially reduced following calcium depletion (Dawson et al., 1995) or blockade of voltage-gated calcium channels (Baker et al., 2002; Xi et al., 2002), but see Westerink et al. (1989) and You et al. (1994). Further, dialysate
42
glutamate levels are sensitive to voltage-gated sodium and calcium channels following a number of manipulations, including group II/III mGluR blockade (Xi et al., 2002), electrical stimulation of the prefrontal cortex (Lada et al., 1998), presentation of an appetitive stimulus (Saulskaya and Soloviova, 2004), or cocaine administration (Pierce et al., 1996; McFarland et al., 2003). Collectively, these studies indicate that microdialysis can sample synaptic glutamate and many of these studies have advanced our understanding of the contribution of glutamate to pathological states including ischemia-induced toxicity and cocaine addiction.
VI. Therapeutic targets detected by microdialysis Studies utilizing microdialysis have been instrumental in efforts to reveal the pathology and identify novel therapeutic targets for a variety of neurological disorders including ischemia, epilepsy, and schizophrenia; since these advances are the subject of latter chapters in this book they will not be described here. However, microdialysis has been particularly useful in identifying pathogenic changes in glutamate neurotransmission contributing to compulsive cocaine-seeking. Repeated cocaine administration produces a persistent reduction in basal glutamate levels in the nucleus accumbens (Pierce et al., 1996; Baker et al., 2003) that persists for at least 60 days (Baker et al., unpublished data). The reduction in basal glutamate levels contributes to a phasic elevation of glutamate observed following a cocaine challenge (Pierce et al., 1996; Reid and Berger, 1996; Reid et al., 1997; Baker et al., 2003), and this rise in glutamate is necessary for primed drug-seeking behavior (Baker et al., 2003; McFarland et al., 2003). Interestingly, the reduction in basal glutamate levels in the nucleus accumbens involves cocaine-induced blunting of cystine–glutamate exchange and this effect can be masked or reversed using cysteine prodrugs including N-acetylcysteine (Baker et al., 2003). Further, extant clinical data supports the anticraving efficacy of N-acetylcysteine as a novel pharmacotherapeutic agent for cocaine addiction (LaRowe et al., 2006).
VII. Conclusion The study of glutamate homeostasis has produced a number of seminal findings that have led many to challenge dogma regarding how the brain functions. At the very least, it is now evident that the regulation of glutamate homeostatis is vastly more complex than traditional neurotransmitters and that constraints applicable to traditional neurotransmitters may be inappropriate for glutamate. Unlike most neurotransmitters, in vivo levels of glutamate levels monitored using microdialysis are only partially maintained by vesicular release; instead extrasynaptic glutamate levels are primarily maintained by nonvesicular release mechanisms likely originating in astrocytes. The existence of vesicular and nonvesicular release mechanisms has also been detected in electrophysiological studies which have demonstrated that vesicular and nonvesicular release are capable of stimulating glutamate receptors, especially when the receptors are located in the extrasynaptic domain. As a result, it appears that extrasynaptic glutamate levels, unlike traditional neurotransmitters, do not simply reflect neurotransmitter overflow, but may be maintained by a variety of release mechanisms that are unique to glutamate. Potential cellular processes include vesicular and nonvesicular release from astrocytes, voltage-sensitive organic anion channels, hemichannels, NAAG metabolism, and cystine–glutamate exchange; all of which may ultimately represent novel therapeutic targets for a number of neurological disorders involving altered glutamate signaling. Interestingly, sodium-dependent transporters appear to compartmentalize synaptic and extrasynaptic pools of glutamate. This poses the scenario that there are at least two distinct extracellular pools of glutamate, each with respective receptors. The contribution of most release mechanisms to the levels of glutamate measured by in vivo microdialysis has yet to be determined, however, many of these release mechanisms have been implicated in pathological states, underscoring the need to further investigate these cellular processes. One mechanism that has been linked to in vivo basal levels of glutamate, at least in the nucleus accumbens, is cystine–glutamate exchange. Cystine–glutamate exchange was
43
identified as a novel therapeutic target in the treatment of cocaine addiction largely through the use of in vivo microdialysis. As a result, microdialysis is a critical tool that has the potential to advance our understanding of glutamate signaling in the normal and diseased states. Further, the capacity of microdialysis to identify cellular processes regulating extrasynaptic glutamate provides a complimentary approach to the use of electrophysiological studies to monitor processes regulating synaptic glutamate. References Anderson, C.M. and Swanson, R.A. (2000) Astrocyte glutamate transport: review of properties, regulation, and physiological functions. Glia, 32: 1–14. Angulo, M.C., Kozlov, A.S., Charpak, S. and Audinat, E. (2004) Glutamate released from glial cells synchronizes neuronal activity in the hippocampus. J. Neurosci., 24: 6920–6927. Araque, A., Sanzgiri, R.P., Parpura, V. and Haydon, P.G. (1998) Calcium elevation in astrocytes causes an NMDA receptor-dependent increase in the frequency of miniature synaptic currents in cultured hippocampal neurons. J. Neurosci., 18: 6822–6829. Baker, D.A., McFarland, K., Lake, R.W., Shen, H., Tang, X.C., Toda, S. and Kalivas, P.W. (2003) Neuroadaptations in cystine–glutamate exchange underlie cocaine relapse. Nat. Neurosci., 6: 743–749. Baker, D.A., Xi, Z.X., Shen, H., Swanson, C.J. and Kalivas, P.W. (2002) The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci., 22: 9134–9141. Bannai, S., Takada, A., Kasuga, H. and Tateishi, N. (1986) Induction of cystine transport activity in isolated rat hepatocytes by sulfobromophthalein and other electrophilic agents. Hepatology, 6: 1361–1368. Basarsky, T.A., Feighan, D. and MacVicar, B.A. (1999) Glutamate release through volume-activated channels during spreading depression. J. Neurosci., 19: 6439–6445. Baskys, A. and Malenka, R.C. (1991) Agonists at metabotropic glutamate receptors presynaptically inhibit EPSCs in neonatal rat hippocampus. J. Physiol., 444: 687–701. Benveniste, H., Drejer, J., Schousboe, A. and Diemer, N.H. (1984) Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem., 43: 1369–1374. Bergles, D.E., Roberts, J.D., Somogyi, P. and Jahr, C.E. (2000) Glutamatergic synapses on oligodendrocyte precursor cells in the hippocampus. Nature, 405: 187–191. Bezzi, P., Gundersen, V., Galbete, J.L., Seifert, G., Steinhauser, C., Pilati, E. and Volterra, A. (2004) Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nat. Neurosci., 7: 613–620.
Blakely, R.D., Robinson, M.B., Thompson, R.C. and Coyle, J.T. (1988) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate: subcellular and regional distribution, ontogeny, and the effect of lesions on N-acetylated-alpha-linked acidic dipeptidase activity. J. Neurochem., 50: 1200–1209. Bordi, F. and Ugolini, A. (1999) Group I metabotropic glutamate receptors: implications for brain diseases. Prog. Neurobiol., 59: 55–79. Bo¨ttcher, T., Goiny, M., Bering, J., Domhof, S., Nau, R. and Ungerstedt, U. (2003) Regional differences in glutamine synthetase inhibition by L-methionine sulfoximine: a microdialysis study in the rabbit brain. Exp. Brain Res., 150: 194–200. Bradford, H.F., Young, A.M. and Crowder, J.M. (1987) Continuous glutamate leakage from brain cells is balanced by compensatory high-affinity reuptake transport. Neurosci. Lett., 81: 296–302. Breukel, A.I., Besselsen, E., Lopes da Silva, F.H. and Ghijsen, W.E. (1998) A presynaptic N-methyl-D-aspartate autoreceptor in rat hippocampus modulating amino acid release from a cytoplasmic pool. Eur. J. Neurosci., 10: 106–114. Bridges, C.C., Kekuda, R., Wang, H., Prasad, P.D., Mehta, P., Huang, W., Smith, S.B. and Ganapathy, V. (2001) Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci., 42: 47–54. Bruno, V., Wroblewska, B., Wroblewski, J.T., Fiore, L. and Nicoletti, F. (1998) Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells. Neuroscience, 85: 751–757. Cartmell, J. and Schoepp, D.D. (2000) Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem., 75: 889–907. Cavelier, P. and Attwell, D. (2005) Tonic release of glutamate by a DIDS-sensitive mechanism in rat hippocampal slices. J. Physiol., 564: 397–410. Cho, Y. and Bannai, S. (1990) Uptake of glutamate and cysteine in C-6 glioma cells and in cultured astrocytes. J. Neurochem., 55: 2091–2097. Cochilla, A.J. and Alford, S. (1998) Metabotropic glutamate receptor-mediated control of neurotransmitter release. Neuron, 20: 1007–1016. Conn, P.J. and Pin, J.P. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol., 37: 205–237. Danbolt, N.C. (2001) Glutamate uptake. Prog. Neurobiol., 65: 1–105. Dawson, L.A., Stow, J.M., Dourish, C.T. and Routledge, C. (1995) Analysis of glutamate in striatal microdialysates using capillary electrophoresis and laser-induced fluorescence detection. J. Chromatogr. A, 700: 81–87. Dehnes, Y., Chaudhry, F.A., Ullensvang, K., Lehre, K.P., Storm-Mathisen, J. and Danbolt, N.C. (1998) The glutamate transporter EAAT4 in rat cerebellar Purkinje cells: a glutamate-gated chloride channel concentrated near the synapse in parts of the dendritic membrane facing astroglia. J. Neurosci., 18: 3606–3619.
44 Drew, K.L., Pehek, E.A., Rasley, B.T., Ma, Y.L. and Green, T.K. (2004) Sampling glutamate and GABA with microdialysis: suggestions on how to get the dialysis membrane closer to the synapse. J. Neurosci. Methods, 140: 127–131. Fillenz, M. (2005) In vivo neurochemical monitoring and the study of behaviour. Neurosci. Biobehav. Rev., 29: 949–962. Fonnum, F. (1993) Regulation of the synthesis of the transmitter glutamate pool. Prog. Biophys. Mol. Biol., 60: 47–57. Garcia-Espinosa, M.A., Rodrigues, T.B., Sierra, A., Benito, M., Fonseca, C., Gray, H.L., Bartnik, B.L., Garcia-Martin, M.L., Ballesteros, P. and Cerdan, S. (2004) Cerebral glucose metabolism and the glutamine cycle as detected by in vivo and in vitro 13C NMR spectroscopy. Neurochem. Int., 45: 297–303. Glavinovic´, M.I. (1999) Monte Carlo simulation of vesicular release, spatiotemporal distribution of glutamate in synaptic cleft and generation of postsynaptic currents. Pflugers Arch., 437: 462–470. Gomes, A.R., Correia, S.S., Carvalho, A.L. and Duarte, C.B. (2003) Regulation of AMPA receptor activity, synaptic targeting and recycling: role in synaptic plasticity. Neurochem. Res., 28: 1459–1473. Gorji, A. (2001) Spreading depression: a review of the clinical relevance. Brain Res. Brain Res. Rev., 38: 33–60. Gottesman, J. and Miller, R.F. (2003) N-methyl-D-aspartate receptors contribute to the baseline noise of retinal ganglion cells. Vis. Neurosci., 20: 329–333. Had-Aissouni, L., Re, D.B., Nieoullon, A. and Kerkerian-Le Goff, L. (2002) Importance of astrocytic inactivation of synaptically released glutamate for cell survival in the central nervous system – are astrocytes vulnerable to low intracellular glutamate concentrations? J. Physiol. Paris, 96: 317–322. Haydon, P.G. (2001) GLIA: listening and talking to the synapse. Nat. Rev. Neurosci., 2: 185–193. Hertz, L., Dringen, R., Schousboe, A. and Robinson, S.R. (1999) Astrocytes: glutamate producers for neurons. J. Neurosci. Res., 57: 417–428. Hofer, A. and Dermietzel, R. (1998) Visualization and functional blocking of gap junction hemichannels (connexons) with antibodies against external loop domains in astrocytes. Glia, 24: 141–154. Hu, G., Duffy, P., Swanson, C., Ghasemzadeh, M.B. and Kalivas, P.W. (1999) The regulation of dopamine transmission by metabotropic glutamate receptors. J. Pharmacol. Exp. Ther., 289: 412–416. Hutchinson, P.J., O’Connell, M.T., Kirkpatrick, P.J. and Pickard, J.D. (2002) How can we measure substrate, metabolite and neurotransmitter concentrations in the human brain? Physiol. Meas., 23: R75–R109. Jabaudon, D., Shimamoto, K., Yasuda-Kamatani, Y., Scanziani, M., Gahwiler, B.H. and Gerber, U. (1999) Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc. Natl. Acad. Sci. U.S.A., 96: 8733–8738. Jackson, P.S. and Strange, K. (1993) Volume-sensitive anion channels mediate swelling-activated inositol and taurine efflux. Am. J. Physiol., 265: C1489–C1500.
Kamermans, M., Fahrenfort, I., Schultz, K., Janssen-Bienhold, U., Sjoerdsma, T. and Weiler, R. (2001) Hemichannel-mediated inhibition in the outer retina. Science, 292: 1178–1180. Kato, T., Otsu, Y., Furune, Y. and Yamamoto, T. (1992) Different effects of L-, N- and T-type calcium channel blockers on striatal dopamine release measured by microdialysis in freely moving rats. Neurochem. Int., 21: 99–107. Kharazia, V.N. and Weinberg, R.J. (1999) Immunogold localization of AMPA and NMDA receptors in somatic sensory cortex of albino rat. J. Comp. Neurol., 412: 292–302. Kimelberg, H.K., Goderie, S.K., Higman, S., Pang, S. and Waniewski, R.A. (1990) Swelling-induced release of glutamate, aspartate, and taurine from astrocyte cultures. J. Neurosci., 10: 1583–1591. Krebs, M.O., Trovero, F., Desban, M., Gauchy, C., Glowinski, J. and Kemel, M.L. (1991) Distinct presynaptic regulation of dopamine release through NMDA receptors in striosomeand matrix-enriched areas of the rat striatum. J. Neurosci., 11: 1256–1262. Kreft, M., Stenovec, M., Rupnik, M., Grilc, S., Krzan, M., Potokar, M., Pangrsic, T., Haydon, P.G. and Zorec, R. (2004) Properties of Ca(2+)-dependent exocytosis in cultured astrocytes. Glia, 46: 437–445. Kulagina, N.V., Shankar, L. and Michael, A.C. (1999) Monitoring glutamate and ascorbate in the extracellular space of brain tissue with electrochemical microsensors. Anal. Chem., 71: 5093–5100. Kvamme, E., Roberg, B., Johansen, L. and Torgner, I.A. (1988) Interrelated effects of calcium and sulfhydryl reagents on renal phosphate-activated glutaminase. Contrib. Nephrol., 63: 156–160. Lada, M.W., Vickroy, T.W. and Kennedy, R.T. (1998) Evidence for neuronal origin and metabotropic receptormediated regulation of extracellular glutamate and aspartate in rat striatum in vivo following electrical stimulation of the prefrontal cortex. J. Neurochem., 70: 617–625. Larowe, S.D., Mardikian, P., Malcolm, R., Myrick, H., Kalivas, P., McFarland, K., Saladin, M., McRae, A. and Brady, K. (2006) Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am. J. Addict., 15: 105–110. Lehre, K.P. and Danbolt, N.C. (1998) The number of glutamate transporter subtype molecules at glutamatergic synapses: chemical and stereological quantification in young adult rat brain. J. Neurosci., 18: 8751–8757. Levi, G. and Raiteri, M. (1993) Carrier-mediated release of neurotransmitters. Trends Neurosci., 16: 415–419. Liu, T.F., Li, H.Y., Atkinson, M.M. and Johnson, R.G. (1995) Intracellular lucifer yellow leakage from Novikoff cells in the presence of ATP or low extracellular Ca: evidence for hemigap junction channels. Methods Find Exp. Clin. Pharmacol., 17: 23–28. Malva, J.O., Carvalho, A.P. and Carvalho, C.M. (1994) Modulation of dopamine and noradrenaline release and of intracellular Ca2+ concentration by presynaptic glutamate receptors in hippocampus. Br. J. Pharmacol., 113: 1439–1447.
45 Matsui, K. and Jahr, C.E. (2003) Ectopic release of synaptic vesicles. Neuron, 40: 1173–1183. Matsui, K., Jahr, C.E. and Rubio, M.E. (2005) High-concentration rapid transients of glutamate mediate neuralglial communication via ectopic release. J. Neurosci., 25: 7538–7547. McCall, A., Glaeser, B.S., Millington, W. and Wurtman, R.J. (1979) Monosodium glutamate neurotoxicity, hyperosmolarity, and blood-brain barrier dysfunction. Neurobehav. Toxicol., 1: 279–283. McFarland, K., Lapish, C.C. and Kalivas, P.W. (2003) Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior. J. Neurosci., 23: 3531–3537. Melendez, R.I., Vuthiganon, J. and Kalivas, P.W. (2005) Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. J. Pharmacol. Exp. Ther., 314: 139–147. Mena, F.V., Baab, P.J., Zielke, C.L., Huang, Y. and Zielke, H.R. (2005) Formation of extracellular glutamate from glutamine: exclusion of pyroglutamate as an intermediate. Brain Res., 1052: 88–96. Miele, M., Boutelle, M.G. and Fillenz, M. (1996) The source of physiologically stimulated glutamate efflux from the striatum of conscious rats. J. Physiol., 497(Pt 3): 745–751. Moran, M.M., McFarland, K., Melendez, R.I., Kalivas, P.W. and Seamans, J.K. (2005) Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J. Neurosci., 25: 6389–6393. Morari, M., O’Connor, W.T., Ungerstedt, U. and Fuxe, K. (1993) N-methyl-D-aspartic acid differentially regulates extracellular dopamine, GABA, and glutamate levels in the dorsolateral neostriatum of the halothane-anesthetized rat: an in vivo microdialysis study. J. Neurochem., 60: 1884–1893. Murphy, T.H., Schnaar, R.L. and Coyle, J.T. (1990) Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J., 4: 1624–1633. Newman, E.A. (2003) New roles for astrocytes: regulation of synaptic transmission. Trends Neurosci., 26: 536–542. Osborne, P.G., O’Connor, W.T. and Ungerstedt, U. (1991) Effect of varying the ionic concentration of a microdialysis perfusate on basal striatal dopamine levels in awake rats. J. Neurochem., 56: 452–456. Ottersen, O.P., Takumi, Y., Matsubara, A., Landsend, A.S., Laake, J.H. and Usami, S. (1998) Molecular organization of a type of peripheral glutamate synapse: the afferent synapses of hair cells in the inner ear. Prog. Neurobiol., 54: 127–148. Ozawa, S., Kamiya, H. and Tsuzuki, K. (1998) Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol., 54: 581–618. Parpura, V., Basarsky, T.A., Liu, F., Jeftinija, K., Jeftinija, S. and Haydon, P.G. (1994) Glutamate-mediated astrocyteneuron signalling. Nature, 369: 744–747.
Parpura, V. and Haydon, P.G. (2000) Physiological astrocytic calcium levels stimulate glutamate release to modulate adjacent neurons. Proc. Natl. Acad. Sci. U.S.A., 97: 8629–8634. Patneau, D.K. and Mayer, M.L. (1990) Structure–activity relationships for amino acid transmitter candidates acting at Nmethyl-D-aspartate and quisqualate receptors. J. Neurosci., 10: 2385–2399. Paulsen, R.E. and Fonnum, F. (1989) Role of glial cells for the basal and Ca2+-dependent K+-evoked release of transmitter amino acids investigated by microdialysis. J. Neurochem., 52: 1823–1829. Pierce, R.C., Bell, K., Duffy, P. and Kalivas, P.W. (1996) Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J. Neurosci., 16: 1550–1560. Pittaluga, A. and Raiteri, M. (1990) Release-enhancing glycinedependent presynaptic NMDA receptors exist on noradrenergic terminals of hippocampus. Eur. J. Pharmacol., 191: 231–234. Reid, M.S. and Berger, S.P. (1996) Evidence for sensitization of cocaine-induced nucleus accumbens glutamate release. Neuroreport, 7: 1325–1329. Reid, M.S., Hsu, K. Jr. and Berger, S.P. (1997) Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: studies on the involvement of dopamine. Synapse, 27: 95–105. Ronne-Engstrom, E., Carlson, H., Liu, Y., Ungerstedt, U. and Hillered, L. (1995) Influence of perfusate glucose concentration on dialysate lactate, pyruvate, aspartate, and glutamate levels under basal and hypoxic conditions: a microdialysis study in rat brain. J. Neurochem., 65: 257–262. Rossell, S., Gonzalez, L.E. and Hernandez, L. (2003) One-second time resolution brain microdialysis in fully awake rats Protocol for the collection, separation and sorting of nanoliter dialysate volumes. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 784: 385–393. Rothman, D.L., Behar, K.L., Hyder, F. and Shulman, R.G. (2003) In vivo NMR studies of the glutamate neurotransmitter flux and neuroenergetics: implications for brain function. Annu. Rev. Physiol., 65: 401–427. Rumbaugh, G. and Vicini, S. (1999) Distinct synaptic and extrasynaptic NMDA receptors in developing cerebellar granule neurons. J. Neurosci., 19: 10603–10610. Rusakov, D.A. and Kullmann, D.M. (1998) Extrasynaptic glutamate diffusion in the hippocampus: ultrastructural constraints, uptake, and receptor activation. J. Neurosci., 18: 3158–3170. Sato, H., Tamba, M., Ishii, T. and Bannai, S. (1999) Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins. J. Biol. Chem., 274: 11455–11458. Saulskaya, N.B. and Soloviova, N.A. (2004) Tetrodotoxindependent glutamate release in the rat nucleus accumbens during concurrent presentation of appetitive and conditioned aversive stimuli. J. Neurosci. Methods, 140: 15–21.
46 Schousboe, A., Westergaard, N., Waagepetersen, H.S., Larsson, O.M., Bakken, I.J. and Sonnewald, U. (1997) Trafficking between glia and neurons of TCA cycle intermediates and related metabolites. Glia, 21: 99–105. Slusher, B.S., Vornov, J.J., Thomas, A.G., Hurn, P.D., Harukuni, I., Bhardwaj, A., Traystman, R.J., Robinson, M.B., Britton, P., Lu, X.C., Tortella, F.C., Wozniak, K.M., Yudkoff, M., Potter, B.M. and Jackson, P.F. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med., 5: 1396–1402. Smith, Q.R. (2000) Transport of glutamate and other amino acids at the blood-brain barrier. J. Nutr., 130: 1016S–1022S. Stevens, C.F. and Tsujimoto, T. (1995) Estimates for the pool size of releasable quanta at a single central synapse and for the time required to refill the pool. Proc. Natl. Acad. Sci. U.S.A., 92: 846–849. Stocca, G. and Vicini, S. (1998) Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. J. Physiol., 507(Pt 1): 13–24. Strange, K., Emma, F. and Jackson, P.S. (1996) Cellular and molecular physiology of volume-sensitive anion channels. Am. J. Physiol., 270: C711–C730. Timmerman, W. and Westerink, B.H. (1997) Brain microdialysis of GABA and glutamate: what does it signify? Synapse, 27: 242–261. Tovar, K.R. and Westbrook, G.L. (1999) The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J. Neurosci., 19: 4180–4188. Ventura, R. and Harris, K.M. (1999) Three-dimensional relationships between hippocampal synapses and astrocytes. J. Neurosci., 19: 6897–6906. Verkhratsky, A., Orkand, R.K. and Kettenmann, H. (1998) Glial calcium: homeostasis and signaling function. Physiol. Rev., 78: 99–141. Verma, A. and Moghaddam, B. (1998) Regulation of striatal dopamine release by metabotropic glutamate receptors. Synapse, 28: 220–226. Volterra, A. and Meldolesi, J. (2005) Astrocytes, from brain glue to communication elements: the revolution continues. Nat. Rev. Neurosci., 6: 626–640. Waagepetersen, H.S., Bakken, I.J., Larsson, O.M., Sonnewald, U. and Schousboe, A. (1998) Comparison of lactate and
glucose metabolism in cultured neocortical neurons and astrocytes using 13C-NMR spectroscopy. Dev. Neurosci., 20: 310–320. Wang, J.K., Andrews, H. and Thukral, V. (1992) Presynaptic glutamate receptors regulate noradrenaline release from isolated nerve terminals. J. Neurochem., 58: 204–211. Westbrook, G.L., Mayer, M.L., Namboodiri, M.A. and Neale, J.H. (1986) High concentrations of N-acetylaspartylglutamate (NAAG) selectively activate NMDA receptors on mouse spinal cord neurons in cell culture. J. Neurosci., 6: 3385–3392. Westerink, B.H., Damsma, G. and de Vries, J.B. (1989) Effect of ouabain applied by intrastriatal microdialysis on the in vivo release of dopamine, acetylcholine, and amino acids in the brain of conscious rats. J. Neurochem., 52: 705–712. Westerink, B.H., Tuntler, J., Damsma, G., Rollema, H. and de Vries, J.B. (1987) The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn Schmiedebergs Arch. Pharmacol., 336: 502–507. Wroblewska, B., Wroblewski, J.T., Pshenichkin, S., Surin, A., Sullivan, S.E. and Neale, J.H. (1997) N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem., 69: 174–181. Xi, Z.X., Baker, D.A., Shen, H., Carson, D.S. and Kalivas, P.W. (2002) Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J. Pharmacol. Exp. Ther., 300: 162–171. Ye, Z.C., Wyeth, M.S., Baltan-Tekkok, S. and Ransom, B.R. (2003) Functional hemichannels in astrocytes: a novel mechanism of glutamate release. J. Neurosci., 23: 3588–3596. You, Z.B., Herrera-Marschitz, M., Nylander, I., Goiny, M., O’Connor, W.T., Ungerstedt, U. and Terenius, L. (1994) The striatonigral dynorphin pathway of the rat studied with in vivo microdialysis – II. Effects of dopamine D1 and D2 receptor agonists. Neuroscience, 63: 427–434. Zhang, Q., Pangrsic, T., Kreft, M., Krzan, M., Li, N., Sul, J.Y., Halassa, M., Van Bockstaele, E., Zorec, R. and Haydon, P.G. (2004) Fusion-related release of glutamate from astrocytes. J. Biol. Chem., 279: 12724–12733. Zhou, J., Neale, J.H., Pomper, M.G. and Kozikowski, A.P. (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug Discov., 4: 1015–1026.
CHAPTER 1.4
The validity of intracerebral microdialysis Kevin C. Chen Department of Chemical and Biomedical Engineering, Florida State University, Tallahassee, FL, USA
Abstract: Notwithstanding its invasiveness, intracerebral microdialysis has become a popular tool in monitoring and interpreting neurochemical processes in the brain in conjunctions with various stimuli or pharmacological/pathological alterations in behavioral or pharmacological studies. The most widely used quantitative methods are the zero-net-flux (ZNF) method and the varied flow rate method, both of which have been questioned about their validity to determine the true ‘‘unperturbed’’ basal concentration of extracellular neurotransmitters. This inability is attributed to the inevitable disruption of both neurotransmitter release and uptake sites during microdialysis probe implantation. Model simulations show that if microdialysis impairs the neurotransmitter release site more than the corresponding uptake sites, underestimation of the unperturbed basal concentration by these quantitative methods occurs and the trend of the in vivo recovery of the neurotransmitter with the uptake inhibition would reverse as compared with that of microdialysis extraction. Two modified DA kinetic models accounting for the presence of DA baseline were presented and compared to assess the basal extracellular DA, [DA]e, in rat striatum. Examining the data from the microdialysis ZNF measurements and fast-scan cyclic voltammetry experiments on striatal DA systems shows reasonable doubt that the current ZNF measurement on striatal DA (5–10 nM) did underestimate the basal level [DA]e However, the underestimation is not as serious as previously thought by Michael and coworkers. Although the striatal [DA]e could be much higher than the single-digit nanomolar range determined by the microdialysis ZNF method, the basal [DA]e is probably still confined within nanomolar range, perhaps fewer than 100 nM.
neuroscientists to observe real-time chemical events and intercellular processes in the brains. This widespread use is reflected on the fact that as of February, 2007, PubMed listed some 9000+scientific and clinical papers describing applications of this technique; and the number is still growing. Depending on different research needs, the microdialysis probe also has different designs. This chapter focuses on intracerebral microdialysis of the concentric probe, as this is the one which is mostly used in neuroscientific research. The methodology and principles of microdialysis operation have been introduced in other chapters and complete reviews in this regard can be found in the literature (e.g., Benveniste and Huttemeier, 1990; Justice, 1993; Kehr, 1993; Stenken, 1999; Bourne, 2003; Plock
I. Introduction Originally developed for neuroscientific research, microdialysis has now become a popular tool applied to monitor extracellular analyte concentrations in many different tissues and organs in many disciplines, including pharmacophysiology (De Lange et al., 2000; Chefer et al., 2003), neurobiology/neurochemistry (Smith and Justice, 1994; Cosford et al., 1996; Bourne, 2003), sports medicine (MacLean et al., 1999), and tumor oncology (Dabrosin, 2005). Albeit invasive, intracerebral microdialysis becomes popular by allowing Corresponding author: E-mail:
[email protected]
B.H.C. Westerink and T.I.F.H. Cremers (Eds.) Handbook of Microdialysis, Vol. 16 ISBN 0-444-52276-X
47
DOI: 10.1016/S1569-7339(06)16004-X Copyright 2007 Elsevier B.V. All rights reserved
48
and Kloft, 2005). Therefore, this chapter will mainly focus on the validity of microdialysis data associated with tissue trauma and current status in assessing such knowledge on quantitative microdialysis. Concern over the possibility of microdialysis data compromised by probe-induced tissue trauma is non-trivial if one is to establish microdialysis as a credible tool in neuroscience research.
I.A. Microdialysis – an invasive technique Two major criticisms about microdialysis are its inability to monitor real-time responses of in vivo neurochemical events and its invasive nature. What is lacking in the time resolution of microdialysis sampling is more or less compensated by its capability to analyze diverse compounds when coupled to other high-precision analytical instrument, such as high-performance liquid chromatography or scintillation counter. Nonetheless, the tissue damage caused by probe implantation is a serious issue. Because this method must insert its probe into the desired brain region to collect extracellular fluid for compositional analysis, microdialysis sampling inevitably disrupts the morphological structure of connective tissue and processes at the insertion site. As one learns more from and about microdialysis, concerns over its invasive nature, and hence the credibility of resulting data, also increase (Di Chiara et al., 1996; Westerink and Timmerman, 1999; De Lange et al., 2000). Many works have already subjected the tissue trauma exerted by microdialysis implantation to morphological and neurochemical examination. Generally, insertion of the microdialysis probe causes edema and hemorrhage, as well as gliosis and fibrosis, in the surrounding tissue (Benveniste and Diemer, 1987; Benveniste and Huttemeier, 1990; Grabb et al., 1998). Probe insertion also disrupts the otherwise intact blood-brain barrier (Morgan et al., 1996; Groothuis et al., 1998). Whereas consensus regarding the microdialysis-induced morphological disruption and subsequent inflammatory responses is firmly established, the influences of these damages on the functional neurochemical data obtained by microdialysis are often unclear and still under debates. It is not
uncommon to find controversial experimental results and conclusions regarding how traumatized tissues affect microdialysis data. For example, destructive and irrecoverable effects of the microdialysis-induced trauma on the nearby neuronal processes and synaptic number density have been reported (e.g., Shuaib et al., 1990; ClappLilly et al., 1999). In particular, Grabb et al. (1998) compared several amino acids with purine metabolites in the dialysate contents in the rat brains implanted with microdialysis probes chronically (24 h) or acutely (2 h), and reported that rat brains implanted with chronic microdialysis showed abnormal responses of these dialysates, both in magnitudes and response time, to ischemic insults. In contrast, more positive conclusions on the intrusive nature of microdialysis sampling can also be found (e.g., Georgieva et al., 1993; Martin-Fardon et al., 1997; West et al., 2002), both from observing a fairly constant dialysate content of various neurotransmitters and peptides over repeated probe insertion (assuming the use of a guide cannula implanted permanently) or from morphological examination. It appears that in chronic microdialysis, the dialysate content of many neurotransmitters can maintain quite a constant level, while their metabolites increased initially (a few hours after probe insertion), followed by a gradual decline over a long-time period (2–3 days later). This trend has been observed in the microdialysis studies for dopamine (DA) and its metabolite L-DOPA in rat striatum (Robinson and Camp, 1991; Marburger et al., 2000). The question has been raised as to whether the neurotransmitter metabolites, not the neurotransmitters themselves, should be used as a better indicator for tissue integrity and recovery from microdialysis probe implantation. Whereas many pharmacological and neurochemical studies have firmly established that microdialysis implantation inevitably disrupted tissue structure and possibly damaged neuronal processes, no quantitative suggestion was made as to how and to what extent these tissue damages affect microdialysis sampling accuracy and interpretation of the corresponding data. Note that the concern brought in this chapter is not whether the dialysate neurotransmitters genuinely reflect functional release from nearby neurons, as discussed in
49
Di Chiara et al. (1996) and Westerink and Timmerman (1999). On the contrary, the concern herein is whether the microdialysis-induced tissue trauma would be so significant as to completely compromise the validity of microdialysis, and hence askew the interpretation of quantitative microdialysis data. These quantitative methods include the zeronet-fluxmethod and the varied perfusion method, and will be introduced later. The same issue is also discussed in Chapter 1.6 by A.C. Michael.
I.B. The main issues I.B.1. Passive diffusion To apply microdialysis to quantify the endogenous concentration of compounds of interests in the brain extracellular space (ECS), one needs to deal with two issues. One is the fact that the diffusion resistance encountered in the tissue is different from that of the quiescent medium in vitro. This difference in the diffusion resistances between in vitro and in vivo experiments originates partly from: (i) the much reduced diffusible space in the brain [20% of the total brain volume belongs to ECS (Nicholson and Sykova, 1998)], which increases the interstitial diffusional resistance, and partly from (ii) the active processes in the tissue. According to the existing microdialysis theory (e.g., Benveniste and Huttemeier, 1990; Bungay et al., 1990; Chen et al., 2002), the reduced ECS (characterized by the ECS volume fraction fe) and the increased interstitial diffusion path (characterized by a tortuosity factor l) make the tissue diffusion resistance much larger than that of the medium in vitro (which usually is a quiescent bulk liquid, with a volume percentage of diffusible space equal to 100%), thus reducing the microdialysis recovery in vivo. But the active processes of the endogenous analyte (such as release, uptake, active transporters and exchangers, or metabolism) act in the opposite way to enhance the in vivo recovery of these neurotransmitters in the brains (Parsons and Justice, 1992, 1994). The theoretical basis of how active processes can affect microdialysis characteristics (such as microdialysis recovery and extraction) was first proposed by Bungay et al. (1990), and later experimentally verified by
Justice and coworkers (Parsons et al., 1991; Parsons and Justice, 1992; Smith and Justice, 1994; Cosford et al., 1996). Because of the interplays between these unknown factors in the brains, it was soon realized that in vitro calibration cannot be applied in vivo due to the unknown tissue diffusion resistance, which can be either larger or smaller than that of the in vitro resistance1. I.B.2. Active processes A second issue related to practicing quantitative microdialysis to sample endogenous neurotransmitters is whether the microdialysis probe significantly damages the neurotransmitter release and/or uptake sites. The role of active processes in defining the basal level of extracellular neurotransmitters is different from their roles in shaping the microdialysis extraction and recovery ratio. Relative changes in the neurotransmitter release and uptake directly modifies the basal level of extracellular neurotransmitter, a consequence of the mass balance between neurotransmitter release and uptake rates. As microdialysis only samples the extracellular neurotransmitters in its immediate surroundings, quantitative methods, like the zero-net-flux (ZNF) method or the varied flow rate method, can only reflect such changed basal level near the probe but not the intact one at further distances away. Hence, disruption in the neurotransmitter release and uptake brought about by probe insertion can seriously compromise the ability of microdialysis to quantify the basal level of extracellular neurotransmitters in the undisturbed state. There have been reports indicating that microdialysis probe insertion overwhelmingly destroyed DA release sites in the vicinity of the probe (Lu et al., 1998; Peters and Michael, 1998; Yang et al., 1998; Borland et al., 2005). A consequence of this preferential destruction on the neurotransmitter release sites (including the closed synapses at axonal terminals as well as the open synapses on somatic dendrites) will be a lowered level of the extracellular neurotransmitters surrounding the microdialysis probe. Both issues discussed above are all related to the microdialysis-induced tissue trauma. The passive 1 For the in vivo microdialysis, only the quiescent case is discussed and compared.
50
II. Theory of single-probe microdialysis II.A. Quantitative microdialysis (blind shoot method) Before introducing some more complete mathematical microdialysis theory, it is necessary to introduce a few microdialysis methods (specifically, the ZNF method and the slow perfusion method), which are widely employed to quantify extracellular concentrations of compounds of interest. Because both methods are based on the fundamental mass balance principle, it was once believed that these two methods can adequately sample the extracellular level of the substances of interest without any prior knowledge of the tissue diffusive properties and neurochemical processes. II.A.1. Zero-net-flux method This method, originally proposed by Lonnroth et al. (1987) as the ‘‘concentration difference method’’, is based on the idea that the extracellular concentration of analyte in the surrounding tissue should equal the concentration in the infused dialysate fluid when a net-zero exchange of the analyte occurs between the dialysate within the probe and the extracellular fluid outside the probe. The difference between the infusion (‘in’) and outflow (‘out’) analyte concentrations in the dialysates
3
Cin Cout (nM)
diffusion is closely dependent on the diffusion properties (i.e., the ECS volume fraction and the effective diffusion coefficient) in the surrounding tissue, which can be altered due to edema or fibroblast proliferation resulting from probe insertion. The active release or uptake processes, which set the basal level of extracellular analyte to be sampled by microdialysis, can be physically destroyed on sites during probe insertion or later on when neuronal degeneration occurs. Thus, a quantitative microdialysis model should try to address both issues and provide theoretical predictions on how these factors influence microdialysis performance. This chapter will briefly review the history of microdialysis theory development; then discuss current development on assessing how tissue trauma affects the practice of quantitative microdialysis.
control uptake inhibition
2 1 0 -1 -2 0
2.5
5.0
7.5
10.0
12.5
15.0
Cin(nM) Fig. 1. The concentration difference plot showing the hypothetic situation that after neurotransmitter extrasynaptic uptake is inhibited, the plot slope (E) decreases and the ZNF concentration (CZNF) increases; but the dialysate Cout (when Cin ¼ 0) decreases. Thus using the Cout solely to judge the increase or decrease of extracellular neurotransmitter could be problematic, as in this figure conclusion regarding increase or decrease of C* after pharmacological application based on the dialysate Cout (when Cin ¼ 0) is opposite to that based on CZNF.
(denoted as Cin and Cout, respectively) is plotted against the infusion concentration Cin (Fig. 1). The dialysate concentration at the ZNF point (CZNF) is taken to be the infusion concentration Cin when a ZNF condition is achieved, that is, Cin Cout ¼ 0. This value CZNF at the ZNF condition was initially taken as the mean ECS concentration C* in the unperturbed tissue. As the issue of tissue trauma was later recognized, the equivalency between CZNF and C* was challenged. To distinguish between the specific infusing analyte concentration at the ZNF point and the true tissue ECS concentration C*, this chapter designates the former value the CZNF, and will not assume the equivalency of CZNF and C*. It should be noted that even if CZNF is not equal to the C* in the distant unperturbed tissue, the CZNF so measured is still the mean ECS concentration in the damaged tissue nearby the inserted probe. From the microdialysis theory (Bungay et al., 1990), the slope of the concentration difference curve is termed the ‘‘in vivo extraction efficiency’’, E, of the probe (Bungay et al., 1990). Another commonly used factor characterizing microdialysis performance is the relative recovery, defined as C out R ¼ when C in is zero; (1) C
51
Traditional qualitative approach in studying the effect of specific pharmacological agents on neurochemistry is to perfuse the probe with the blank Ringer (Cin ¼ 0) and observe the relative changes of Cout in the dialysate in comparison with the control. The relative change in Cout is used to infer the increase/decrease of the analyte in the ECS due to the action of the pharmacological agent, assuming that relative changes in Cout monotonically reflects relative changes in C*. It is possible, thought not yet demonstrated in experiments, that a decrease in Cout after pharmacological applications may not necessarily imply a decrease in the CZNF or C* (see Fig. 1). However, a quantitative microdialysis method like the ZNF method can clarify if the relative increase/decrease of the dialysate Cout can truly reflect the same trend of the CZNF, and hence of the basal C*. Of course, it is based on the implicit assumption that a monotonic relationship exists between CZNF and C*. Initially, the relative recovery R was implicitly viewed to be the same as the extraction efficiency E. This equality was demonstrated in the theoretical works of Bungay et al. (1990), where the tissue was treated as a single-phase uniform medium. For the ZNF method, Bungay et al. (1990) elegantly showed that the following equation, 0
1
C in C out ¼ E @C in |{z} C A
(2)
C ZNF
can be derived from the mass balance equation across microdialysis membrane and between dialysate inlet and outlet. From Eq. (2), it is obvious that when Cin Cout ¼ 0, Cin ¼ CZNF ¼ C*. Furthermore, Eq. (2) also shows that when Cin ¼ 0, R ¼ E. Initially, Eq. (2) was believed to be adequate since the concentration difference plot constructed from experimental data always yields a straight line, implying that reversal operation from recovery (when Cin is lower than CZNF) to delivery (when Cin is higher than CZNF) around the ZNF point is symmetric (Parsons and Justice, 1994). As recent works from Michael and coworkers (Peters and Michael, 1998; Yang et al., 1998; Peters et al., 2000; Yang et al., 2000) started to question the equality between R and E due to the
probe-induced damages to neurotransmitter release (and possibly uptake), a more general relations was proposed, 0
1
B R C C C in C out ¼ E B @C in E C A, |ffl{zffl}
(3)
C ZNF
where it is seen that the measured ZNF concentration CZNF will not be the true ECS concentration C* if R is not equal to E, and vice versa. Furthermore, any difference between R and E should be reflected on the difference between CZNF and C*. When Eq. (3) is used to interpret the concentration difference plot, such plots can only determine E and CZNF, but not R (since C* is unknown and cannot be assumed to be equal to CZNF). II.A.2. Varied flow rate method This method is based on the idea that if a nonperfusing microdialysis probe is placed in the tissue, long enough, eventually diffusion equilibrium is achieved and the neurochemical contents inside and outside of the probe should be the same. Analyzing the dialysate content (Cout) of various analytes in equilibrium gives a direct indication of their mean extracellular concentrations in the surrounding tissue, which, hypothetically, should be the same as the CZNF determined by the ZNF method2. Since a true zero perfusion flow rate cannot be achieved for the purpose of collecting dialysate fluid in sufficient quantity, a non-zero flow rate, notwithstanding its smallness, disturbs concentration equilibrium and creates diffusion gradients for all kinds of analytes across the probe membrane. Hence, an alternative to circumvent this dilemma is to perform microdialysis sampling at various low perfusion flow rates. Then the curve of the dialysate concentration versus the flow rate is extrapolated to the zero flow condition to obtain the ideal extracellular concentration. Whereas extrapolation may create quite significant errors, theory had been developed to help 2 Originally, it was believed that the concentration determined at the no-flow condition will reflect the true C* in the undisturbed tissue. Now it is understood that it is in fact CZNF.
52 10 best fit with theory extrapolations
Cout (nM)
8 6 4 2 0 0
0.25
0.5
0.75 1.0 Q (µL/min)
1.25
1.5
Fig. 2. Plot of the varied perfusion flow method illustrating the possible errors in the extrapolation process. As can be seen, extrapolation without theoretical fitting could return erroneous results at the zero flow rate. Hence, prediction of CZNF can be greatly facilitated by fitting the data first.
reduce possible extrapolation errors (Jacobson et al., 1985; Bungay et al., 1990), C out ¼ 1 expðK m A=QÞ, C ZNF
(4)
where Km is the mean mass transfer coefficient, A the active membrane surface area, and Q the probe perfusion flow rate. In Fig. 2, one can see that the theoretical curve of Eq. (4) actually levels off slightly as the flow rate Q approaches zero. Thus extrapolation to the no-flow condition without the help of theoretical fitting is dangerous. II.B. More theoretical models The development of microdialysis models can be roughly divided into two stages, depending on whether the tissue trauma was specifically considered. In the early stage (the first stage), the microdialysis model was developed without explicitly considering the traumatized tissue (in terms of altered tissue ECS structure and impaired neurotransmitter release and uptake). It is noticed, however, that if the traumatized tissue extends sufficiently wide, it becomes the sole medium interacting with the microdialysis probe. In this case, the presence of the healthy tissue can be ignored and the single-medium model is still applicable as long as the parameters for the single-phase tissue
can properly reflect those of the traumatized tissue. In the second (also the latest) stage, microdialysis models explicitly incorporated a layer of traumatized tissue between the microdialysis probe and the outermost healthy tissue. Apparently, model of this kind, although more complex by nature due to incorporating more unknown parameters, is better equipped to study how preferential damages in the neurotransmitter release and uptake affect the accuracy of quantitative microdialysis. II.B.1. Theory without specifically considering tissue trauma Benveniste et al. (1989) were the first to recognize that the in vitro calibration method (i.e., using the in vitro recovery ratio Rin vitro to estimate C* by CoutXRin vitro) could be problematic in predicting the extracellular concentrations of some analyte (especially true for K+, Ca2+, and mannitol), mainly because of the uncertainty of the diffusional resistances of these analytes in the surrounding tissue. To correct the in vitro recovery to estimate C* in vivo, they proposed a semi-empirical relation to account for the increased diffusion resistance in the tissue, l2 C out C ¼ K (5) fe Rin vitro where l is the diffusional tortuosity in the tissue ECS (Nicholson and Sykova, 1998), fe the ECS volume fraction. The constant K represents a compensating factor for the concentration gradient across the probe membrane, but can be used to account for other factors as well. A value of K ¼ 0.7 was estimated based on microdialysis data of K+, Ca2+, and mannitol (Benveniste et al., 1989). It should be noted that derivation of Eq. (5) was based on pure diffusion and did not consider influence of active processes. Another notable microdialysis theory was at the same time developed by Amberg and Lindefors (1989), who considered the diffusion resistances in the tissue as well as in the probe membrane and the perfusing dialysate. Their main result can be summarized by the following equation, R¼
4pLfe De hðtÞ, Q
(6)
53
C ¼
C out Q C out Q C out ¼ . R 4pLfe De hðtÞ 0:8pLfe De
(7)
Similarly, Amberg and Lindefors (1989) did not consider the active processes in their model. Because of this, models of both groups cannot be applied to compounds governed by highly active processes such as neurotransmitters. Their theory can be applied to quantify extracellular neurotransmitter concentrations only when the active processes are obliterated (e.g., by 6-OHDA lesions to destroy dopaminergic innervation) or inhibited (by various pharmacological blockers). II.B.2. Theory considering tissue trauma Theoretical modeling to study the impact of possible tissue trauma on microdialysis sampling characteristics started with Peters and Michael (1998), who constructed a simple, discrete release model to explain their experimental observations (Lu et al., 1998; Yang et al., 1998) in rat striatum. In their experiments incorporating both microdialysis sampling and fast-scan cyclic voltammetry (FSCV), they found that evoked response of extracellular DA as recorded by a carbon-fiber microelectrode placed immediately adjacent to the microdialysis probe was absent, but became detectable after DA uptake inhibitor nomifensine was systemically applied. Whereas their model can capture qualitative behaviors in agreement with their experimental data and support their claims, their model is not without drawback. For example, only one single DA release site was considered in the initial model of Peters and Michael (1998). Although later on, a more realistic model with multi-discrete release sites was introduced (Yang et al., 2000), it appears that the more systematic investigation on how microdialysis-induced tissue trauma affect microdialysis sampling can be obtained from more rigorous and well-constructed models. Since the works of Michael and
coworkers, Bungay et al. (2003) and Chen (2005a, 2005b, 2006) also attempted to build mathematical models to examine the effects of tissue trauma on the sampling composition and accuracy of quantitative microdialysis methods, especially the ZNF method. In these models, the probe-induced ‘‘tissue trauma’’ is categorized as (i) tissue morphological alterations in terms of abnormal tissue ECS and extracellular diffusivity and (ii) physiological impairment in neurotransmitter release and uptake. The model in Bungay et al. (2003) will be further introduced in another chapter of the book. Hence only the model from Chen (2006) is described here. It should be noted that both models from Bungay et al. (2003) and Chen (2006) are extremely similar and were built on the same framework. Fig. 3 depict the schematics of Chen’s microdialysis model. A glossary of the symbols used in the model is given in Table 1. Along the radial direction, the diffusible space was divided into three regions, the probe membrane (region 1: [ri, ro]), the traumatized tissue layer (region 2: [ro, rt]), and the external normal tissue region (region 3: [rt, N]). The parameters for ECS diffusion and
membrane
traumatized tissue
normal tissue
Di =
Dm
Dt
De
φi =
φm
φt
φe
κi =
0
κt = εκ κe
κe
σi =
0
σt = εσσe
σe
r
~ ~
where h(t) is a scaled time-dependent factor, De the effective diffusivity of analyte in the brain ECS, and L the probe membrane length. The function h(t) declines monotonically to 0.2 after a reasonably long time (1 h). Hence,
ri
ro
rt
Fig. 3. Schematic representation of the microdialysis model showing the three consecutive diffusion regions in the radial diffusion direction, respectively, the membrane [ri, ro], the trauma tissue layer [ro, rt], and the normal tissue [rt, N]. Each region is characterized by its distinct diffusion properties (D and f), neurotransmitter release rate density (s) and linear uptake rate constant (k), with different subscripts indicating the different regions. Figure reproduced from Chen (2005a) with permission.
54 Table 1. Glossary of the model variables and parameters Symbols ri ro rt Q L Cin Cout CZNF C* fm ft fe Dm Dt De kt ke kt se rm rt re Gt Ge w
Inner radius of the microdialysis probe membrane Outer radius of the microdialysis probe membrane Outer radius of the traumatized tissue layer Microdialysis infusion flow rate Probe membrane length Dialysate analyte concentration at inlet Dialysate analyte concentration at outlet Dialysate analyte concentration at zero-net-flux point Basal ECS concentration in normal tissue Volume fraction of diffusible space in probe membrane Volume fraction of the ECS in the trauma tissue Volume fraction of the ECS in the normal tissue Effective diffusivity of the analyte in the membrane Effective diffusivity of the analyte in the trauma tissue Effective diffusivity of the analyte in the normal tissue First-order uptake rate constant in the trauma tissue First-order uptake rate constant in the normal tissue Constant release rate of the analyte in the trauma tissue Constant release rate of the analyte in the normal tissue Diffusion resistance in the membrane region Diffusion resistance in the trauma tissue Diffusion resistance in the normal tissue Diffusion penetration distance in the trauma tissue pffiffiffiffiffiffiffiffiffiffiffiffi ð¼ Dt =kt Þ Diffusion penetration distance in the normal tissue pffiffiffiffiffiffiffiffiffiffiffiffiffi ð¼ De =ke Þ Concentration weighting function, defined in Eq. (10)
neurotransmitter release/uptake processes in each region are indicated in the figure. By solving the coupled mass balance equation in each region simultaneously, the analytical concentration profile within each region was obtained and the theoretical expression for E was found to be 1 E ¼ 1 exp , (8) Qðrm þ rt þ re Þ where rm, rt, and re are the diffusion resistances in the probe membrane, the traumatized tissue layer, and the normal tissue, respectively, and are
specifically given as ln rroi rm ¼ 2pLfm Dm Gt F t Grot ; Grtt ro and rt ¼ 2pLft Dt F ro ; rt ; rt G t G t Ge Ge K 0 Grte F e Grot ; Grtt rt re ¼ 2pLfe De K 1 rt F ro ; rt ; rt Ge Gt Gt Ge where K0( ) and K1( ) are the modified Bessel functions of the second kind of order zero and one, respectively, Fe, Ft, and F* are some geometric functions associated with the dimensions and properties of the microdialysis probe and tissues. These functions exist partly due to the arbitrary distinction of the tissue trauma layer from the normal tissue3, and are defined as ro rt ro rt rt ro Ft ; ¼ K0 I0 K0 I0 Gt Gt Gt Gt Gt Gt
rt ro rt Fe K0 ¼ I1 ro Gt Gt rt ro þK 1 I0 Gt Gt ro rt ro rt rt F ; ; ¼ K1 I0 Gt Gt Ge Gt Gt rt ro þ K0 I1 Gt Gt ro K 0 Ge G e f t Dt þ Gt fe De K 1 rt Ge ro rt K0 I1 Gt Gt rt ro þ K1 I0 Gt Gt ro rt ; Gt Gt
3
It should be understood that microdialysis-induced tissue trauma is not distinctly confined within close proximity of the probe but is progressively distributed. Hence, the rt in the model represents a cut-off distance similar in concept to the molecular size cut-off for the microdialysis membrane permeability. The Dt, ft, es, and ek represent the averaged properties within the conceptualized distinct trauma region.
55
where I0( ) and I1( ) are the modified Bessel functions of the first kindffi of order zero and ffione, pffiffiffiffiffiffiffiffiffiffiffi pffiffiffiffiffiffiffiffiffiffiffiffi respectively, Gt ð¼ Dt =kt Þand Ge ð¼ De =ke Þare the diffusion penetration distances in the traumatized and normal tissue, respectively. Another important theoretical result from the model is that the CZNF is related to C* by s C ZNF ¼ ð1 wÞ þ w C , k |fflfflfflfflfflfflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflfflfflfflfflfflffl}
(9)
R=E
where es and ek are the remaining fractions of the release and uptake strengths, respectively, in the traumatized tissue (see Fig. 3 for symbol clarification). The w is a weighting function between the normal baseline C* and the altered baseline (Ct ¼ es C*/ek) in the traumatized layer, and is defined as w¼
G =r t o
F Grot ; Grtt ; Grte
.
(10)
Since the factor between CZNF and C* is the ratio R/E, the in vivo recovery R is theoretically expressed as R¼
1 1 exp Qðrm þ rt þ re Þ s ð1 wÞ þ w , k
ð11Þ
in which the first term in the brackets represents the extraction efficient E defined in Eq. (8). As the model was specifically built for studying the microdialysis ZNF method sampling endogenous neurotransmitter, several conclusions regarding the ZNF operation were made from the model simulations. First, the model shows that changes in the ECS structure (reflected by the modified Dt and ft) of the surrounding tissue do not affect the accuracy of the ZNF method. This prediction is reasonable since microdialysis ZNF method is supposed to operate under quasi-steady states. Second, microdialysis-induced damage on neurotransmitter release and uptakes can cause either underestimate or overestimate of the basal
ECS concentration of the affected neurotransmitters as determined by the microdialysis ZNF method, depending on which process is damaged more. Underestimation (i.e., CZNFoC*) occurs when the probe impairs more of the neurotransmitter release sites than the uptake site in the tissue surrounding the probe, and the reverse is also true. Third, the consequence of a serious ZNF underestimation (due to the overwhelming damage to the neurotransmitter release sites) is that the in vivo recovery R of the endogenous neurotransmitter would ‘‘increase’’ after systemic application of the specific neurotransmitter uptake blockers, exactly opposite of the known trend of the microdialysis extraction efficiency E with neurotransmitter uptake inhibition4. The three predictions all agree with the experimental and theoretical works of Michael and coworkers. However, one more in-depth observation from the model simulation is that the in vivo recovery of neurotransmitter R starts to increase with systemic uptake inhibition only when the neurotransmitter release site are damaged more than the corresponding uptake sites in the surrounding tissue. How much more of the neurotransmitter release damage is required for the R to exhibit a rising trend with systemic uptake inhibition? Model simulations (Chen, 2006) indicate that for this rising trend (i.e., an increasing R of [DA]e following DA uptake inhibition) to occur is when es/eko0.4 (see the Fig. 11 in Chen, 2006). This criterion is based on a relative scale. That is, if the uptake sites surrounding the microdialysis probe were also damaged such that ek is, say, 0.5, then the maximum es to exhibit a rising R upon uptake inhibition is 0.4 0.5 ¼ 0.2. 4 Experiments on the microdialysis ZNF method have demonstrated that the slope of the concentration difference plot (i.e., the extraction efficiency E) of several neurotransmitters decreased upon application of neurotransmitter uptake inhibitors. The tested neurotransmitters include dopamine (Smith and Justice, 1994), serotonin and norepinephrine (Cosford et al., 1996). In the opposite direction of uptake inhibition, Zapata and Shippenberg (2002) showed that dopamine D3 receptor agonist significantly ‘‘increased’’ the microdialysis extraction efficiency of dopamine and ‘‘decreased’’ dopamine ZNF concentration, indicating involvement of D3 receptors on DA transporter activity.
56
Although the mathematical models of Bungay et al. (2003) and Chen (2005b, 2006) allow the effects of tissue trauma on microdialysis performance to be studied, the models also introduce more unknown parameters, most of which cannot be obtained experimentally. For example, the models characterize the tissue trauma by a distinct tissue layer of different diffusive and release/uptake properties immediately outside of the probe. It should be understood that microdialysis-induced tissue trauma is not distinctly confined within close proximity of the probe but is progressively distributed. Therefore, the trauma layer distance rt in the model represents a cut-off distance similar in concept to the molecular size cut-off for the microdialysis membrane permeability. Furthermore, the es and ek represent the averaged properties within the conceptualized distinct trauma region. What the models offer allow us to analyze, from a theoretical perspective, how the microdialysis characteristics would be changed if tissue trauma did occur. III. Studying basal DA to infer errors in quantitative microdialysis III.A. Introduction The microdialysis-induced tissue damage on neurotransmitter release and uptake processes has particularly important implications in the microdialysis data studying extrasynaptic transmission and tonic regulation of neuronal activity by extracellular neurotransmitters. The experimental and theoretical works of Michael and coworkers (Lu et al., 1998; Peters and Michael, 1998; Yang et al., 1998; Borland et al., 2005) on extracellular DA in rat striatum had led them to the following conclusions: (1) Microdialysis probe implantation would traumatize the tissue immediately surrounding the probe, within which an overwhelmingly large number of the DA release sites are damaged compared with uptake sites. (2) Because of the preferential damage in DA release, the probe relative recovery is much smaller than the corresponding extraction efficiency of DA.
(3) For DA, not only is R smaller than E, R also exhibits the opposite trend of E in response to pharmacological DA uptake inhibitors. (4) The measured ZNF concentration CZNF significantly underestimates the basal ECS concentration of DA in striatal tissues. From their experimental data (Lu et al., 1998; Yang et al., 1998; Borland et al., 2005), the damaged DA release induced by acute probe implantation was estimated to yield a CZNF as low as only 2% of the unperturbed ECS DA concentration C* in the striatum (Peters and Michael, 1998; Peters et al., 2000). Since the microdialysis ZNF concentration of ECS DA in the general region of rat striatum has been reported to be within the 6–12 nM range; in rat striatum (Sam and Justice, 1996; Jones et al., 1998), in nucleus accumbens (Parsons et al., 1991; Parsons and Justice, 1992; Smith and Justice, 1994; Yim and Gonzales, 2000), Michael and coworkers concluded that the resting level of striatal [DA]e should be at least 500 nM (Kulagina et al., 2001), and could be as high as 2 mM (Borland and Michael, 2004; Borland et al., 2005). Obviously, the conclusions and criticisms drawn from Michael and coworkers regarding the errors in microdialysis ZNF method have a profound impact on the use of microdialysis. Theoretical simulations modeling microdialysis characteristics under damaged neurotransmitter release and uptake (Peters and Michael, 1998; Bungay et al., 2003; Chen 2005a, 2005b, 2006) have shown that the above predictions are true if probe implantation indeed caused preferential damage on the neurotransmitter release sites. What is not shown independently is whether striatal [DA]e is at the micromolar level. To investigate if the reported ZNF concentrations for ECS DA seriously underestimate the basal [DA]e in rat striatum, one must examine current evidence of the true resting level of striatal [DA]e obtained by means other than microdialysis. As the tonic [DA]e sets the background level of DA signaling as well as the transmission of other excitatory neurotransmitters, investigation of the tonic level of ECS DA is itself highly important aside from the issue of microdialysis validity.
57
III.B. Basal level of extracellular DA in rat striatum Since the accuracy of the ZNF method in measuring the true, unperturbed C* is being questioned, the data obtained by real-time FSCV are particularly relevant because the smaller carbon-fiber sensor is believed to induce less tissue disruption (Khan and Michael, 2003). Unfortunately, most FSCV studies are designed to measure only the dynamic changes of extracellular monoamines during electrical stimulation because stable signals from the basal [DA]e in vivo cannot be reliably obtained. Besides the fact that the voltammetric currents are prone to shifts in the ionic environment of the brain, the active DA uptake and metabolism are thought to keep the [DA]e so low that other electroactive substances that oxidize at similar voltage potentials, such as DOPAC (5 mM) and ascorbate acid (400 mM), seriously mask the true DA signals (Rice and Nicholson, 1995). If striatal [DA]e is indeed 2 mM, there seems to be no reason why such a high basal [DA]e cannot be detected by FSCV. The hypothesis of a low basal ECS DA and high interferences from DA metabolites in striatum is plausible because the basal [DA]e in the retina, where we believe DA uptake is minimal and extracellular DOPAC is low, could be voltammetrically measured without difficulty (300 nM; Witkovsky et al., 1993). The same reasoning also explains why in vitro a much lower DA concentration (at the nanomalar range) can always be measured in a beaker (perhaps because no significant interferences from other ions or metabolites).
III.B.1. Evidence for a nanomolar DA Within the few voltammetry studies that used different techniques to measure the basal DA in the striatum of anesthetized rats, the reported values for [DA]e are quite random but consistently at the nanomolar range. Crespi and Mobius (1992) reported a basal DA level of 1.5 nM with differential pulse voltammetry (DPV), whereas Gonon and Buda (1985) and Suaud-Chagny et al. (1992) obtained higher values (26 and 8 nM, respectively) with differential normal pulse voltammetry. Particular attention should be paid to the work of
Blaha (1996), where he applied chronoamperometry with stearate–graphite paste electrode (SGE) and estimated a striatal [DA]e 85 nM. However, this estimation may be erroneous because Blaha used the total delivered DA concentration (Cin – Cout) to be the ECS concentration immediately outside of the microdialysis probe in his calculation. To make corrections on his data, it is necessary to first summarize his experimental procedure. Blaha (1996) placed the SGE (o.d. 0.15 mm) next to a concentric microdialysis probe (o.d. 0.34 mm) implanted in rat striatum. After maximally inhibiting DA uptake by nomifensine (a DA transporter blocker) followed by perfusing the probe with Ca2+-free Ringer, Blaha performed retrodialysis with exogenous DA ranging between 0.5 and 2.5 mM and recorded the DA signals immediately outside the probe with the SGE. The combined use of a Ca2+-free Ringer and repeated nomifensine applications ensured that the surrounding tissue was free of spontaneous DA release and active uptake, and hence could be viewed as a passive medium. Under this circumstance, the DA signals recorded next to the microdialysis probe may truly reflect the infused concentration of exogenous DA. From the retrodialysis calibration, he found that the DA signals corresponding to Cin ¼ 2 mM was the same as the pre-nomifensine baseline (Fig. 4). Since Cin ¼ 2 mM also resulted in Cin Cout, ¼ 85 nM, he concluded that the basal [DA]e is about 85 nM, which obviously may not be the ECS DA concentration surrounding the probe. To recalculate the actual [DA]e outside of the probe, we can assume that the perfusion of Ca2+free Ringer completely inhibits synaptic DA release in the surrounding tissue so that the CZNF outside of the probe is zero and the microdialysis extraction efficiency can be calculated as (Cin Cout)/Cin ¼ 85 nM/2000 nM ¼ 0.043. According to the microdialysis theory developed in Chen et al. (2002), the steady-state extracellular concentration distribution under passive diffusion (valid when a very small k was used) is CðrÞ ¼ C in UðrÞ; with the normalized distribution U(r) defined as r K 0 Ge r U (12) ¼ ro ln ro ro fe De K 1 ro þ K 0 ro ri
Ge f m D m
Ge
Ge
58
Fig. 4. In vivo calibration by retrodialysis. Nomifensine was first applied (2.5 mg/kg) with a bolus i.v. injection, followed by the same dose for every 30 min for the first hour and every hour thereafter. At the time nomifensine induced maxima uptake inhibition (observed by the increase of SGE signals), dialysis probe was perfused with a Ca2+-free Ringer at 5 mL/min. One hour after the start of Ca2+-free perfusion, which was when SGE signals started to decline, DA was added to the Ca2+-free Ringer in concentrations of 0.5, 1.0, 1.5, 2.0, and 2.5 mM. HPLC analysis indicated that Cin Cout ¼ 1976, 4573, 67710, 8676, and 11079 nM for each DA concentration infusion, respectively. The horizontal dashed line represents the pre-nomifensine level. Figure reproduced from Blaha (1996) with permission.
In the work of Blaha (1996), the microdialysis probe had an outer diameter 0.34 mm, an active membrane length 0.4 mm, and was perfused at the flow rate 5 mL/min. Using ro ¼ 0.17 mm, L ¼ 0.4 mm, Q ¼ 5 mL/min, and other assumed parameters [fe ¼ 0.4 (according to Bungay et al., 2003), De ¼ 1.5 (2.4 10–6) cm2/s (control value increased by 1.5-fold due to increased fe), k ¼ 0.1 1/s (due to nomifensine application)], the following parameters are adjusted: ri ( ¼ 0.12 mm), fm ( ¼ 0.2), and Dm ( ¼ De), until the extraction efficiency, ! 2pro fe De L dU E ¼ 1 exp , (13) Q dr r¼ro agrees with the experimental value 0.043. To obtain the averaged [DA]e outside of the probe as measured by SGE, the spatial distribution of the theoretical ECS DA was averaged from r ¼ ro to r ¼ 5ro, which corresponds to the regions possibly interacted with the SGE, and yielded an averaged C¯ ¼ 20 nM. Hence, the baseline signals obtained in Blaha (1996) correspond to [DA]e ¼ 20 nM instead of the higher 85 nM. Nonetheless, it is cautioned that this nanomolar estimate of [DA]e in
the vicinity of the microdialysis probe can also be used to support the preferential damages on DA release sites surrounding the probe, hence favoring the claim of a much higher basal [DA]e in the distant, undisrupted tissue. In view of the available voltammetry data for baseline DA, the randomness in the reported data from different groups probably reflects the aforementioned hypothesis that voltammetry is not suitable for measuring the baseline level of electroactive substances that are in scarce quantity, especially in vivo where other interferences may be present. Hence the randomness is more or less expected. Nonetheless, all reported data fall within the nanomolar range, which is consistent with the conventional hypothesis that the basal [DA]e in the striatum is low. In addition to directly measuring ECS DA by voltammetry, several studies also attempted to estimate the basal ECS level of DA using voltammetrically derived kinetic data. Kawagoe et al. (1992) measured the DA uptake kinetic parameters and used them in a further analysis, estimating the time-averaged ECS DA 2 mm away from a DA synaptic cleft to be 6 nM. In a complex finitedifference model to simulate the tonic and phasic
59
DA releases in the caudate-putamen, Venton et al. (2003) predicted a tonic background [DA]e 30 nM using voltammetrically derived parameters. Although a consensus among all simulation works is that a low-basal ECS DA is consistent with the current voltammetrically measured DA kinetics, these simulation results may not be very conclusive because some other unknown mechanisms may not be accounted for. III.B.2. Evidence for a micromolar DA Nonetheless, evidence supporting a higher level of ECS DA is also available, mainly from the laboratory of Michael and coworkers. For example, Kulagina et al. (2001) recently found that intrastriatal infusion of the ionotropic glutamate receptor antagonist kynurenate caused a steep drop in the DA-like electrochemical signals equivalent to 500 nM of the ECS DA, implying that the ECS DA level must be at least above 500 nM to afford such concentration drops. Borland and Michael (2004) found even larger drops in the FSCV signals equivalent to 2 mM of extracellular DA. Some other indirect evidence also comes from the voltammetry recording of evoked DA release immediately adjacent to and distant from an acutely implanted microdialysis in the striatum while electrically stimulating the medial forebrain bundle (Lu et al., 1998; Yang et al., 1998; Borland et al., 2005). They found that the evoked DA response immediately adjacent to the probe was lacking while the DA response 1 mm away from the probe was robust. After systemic administration of nomifensine, evoked [DA]e response adjacent to the probe became detectable. They concluded that the lack of evoked DA response immediately adjacent to the microdialysis probe before nomifensine is due to the probe-induced destruction of essentially all the DA release sites in the same tissue region, while most uptake sites remained intact. After applying nomifensine to inhibit uptake, noticeable DA response adjacent to the probe was due to the prolonged diffusion of extracellular DA released from distant viable DAergic synapses. If this argument is true, one would expect a time delay in the DA signals at the probe after nomifensine because most of the DA signals recorded here should come from diffusion of the evoked DA
released at certain distances away from the probe. However, their recorded traces did not show such time delays. It is uncertain whether the recorded signals adjacent to the probe after nomifensine resulted from (i) a local DA release or (ii) a distant DA release plus diffusion. Additionally, Borland et al. (2005) found no increase in the non-evoked base line for [DA]e after nomifensine application. This is in contrast to the common understanding that nomifensine increases the local motor activity (Nakachi et al., 1995; Stanford et al., 2002; Garris et al., 2003), which can also be triggered by increases in [DA]e (Costall et al., 1983; Steinpreis and Salamone, 1993; Ando et al., 1994; Fan et al., 2000). The lack of noticeable changes in DA baseline in response to nomifensine may be attributed to the inability of FSCV to measure the non-evoked basal [DA]e, even after DA uptake process was blocked. However, a similar study performed by Blaha et al. (1996) also measured the basal [DA]e level in striatum from a SGE (stearate–graphite past electrode) standing alone or placed next to a microdialysis probe. Contrary to the findings of Borland et al. (2005), Balha et al. (1996) found increased basal [DA]e recorded from the stand-alone SGE after nomifensine application. Although their electrode is quite large in size (0.15 mm o.d.), they argued that the active recording area, confined to the tip surface of the graphite paste, is quite small and not in direct contact with the highly traumatized tissue in the shaft region of the electrode. It appears that even with voltammetry technique, many results obtained from different groups regarding the basal [DA]e itself and the effect of DA uptake inhibitors on basal [DA]e can still be inconsistent. Currently, there appear to be no ready explanations to satisfactorily resolve these conflicting findings for the basal level of striatal [DA]e as measured by different voltammetry methods. Could the differences be attributed to acute and chronic microdialysis? Whereas the lack of evoked DA response in the tissue adjacent to an acutely implanted microdialysis probe has been positively verified by Michael and coworkers, it is uncertain whether this unresponsiveness of neurotransmitter release to impulses still persists over longer periods of time, as it has been hypothesized that synaptic
60
connection and synaptic transmission could be self-repaired to certain extent after inflammatory response subsided (Georgieva et al., 1993; MartinFardon et al., 1997; Hasbani et al., 2000). An ad hoc hypothesis here is that the traumatized tissue, given time, could partially recover from the implantation of the foreign object at about the same time the inflammatory response subside (which is what the recovery period is for in chronic microdialysis). Thus, it would be desirable if the microdialysis/voltammetry experiments of Michael and coworkers could be extended to chronic situations for further verification.
III.C. Extracting basal extracellular DA level from DA kinetic study
assumed to be zero. In its current form, Eq. (14) is insufficient to describe the DA kinetics immediately following electrical stimulation, for it implies that after stimulation the absolute [DA]e eventually declines to zero. An appropriate DA kinetic model must also recognize the fact that during the evoked DA overflow experiments, the carbon fiber electrode in fact registers the relative changes in [DA]e, DC, rather than the absolute [DA]e level, C ¼ C*+DC (Wightman and Zimmerman, 1990; Jones et al., 1998). Since the Michaelis–Menten uptake mechanism is commonly known to apply to the absolute concentration C, not DC (as demonstrated by many receptor binding experiments on synaptosomes), Eq. (14) cannot be used with the symbol C simply replaced by DC. Thus, this DA kinetic model needs to be modified.
Indirect estimates for a low ECS concentration of DA can also be made from DA kinetic studies using FSCV combined with carbon fiber microelectrodes (e.g., Wightman and Zimmerman, 1990; Kawagoe et al., 1992; Garris et al., 1994; Wu et al., 2001). Before making such estimates, it is necessary to address the baseline issue often ignored in the existing DA kinetic analyses.
III.C.2. Modifications of the DA kinetic model Assuming that [DA]e is non-zero, a basal level for [DA]e (denoted as C*) under non-stimulated condition should be sustained by the basal release rate sand can be described by Eq. (14) under steady ¯ state as
III.C.1. Existing DA kinetic model from voltammetry study In the experiments of cyclic voltammetry coupled with electrical stimulations, the non-linear DA uptake parameters, the maximum uptake velocity Vmax and the Michaelis–Menten constant Km, were obtained by fitting the Michaelis–Menten uptake model (Wightman and Zimmerman, 1990) against the transient profile of the evoked DA,
in which the basal level C* is similarly defined as a mean value averaged over time and space. As noted, the FSCV technique is best suited for monitoring concentration changes (DC) of catecholamine over a short period of time, during which the baseline C* can be assumed constant. Hence, Eq. (14) during electrical stimulation (in which the basal release term is replaced by the synchronized release term, [DA]p f ) can be rewritten as
dC V max C ¼s , dt Km þ C
(14)
where s (nM/s) is the mean DA release rate averaged over space and time as defined in Chen (2005b), and C represents the ECS DA concentration. During the electric stimulation, s is represented as a product of the unit [DA]e increase per stimulus pulse, [DA]p, and the stimulation frequency f (Hz). After stimulation ceases, s is
s¯ ¼
sK V max C ¯ m or C ¼ K m þ C V max s¯
(15)
dðC þ DCÞ dDC V max ðC þ DCÞ ¼ ¼ ½DAp f dt dt K m þ C þ DC (16) To obtain an equation for the measured variable, DC, Eq. (16) is subtracted from the governing equation at steady state, that is, 0¼
dDC V max C ¼ s¯ , dt K m þ C
61
yielding dDC V app max DC ¼ ½DAp f s¯ app , dt |fflfflfflfflfflfflfflffl{zfflfflfflfflfflfflfflffl} K m þ DC
(17)
½DAapp p f
during electrical stimulation, where ½DAapp ¯ ; V app p ¼ ½DAp s=f max ¼ V max K m = ðK m þ C Þ ¼ V max s; ¯ and K app m ¼ K m þ C are the apparent parameters of the current DA kinetic model used in experimental fitting for DC, as in contrast to the intrinsic parameters [DA]p, Vmax, and Km in Eq. (14) for C. The reason to arrange the original Eq. (16) for DC to Eq. (17), which retains the same form as Eq. (14), is that the existing fitting algorithm used in many studies need not be changed then. After the cessation of electrical stimulation, the original DA kinetic model assumed that the tonic firing of DAergic neurons is temporarily inhibited (Wightman and Zimmerman, 1990), thus leaving only DA uptake. However, for a more general form, we can designate the tonic DA release rate after electrical stimulation to be s(t), so that dDC V app max DC ¼ ½sðtÞ s ¯ app dt K m þ DC after electrical stimulation:
ð18aÞ
Note that in theory, one must assume 0 sðtÞ s¯ to obtain sensible results. If the tonic DA release after electrical stimulation is not inhibited, sðtÞ ¼ s; ¯ yielding another version of Eq. (18a) as dDC V app max DC ¼ app ; after electrical stimulation: dt K m þ DC (18b) The reason for particularly mentioning this special case of no post-stimulation inhibition in tonic DA release is that Eq. (18b) is the current equation used to fit the uptake data of evoked DA following electrical stimulation. This implies that the current fitting methodology, commonly applied by many researchers, in fact assumed no post-stimulation inhibition on DA release. On the other hand, since
the work of Kuhr et al. (1987) indicated that DA tonic release after electrical stimulation was indeed temporarily suppressed, one would expect to see the recorded DA signals in the uptake phase fall below the pre-stimulation level. In such case, the extent of the signal undershoot can provide an estimate of the basal [DA]e. Since all voltammetry studies on kinetic DA overflow and uptake did not show such undershoots, it might imply that either the post-stimulation inhibition on DA release is absent or short-lived, or the tonic DA release is largely impulse-independent and hence not affected by electrical stimulation. Alternative explanations for the lack of obvious undershoots in post-stimulation DA kinetics might be that undershoot did occur, but the relative scale of undershoot compared with the evoked DA overflow was too small to be noticed, the baseline level of the ECS DA was too low, or some combination of both. III.C.3. Interpretation of the fitted parameters Since the current DA kinetic model fitted the kinetic data of the evoked DA changes, DC, against Eqs. (17) and (18b), it is obvious that the fitted parameters are the apparent ones when the whole DC curve was fitted (Wu et al., 2001). This means that for most kinetic data measured in rat striatum, including caudate-putamen and nucleus accumbens, the experimental V app max ¼ V max K m = ðK m þ C Þ ¼ 2:526:0mM=s and K app m ¼ Km þ C ¼ 0:1520:35mM (Kawagoe et al., 1992; Wu et al., 2001; Garris et al., 2003). The fitted unit increase of ECS DA concentration is also the apparent one, ½DAapp ¼ ½DAp s=f ¯ ; which is not a constant p but depends on the stimulation frequency f. On average, ½DAapp has a value 0.27 mM/s when f is p 10 Hz (Kawagoe et al., 1992). Assuming s¯ ¼ 0:25mM=s 5Hz ¼ 1:25mM=s (the frequency 5 Hz is the assumed resting firing frequency of DAergic app neurons), the fitted V app max ¼ 3:8mM=s and K m ¼ 0:2mM; one can determine the intrinsic Vmax, Km, and the basal C* from the aforementioned relations by recursive iterations and self-corrections, as demonstrated in Chen (2005b). It was found that the intrinsic Vmax and Km are 5.05 mM/s and 0.15 mM, respectively, resulting from a basal C*49.5 nM.
62
In the literature, there is another type of data analysis: the individual parameters were fitted separately from different regions of the response curve (Kawagoe et al., 1992; Wu et al., 2001). For example, the maximum velocity V app max (or Vmax) was fitted from the largest descending slope of the signal curve immediately following the stimulation, assuming that C at this stage was much higher than Km. The apparent V app max was obtained from the slope if Eq. (18b) was used (i.e., sðtÞ ¼ s). ¯ This experimental V app ð¼ V sÞ is a lower ¯ max max bound of the intrinsic Vmax. In contrast, if sðtÞ ¼ 0; s¯ þ V app max ¼ V max is the slope obtained. Thus the measured slope can range from ðV max sÞ ¯ to V max : Similarly, [DA]p (or ½DAapp ) was deterp mined from the difference of the slopes on both sides of the curve at the end of stimulation: ½DAp ð or
1 dDC dDC ½DAapp , p Þ¼ f dt before dt after (19)
which could yield either [DA]p or ½DAapp p ; depending on if sðtÞis equal to its minimum (zero) or maximum (s) ¯ immediately after electrical stimulation, respectively. As to the Michaelis–Menten constant, Wu et al. (2001) proposed that at lowfrequency stimulations, a new elevated steady state, DCSS, can be reached, such that K app m
¼
! V app max 1 DC SS , ½DAapp p f
(20)
which was derived from Eq. (17) assuming steady states. Regardless of whether the experimental paapp rameters in Eq. (20) are V app or Vmax max and ½DAp and [DA]p, the Michaelis–Menten constant so determined by Eq. (20) appears to be the apparent one, that is, Km+C*. Recently the DA kinetic model of Chen (2005b) was further modified by Michael et al. (2005) by separating the tonic release rate, s(t), from the forced DA release during electrical stimulation: dDC V max ðC þ DCÞ ¼ ½DAp f þ sðtÞ . dt K m þ C þ DC
(21)
The advantage of this slightly modified model is that both the evoked DA release and uptake during and after electric stimulation can be described by one single equation, Eq. (21), by adjusting the time course of s(t), which must similarly be bound between [0, s], ¯ with s¯ being the steady-state resting level. Note that unlike the model of Michael et al. (2005), the s(t) in Eq. (18a) exists only after the cessation of electrical stimulation; during electrical stimulation the s(t) in this chapter is viewed as zero. In contrast, the s(t) in Eq. (21) during electrical stimulations could be non-zero. If the tonic release s(t) during electric stimulations is nonzero, which is the case in the theoretical work of Michael et al. (2005), the DA release during pulse stimulation is composed of two modes, a synchronized release enforced by the stimulation frequency f and a non-synchronized release s(t). Michael and coworkers also contended that the experimentally determined Michaelis–Menten constant K app m is related to its intrinsic counterpart byK app ¼ K m C ;not K app m m ¼ K m þ C : If the C* for striatal DA is indeed 2 mM as claimed (Borland and Michael, 2004; Michael et al., 2005), their model would imply that the intrinsic Km for the striatal DA system would be 2+0.16 ¼ 2.16 mM. This is very different from the many Km measurements found in striatal synaptosomes (e.g., Morel et al., 1998), which, however, are consistent with the FSCV measurements in the lower range (0.15–2.0 mM). A comparison of both models is summarized in Table 2. It should be noted that the relation K app m ¼ K m C exists only when K app was fitted from the m DA concentration corresponding to one-half of the maximal uptake rate, d(–DC)/dt|max. If fitting the whole curve by non-linear regression, K app m ¼ K m þ C should be the relation implied in the fitted parameters. Furthermore, Michael et al. (2005) suspected that the model of Chen (2005b) yields ‘‘unexpected’’ results when the product value ½DAp f is smaller than the basal release rate s: ¯ This ‘‘unexpected’’ result should be attributed to the use of unreasonable parameter values rather than the model’s defect. During electrical stimulations, if the voltammetry signals yield a positive response (i.e., dDC/dt>0), it is expected that the total DA release rate during this stage be larger
63 Table 2. Comparisons of the DA kinetic models incorporating non-zero DA baseline Models
Chen (2005b)
Michael et al. (2005)
Comments
Governing equations
Eqs. (17) and (18a, 18b)
Eq. (21)
Essentially the same
Tonic release time course s(t)
Zero during electrical stimulation
Could be non-zero during electrical stimulation
Baseline C*
Low (nanomolar level); bound by experimental K app m value
High (2 mM); not bound by experimental K app m value
Fundamentally different
Apparent maximal uptake velocity, V app max
V app max ¼ V max K m =ðK m þ C Þ
V app max ¼ V max sðtÞ
Essentially the same. Depending on the poststimulation s(t), the experimental V app max can range from (Vmaxs) ¯ to Vmax
Apparent Michaelis–Menten constant, K app m
K app m ¼ Km þ C
K app m ¼ Km C
Fundamentally different
Intrinsic Michaelis–Menten constant, Km
Low; bound by experimental K app m value
High; must be higher than the baseline C*
Unit DA increase, ½DAapp p
½DAapp ¼ ½DAp s=f ¯ p
No specific relation
Uptake behaviors
Rapid uptake after electrical stimulations is due to a high Vmax and a low s; ¯ release inhibition after electrical is not critical
high. Both Vmax and sare ¯ Rapid uptake after electrical stimulation is due to temporary inhibition of poststimulation DA release
than the basal release rate s: ¯ Irrespective whether the experimentally measured quantity is the intrinsic ½DAp or the apparent ½DAapp p ; it is necessary to impose that ½DAp f 4s¯ in Chen’s model to obtain reasonable simulations. This restriction on reasonable parameters is necessary and universally applicable to all models with no exceptions. For example, if the value
assigned for the total release rate ½DAp f þ sðtÞ in Eq. (21) during electrical stimulation is smaller than the constant basal release rate s; ¯ the model of Michael et al. (2005) similarly produces the ‘‘unexpected’’ negative response. Nonetheless, the most salient point in the model of Michael et al. (2005) is that they offer another possible explanation for the experimentally observed DA clearance kinetics. Since they argued for the high basal [DA]e (2 mM), the tonic DA release rate s¯ must be comparable with the maximal uptake rate constant Vmax, hence resulting a
Experimental ½DAapp p could be the intrinsic or the apparent one
slower than expected DA clearance kinetics. In this case, the rapid DA clearance seen in many voltammetry experiments must be attributed to the temporary inhibition of the on-going tonic release s(t) after electrical stimulation. Without this temporary inhibition in the tonic DA release, the overall DA clearance would be slow, as is the case for the clearance of exogenous DA (Michael et al., 2005), wherein dopaminergic neurons were not electrically stimulated. Whereas this hypothesis is very appealing and can explain the case of exogenous DA clearance, one should bear in mind that to apply this theory to interpret the DA kinetics experiments involving electrical stimulation, the release function s(t) must be manipulated in a rather precise manner: to reduce s(t) greatly immediately after the cessation of electrical stimulation so that a rapid clearance response can be seen, and to recover s(t) back to its basal level s¯ at the right moment so that no undershoot of the signals
64
below the pre-stimulation level could occur. The latter imposes an intriguing question. Could the recovery period of the DA tonic release be delayed by any means (e.g., by applying a stronger or faster stimulation amplitude/frequency, or using various pharmacological agents) to reveal the true signal undershoot in the voltammetry experiments to support the contention of a high basal [DA]e? Answer to this question should be the direction of future studies in the DA kinetics to resolve the current controversies in baseline [DA]e. III.C.4. Behavior of DA recovery with DA uptake inhibition To assess ‘‘indirectly’’ whether microdialysis implantation preferentially destroys the neurotransmitter uptake sites and hence causes the microdialysis ZNF method to underestimate the extracellular neurotransmitter concentrations, one can examine whether the relative recovery of the collected neurotransmitters increases or decreases after blocking the neurotransmitter uptake processes. If the neurotransmitter recovery ‘‘increases’’ upon inhibiting neurotransmitter uptake, this will imply that the claim by Michael and coworkers regarding the preferential damage of neurotransmitter release and the higher DA concentration is true. As mentioned earlier, the difficulty in investigating the trend of microdialysis relative recovery R ( ¼ Cout/C*) with neurotransmitter uptake inhibition lies in the uncertainty of determining C*, as the dialysate content (Cout) can be easily analyzed by HPLC-ECD. Since the validity of the microdialysis ZNF method in determining the basal C* for neurotransmitters is under question, it is necessary to use independent technique such as voltammetry to measure the steady-state C*. In this aspect, the recent data from Budygin et al. (1999, 2000) prove useful in evaluating the behavior of DA recovery with DA uptake inhibition, as both microdialysis and voltammetry techniques were used to evaluate the DA dialysate concentration (Cout) and DA uptake/release parameters, separately. The main findings of their works are that administration of GBR12909 (a selective DA uptake inhibitor) to freely moving rats increased the dialysate DA recovered from the striatum to 300% of the control level, while the K app m value, as fitted from the evoked
DA kinetic data, increased from 160 to 2,500 nM, a 15-fold increase. On the contrary, no significant app were observed with changes in V app max and ½DAp respect to GBR12909. Note that their voltammetry and microdialysis measurements were performed in different groups of rats; so the measured increase app in K app and constant V app by the m max and ½DAp smaller-size carbon-fiber microelectrodes should be free of the concern in tissue disruption as is commonly criticized with microdialysis experiments. If the basal level [DA]e is solely determined by rate balance between DA release and uptake, and indeed remains low at the nanomolar level, a 15-fold app increase in K app m and a constant V max ð¼ 3:8 mM=sÞ would imply that the basal [DA]e also increased 15 fold from the estimated control level (49 nM; Chen, 2005b). Even after considering the action of auto-inhibition exerted by DA autoreceptors, 10fold increase in [DA]e after GBR12909 should still exist. This interpretation is based on the model of Chen (2005b). In contrast, if adopting the rela tionship that K app m ¼ K m C and C* ¼ 2 mM as assumed in Michael et al. (2005), increase of K app m from 160 to 2,500 nM only modifies the intrinsic Km from 2.2 to 4.5 mM. This small increase in Km will probably elevate the basal [DA]e by about twofold, making the DA recovery after GBR12909 larger than the control. In view of this discrepancy in the model predictions, it is impossible at present to draw credible conclusions regarding how DA recovery varies with DA uptake inhibition. It is necessary to clarify which model depicts the actual DA uptake system in the brains before accurate predictions could be drawn. III.C.5. Physiological perspectives It is worth noting the range of the binding affinities for DA receptors, as their physiological levels may also give hints to the ‘‘expected’’ basal [DA]e from the perspective of DA transmission. Numerous binding competition studies have shown that both DA D1 and D2 receptors can exist in two affinity states (e.g., George et al., 1985; Mireylees et al., 1986; Seeman and Grigoriadis, 1987; Richfield et al., 1989; Neve and Neve, 1997; Seeman and Tallerico, 2003). Whereas the low-affinity binding constants of the DA D1 and D2 receptors are at the micromolar level, their high-affinity
65
binding constants fall within the nanomolar ranges. Binding competition between DA and [3H]DA has revealed an equilibrium dissociation constant of the high-affinity D1 receptor with exogenous DA in the range of 0.8–50 nM [0.8 nM – Seeman and Grigoriadis (1987); 10–32 nM – Neve and Neve (1997); 49720 nM – Richfield et al. (1989)]. For the high-affinity D2 receptors, the equilibrium dissociation constant has been reported to be 1.75–50 nM [1.75 nM – Seeman (2002); 7.5 nM – Seeman and Grigoriadis (1987); 4–50 nM – Neve and Neve (1997); 4374 nM – Richfield et al. (1989)]. In view of the high-affinity D1 and D2 receptors and their extrasynaptic distributions, a temporally and spatially averaged ECS DA concentration at the nanomolar level does not exclude the possibility of tonic participation of DA D1 and D2 receptors in DAergic transmission. In contrast, a micromolar-level [DA]e would completely saturate these high-affinity receptors. Considering the functions of DA D1 and D2 receptors, it is likely that the high-affinity receptors regulate the tonic DAergic transmission, as they can be easily activated by the nanomolar [DA]e. During phasic discharge, in which local [DA]e can easily shoot up to micromolar level, the low-affinity receptors are activated as a second gating mechanism to regulate the excitatory synaptic activity. From a neurochemical point of view, too high background DA risks potentiating the DA high-affinity receptors, overwhelming the DAT uptake system during phasic discharges, and consequently, overcoming any concomitant presynaptic inhibition of DA release. According to the current Km values measured from in vivo FSCV and in vitro synaptosomes experiments, a 500 nM ECS DA will keep 500/(200+500) ¼ 71% of the extrasynaptic DAT population occupied, leaving little capacity to further clear the more massive DA overflow that occurs during intense phasic firing. A [DA]e ¼ 2 mM would essentially saturate the complete DAT uptake system. Of course, this estimate is based on that the intrinsic Km is 0.2 mM. If the Km is 2.2 mM instead of 0.2 mM, and [DA]e ¼ 2 mM as claimed (Michael et al., 2005), 50% of the DAT population is still occupied under the resting condition. Whether 50% saturation of the DAT population
at rest constitutes an effective extrasynaptic DAT uptake system deserves further investigation. Excessive [DA]e may induce DA excitoxicity (Alagarsamy et al., 1997; McLaughlin et al., 1998). However, noticeable DA toxicity can only be demonstrated at [DA]e concentrations higher than 50 mM, which hence does not help resolve the issue of baseline [DA]e here. Too much DA in the brain has been implicated in the DAergic attention-deficit hyperactivity disorder (Carboni et al., 2003) and the positive symptoms of schizophrenia (AbiDargham et al., 2000). Many antipsychotic drugs, therefore, act to relieve positive schizophrenic symptoms by reducing the brain DA level (the dopamine hypothesis). In summary, from the aspects of a robust DA homeostatic mechanism and a high signal-to-noise ratio (a clear differentiation between backgrounds or baseline firing signals and those that are evoked by afferent stimulation), a low ECS DA level may be more desirable.
IV. Data from other neurotransmitters IV.A. Glutamate Numerous microdialysis studies of extracellular glutamate (Di Chiara et al., 1996; Herrera-Marschitz et al., 1996; Westerink and Timmerman, 1999) have established that the glutamate content in the dialysate is insensitive to the application of TTX, a fast Na+ channel blocker. For glutamate, this TTX-insensitivity was attributed to the substantial contribution from glia-released glutamate to the ECS pool (Di Chiara et al., 1996; Timmerman and Westerink, 1997; Westerink and Timmerman, 1999). A recent study further supports the hypothesis that the primary origin of extrasynaptic glutamate in the striatum arises from non-vesicular glutamate release by the cystine–glutamate antiporters that are preferentially located on glial elements (Baker et al., 2002). Recently, Khan and Michael (2003) offered an alternative explanation that the TTX-insensitivity of the microdialysis-recovered glutamate is due to the probe-induced tissue trauma, which similarly suppressed glutamate release to such an extent that no further suppression of glutamate release could be seen upon TTX
66
application. Whether the probe-induced tissue trauma is the cause of the TTX-insensitivity in microdialysis glutamate is uncertain; but if it was, one still needs to reconcile why probe-induced tissue trauma did not similarly eradicate the dialysate TTX sensitivity for other neurotransmitters, such as DA, serotonin, noradrenaline, and acetylcholine (Di Chiara et al., 1996; Westerink and Timmerman, 1999). The extracellular glutamate level in rat striatum has been measured by microdialysis ZNF method to be 3 mM (Miele et al., 1996). Using a novel glutamate microsensor, Kulagina et al. (1999) recently estimated the extracellular glutamate level, [GLU]e, to be 29 mM, about ten times as high as the ZNF measurement. Kulagina et al. (1999) interpreted these disparate results between microdialysis and their microsensor studies as an indication that the microdialysis ZNF method similarly underestimates the basal ECS glutamate concentration due to the probe-induced tissue damage to glutamatergic nerve terminals. Interestingly, in a recent work of Kennedy et al. (2002) a silica capillary was used to directly withdraw ECS fluid at ultralow rates (1–50 nL/min) to measure ECS glutamate in rat striatum. Although the size of the silica capillary (o.d. 90 mm) is still larger than the typical carbon-fiber microelectrode, it is considerably smaller than microdialysis probes. Most importantly, the ECS fluid was collected from the tip instead of the shaft region of the capillary; hence fluid drainage is more of an issue than the insertion-induced tissue disruption. Supposedly, these authors induced less tissue disruption in the implanted site than Miele et al. (1996) did with microdialysis; however, Kennedy et al. (2002) obtained the same low ECS glutamate concentration (1.7670.15 mM). A major concern in the method of Kennedy et al. (2002) is whether directly withdrawing ECS fluid would cause local fluid drainage around the sampling capillary. If drainage was not serious, the sampled glutamate content represented the ECS level in the locally damaged tissue only (more or less similar to the CZNF). However, if drainage did occur, this would mean that the sampled ECS fluid was not only from the locally damaged tissue area but also from some more distant regions, where tissue trauma was less
serious. In this case, the glutamate content obtained from the first few withdrawals (before tissue response to ECS fluid drainage kicks in) would still be able to reflect better the undisturbed C*. When considering the basal level of extracellular glutamate, it is also important to recognize that glutamate, though the major excitatory neurotransmitter in the central nervous system, can also become a toxin leading to neuronal excitotoxicity when overly accumulated in the ECS. What is the concentration range for extracellular glutamate to become toxic? In vitro studies (Ankarcrona et al., 1995; Yu et al., 2003) showed that incubation of cerebellar and cortical neurons with as low as 30 mM of glutamate was sufficient to induce cell death (both necrosis and apoptosis). In view of this fact, it is uncertain if the resting [GLU]e in intact brains can be as high as 29 mM.
IV.B. Serotonin DA is not the only neurotransmitter that has been extensively studied by either the microdialysis or the voltammetry technique. Another neurotransmitter, serotonin (5-HT) has also been studied using either methods, hence allowing assessment of the possible errors associated with the measurements of the extracellular 5-HT by the microdialysis ZNF method. In the rat dorsal raphe (a brain region rich with serotonergic neurons), the CZNF of extracellular 5-HT has been reported to be 1.3 nM (Tao et al., 2000). Using the DPV method, however, Crespi et al. (1988) measured the extracellular 5-HT in the dorsal raphe to be 10 nM, about eight times as large as the ZNF estimation. Although the accuracy of the DPV technique in determining the basal level of 5-HT is unclear, kinetic data from evoked release and uptake of 5-HT in the same brain region indicate that this estimate might be very close to the actual value based on the following calculations. Using FSCV, Bunin et al. (1998) measured the 5-HT release and uptake parameters in the dorsal raphe of app rat brains as V app max ¼ 1:3mM=s; K m ¼ 170nM; and [5-HT]p ¼ 100 nM/s. If the basal firing rate of serotonergic neurons can be assumed to be 1.4 Hz (Robichaud and Debonnel, 2005), adopting the
67
same approach in Chen (2005b) for calculation yields a basal [5-HT]e 16 nM, which is very close to the DPV estimate (10 nM). The difference in the results obtained by both methods lends support to that tissue trauma affected the accuracy of the ZNF measurement for 5-HT, which underestimates the undisrupted basal [5-HT]e in dorsal raphe by 10-fold.
future similar experiments could be conducted under chronic situations: one may wish to observe whether the lack of evoked DA overflow next to the microdialysis probe still persists after a sufficiently long recovery time. Only then the validity of the quantitative microdialysis methods sampling brain neurotransmitters could be better assessed.
V. Conclusions
References
Microdialysis probe inevitably damages tissue integrity and neurochemistry, in terms of morphological alterations of tissue ECS structure and physiological impairment of neurotransmitter release/uptake. The damage on the latter two active processes can fundamentally sway the ability of the two commonly used microdialysis methods in sampling the ‘‘unperturbed’’ extracellular neurotransmitters, the ZNF method and the varied flow rate method. Examining the data from the microdialysis ZNF measurements and FSCV experiments on striatal DA systems shows reasonable doubt that the current ZNF measurement on striatal DA (5–10 nM) did underestimate the basal level [DA]e. However, the underestimation is not as serious as previously thought by Michael and coworkers. Namely, although the striatal [DA]e could be much higher than the single-digit nanomolar range determined by the ZNF method, the basal [DA]e is probably still confined within nanomolar level, perhaps fewer than 100 nM. Two modified DA kinetic models accounting for the presence of DA baseline were presented and compared. Considering the various theoretical interpretations of the model together with other evidence such as the existence of high affinity DA receptors and the low Michaelis–Menten uptake constant obtained from synaptosomes, a nanomolar [DA]e appears to be the more consistent conclusion at present. The most convincing evidence for the serious underestimation of the microdialysis ZNF method comes from the experimental data that compared the evoked DA response at sites close to and distant from an acutely implanted microdialysis probe. It would be greatly desirable if in the
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L.S., Weiss, R., Cooper, T.B., Mann, J.J., Van Heertum, R.L., Gorman, J.M. and Laruelle, M. (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. U.S.A., 97: 8104–8109. Alagarsamy, S., Phillips, M., Pappas, T. and Johnson, K.M. (1997) Dopamine neurotoxicity in cortical neurons. Drug Alcohol Depend., 48: 105–111. Amberg, G. and Lindefors, N. (1989) Intracerebral microdialysis: II Mathematical studies of diffusion kinetics. J. Pharmacol. Methods, 22: 157–183. Ando, K., Miyata, H. and Yanagita, T. (1994) Effects of methamphetamine, dopamine and noradrenaline administered into the nucleus accumbens of rats discriminating subcutaneous methamphetamine. Jpn. J. Pharmacol., 64: 35–40. Ankarcrona, M., Dypbukt, J.M., Bonfoco, E., Zhivotovsky, B., Orrenius, S., Lipton, S.A. and Nicotera, P. (1995) Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron, 15: 961–973. Baker, D.A., Xi, Z.-X., Shen, H., Swanson, C.J. and Kalivas, P.W. (2002) The origin and neuronal function of in vivo nonsynaptic glutamate. J. Neurosci., 22: 9134–9141. Benveniste, H. and Diemer, N.H. (1987) Cellular reactions to implantation of a microdialysis tube in the rat hippocampus. Acta Neuropathol. (Berl.), 74: 234–238. Benveniste, H., Hansen, A.J. and Ottosen, N.S. (1989) Determination of brain interstitial concentrations by microdialysis. J. Neurochem., 52: 1741–1750. Benveniste, H. and Huttemeier, P.C. (1990) Microdialysis – theory and application. Prog. Neurobiol., 35: 195–212. Blaha, C.D. (1996) Evaluation of stearate-graphite paste electrodes for chronic measurement of extracellular dopamine concentrations in the mammalian brain. Pharmacol. Bioechm. Behav., 55: 351–364. Blaha, C.D., Coury, A. and Phillips, A.G. (1996) Does monoamine oxidase inhibition by pargyline increase extracellular dopamine concentrations in the striatum? Neuroscience, 75: 543–550. Borland, L.M. and Michael, A.C. (2004) Voltammetric study of the control of striatal dopamine release by glutamate. J. Neurochem., 91: 220–229.
68 Borland, L.M., Shi, G., Yang, H. and Michael, A.C. (2005) Voltammetric study of extracellular dopamine near microdialysis probes acutely implanted in the striatum of the anesthetized rat. J. Neurosci. Methods, 146: 149–158. Bourne, J.A. (2003) Intracerebral microdialysis: 30 years as a tool for the neuroscientist. Clin. Exp. Pharmacol. Physiol., 30: 16–24. Budygin, E.A., Gainetdinov, R.R., Kilpatrick, M.R., Rayevsky, K.S., Mannisto, P.T. and Wightman, R.M. (1999) Effect of tolcapone, a catechol-O-methyltransferase inhibitor, on striatal dopaminergic transmission during blockade of dopamine uptake. Eur. J. Pharmacol., 370: 125–131. Budygin, E.A., Kilpatrick, M.R., Gainetdinov, R.R. and Wightman, R.M. (2000) Correlation between behavior and extracellular dopamine levels in rat striatum: comparison of microdialysis and fast scan cyclic voltammetry. Neurosci. Lett., 281: 9–12. Bungay, P.M., Morrison, P.F. and Dedrick, R.L. (1990) Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci., 46: 105–119. Bungay, P.M., Newton-Vinson, P., Isele, W., Garris, P.A. and Justice, J.B. Jr. (2003) Microdialysis of dopamine interpreted with quantitative model incorporating probe implantation trauma. J. Neurochem., 86: 932–946. Bunin, M.A., Prioleau, C., Mailman, R.B. and Wightman, R.M. (1998) Release and uptake rates of 5-hydroxytryptamine in the dorsal raphe and substantia nigra reticulata of the rat brain. J. Neurochem., 70: 1077–1087. Carboni, E., Silvagni, A., Valentini, V. and Di Chiara, G. (2003) Effect of amphetamine, cocaine and depolarization by high potassium on extracellular dopamine in the nucleus accumbens shell of SHR rats: an in vivo microdialysis study. Neurosci. Biobehav. Rev., 27: 653–659. Chefer, V.I., Kieffer, B.L. and Shippenberg, T.S. (2003) Basal and morphine-evoked dopaminergic neurotransmission in the nucleus accumbens of MOR- and DOR-knockout mice. Eur. J. Neurosci., 18: 1915–1922. Chen, K.C. (2005a) Preferentially impaired neurotransmitter release sites not their discreteness compromise the validity of microdialysis zero-net-flux method. J. Neurochem., 92: 29–45. Chen, K.C. (2005b) Evidence on extracellular dopamine level in rat striatum: implications to validity of quantitative microdialysis. J. Neurochem., 92: 46–58. Chen, K.C. (2006) Effects of tissue trauma on characteristics of microdialysis zero-net-flux method sampling neurotransmitters. J. Theor. Biol., 238: 863–888. Chen, K.C., Hoistad, M., Kehr, J., Fuxe, K. and Nicholson, C. (2002) Theory relating in vitro and in vivo microdialysis with one or two probes. J. Neurochem., 81: 108–121. Clapp-Lilly, K.L., Roberts, R.C., Duffy, L.K., Irons, K.P., Hu, YT. and Drew, K.L. (1999) An ultrastructural analysis of tissue surrounding a microdialysis probe. J. Neurosci. Methods, 90: 129–142. Cosford, R.J.O., Vinson, A.P., Kukoyi, S. and Justice, J.B. (1996) Quantitative microdialysis of serotonin and norepinephrine: pharmacological influences on in vivo extraction fraction. J. Neurosci. Methods, 68: 39–47.
Costall, B., Domeney, A.M. and Naylor, R.J. (1983) A comparison of the behavioural consequences of chronic stimulation of dopamine receptors in the nucleus accumbens of rat brain effected by a continuous infusion or by single daily injections. Naunyn Schmiedebergs Arch. Pharmacol., 324: 27–33. Crespi, F., Martin, K.F. and Marsden, C.A. (1988) Measurement of extracellular basal levels of serotonin in vivo using nafion-coated carbon fiber electrodes combined with differential pulse voltammetry. Neurosci., 27: 885–896. Crespi, F. and Mobius, C. (1992) In vivo selective monitoring of basal levels of cerebral dopamine using voltammetry with nafion modified (NA-CRO) carbon fiber microelectrodes. J. Neurosci. Methods, 42: 149–161. Dabrosin, C. (2005) Microdialysis – an in vivo technique for studies of growth factors in breast cancer. Front. Biosci., 10: 1329–1335. De Lange, E.C.M., De Boer, A.G. and Breimer, D.D. (2000) Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv. Drug Deliv. Rev., 45: 125–148. Di Chiara, G., Tanda, G. and Carboni, E. (1996) Estimation of in vivo neurotransmitter release by brain microdialysis: the issue of validity. Behav. Pharmacol., 7: 640–657. Fan, X.-D., Li, X.-M. and Juorio, A.V. (2000) Substantia nigra pars reticulata lesion induces preconvulsive behavior and changes in glutamate receptor gene expression in the rat brain. Brain Res., 867: 40–51. Garris, P.A., Budygin, E.A., Phillips, P.E.M., Venton, B.J., Robinson, D.L., Bergstrom, B.P., Rebec, G.V. and Wightman, R.M. (2003) A role for presynaptic mechanisms in the actions of nomifensine and haloperidol. Neuroscience, 118: 819–829. Garris, P.A., Ciolkowski, E.L., Pastore, P. and Wightman, R.M. (1994) Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J. Neurosci., 14: 6084–6093. George, S.R., Watanabe, M., Di Paolo, T., Falardeau, P., Labrie, F. and Seeman, P. (1985) The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form. Endocrinol., 117: 690–697. Georgieva, J., Luthman, J., Mohringe, B. and Magnusson, O. (1993) Tissue and microdialysis changes after repeated and permanent probe implantation in the striatum of freely moving rats. Brain Res. Bull., 31: 463–470. Gonon, F.G. and Buda, M.J. (1985) Regulation of dopamine release by impulse flow and by autoreceptors as studied by in vivo voltammetry in the rat striatum. Neurosci., 14: 765–774. Grabb, M.C., Sciotti, V.M., Gidday, J.M., Cohen, S.A. and Van Wylen, D.G.L. (1998) Neurochemical and morphological responses to acutely and chronically implanted brain microdialysis probes. J. Neurosci. Methods, 82: 25–34. Groothuis, D.R., Ward, S., Schlageter, K.E., Itskovich, A.C., Schwerin, S.C., Allen, C.V., Dills, C. and Levy, R.M. (1998) Changes in blood-brain